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Executive Summary 
This is the final report of a study undertaken by the Centre for Health Service Development 
(CHSD), University of Wollongong.  The study was commissioned by the NSW Department of 
Health to provide a costing of blood and marrow transplantation services in NSW.  Blood and 
Marrow Transplantation (BMT) is a high cost and relatively low volume specialty service.  The 
scope of this study encompassed both inpatient and related outpatient BMT services.  The aim 
was to develop an understanding of cost structures associated with BMT services.   
 
Blood and marrow transplantation is used to treat a range of diseases including haematological 
(blood) diseases such as leukaemia, lymphoma and multiple myeloma, as well as some immune 
disorders and, occasionally solid tumours.  There are two main types of stem cell transplants 
autologous (where the patient is their own cell donor) and allogeneic (where stem cells are 
donated by another person).  Allogeneic transplants are considered to be more complex, higher 
risk and consume most resources. 
 
Currently, fifteen hospitals deliver BMT services across NSW and there are eight specialty BMT 
laboratories.  Data collection was restricted to hospitals that operate ‘clinical costing’ systems and 
could therefore produce ‘episode level’ cost data for BMT patients.  This resulted in the inclusion of 
data from eight hospitals: Sydney Children’s Hospital, Children’s Hospital Westmead, St Vincent’s 
Hospital, Royal North Shore Hospital, Westmead Hospital, Nepean Hospital, Prince of Wales 
Hospital and St George Hospital.  Data from these eight hospitals formed what is referred to during 
the remainder of this report as the ‘study dataset’.   
 
We have compared the volume of activity in the study dataset with activity data reported by the 
NSW Department of Health in its annual hospital cost data collection.  This shows that for adults, 
the study dataset represents approximately 90.1% of allogeneic and 58.1% of autologous BMT 
transplant episodes undertaken annually in NSW.  For paediatric services, it represents 96% of 
allogeneic transplants and 97% of autologous transplants undertaken annually in NSW.  On this 
basis, we are confident that the study is representative of BMT services across the State.   
 
The primary questions addressed in this study, as identified in the project brief are as follows:  
• What is the average per patient cost of autologous and allogeneic BMT? 
• What is the breakdown of costs for each of these, in terms of the inpatient and ambulatory 
phase of treatment? 
• Are there available costings from other States in Australia with which to compare, and if 
significantly different, why? 
• What proportion of BMT costs do pharmaceuticals represent? 
• What, if any, difference is there between costs for adult patients and paediatric BMT? 
• What are the financial implications of the projected increase in BMT activity in NSW by 
2011? 
 
This study has developed a set of cost results in relation to each of the above questions.  A range 
of associated cost results are included to provide a more detailed breakdown of various BMT cost 
structures.  The results are presented in the context of the NSW health system and the current 
funding arrangements that operate within that context.   
 
This report is structured to reflect the activities undertaken during the study.  
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Section 2 provides a summary of the consultation process that has informed the study. Over fifty 
consultation sessions occurred with predominantly clinical and costing personnel.  There were 
several purposes to this consultation process, including to: understand the clinical process of BMT; 
inform the decisions about start and end points of the patient journey and identify costing issues of 
concern to clinicians. 
 
Section 3 provides the results of a targeted literature review undertaken to identify any relevant 
previous costing studies of BMT services.  As was expected, one of the major difficulties in 
identifying relevant work is the widely varying objectives and methodologies used in previous 
studies.  In particular, many studies examined the cost of particular components of BMT, such as 
certain types of pharmaceuticals or a particular method of stem cell harvesting.  Whilst these 
results provided useful background information, they often were of limited value in seeking to 
develop an understanding of the overall cost of BMT services.   
 
Section 4 flowcharts and discusses the ‘patient journey’ for all types of BMT services; adult and 
paediatric and autologous and allogeneic.  The patient journey follows similar key steps with all 
autologous transplant patients requiring workup; mobilisation, stem cell harvest and cell 
processing, transplant (including conditioning) and post transplant management.  In addition, 
allogeneic transplant patients require tissue typing and they are not subject to stem cell harvest – a 
donor supplies the cells which must be collected and processed.  The majority of the BMT patient 
journey is consumed by the inpatient admission for transplant.  Several aspects of clinical practice 
were identified during the clinical consultation that could not be costed and this is discussed further 
in the body of the report. 
 
Sections 5 and 6 describe the process for developing the study data collection protocol, 
corresponding dataset and costing methodology.  Data from the eight hospitals previously 
identified formed the ‘study dataset’.  Cost estimates were developed for the various care 
processes involved in the delivery of BMT services including BMT episodes, related inpatient 
episodes and a range of outpatient BMT services.  Several issues emerged during data collections 
which are discussed in detail in Section 5.  A range of preparatory data analysis tasks were 
undertaken and business rules were developed to govern the inclusion of data in the final study 
dataset.  After the adjustments described in Section 6 were completed the final study dataset 
consisted of: 
• 508 BMT episodes 
• 2,258 Related inpatient episodes 
• 7,485 Outpatient medical, nursing and allied health clinic occasions of service 
• 6,272 Outpatient dispensed drugs 
• 435 Other outpatient treatments.  
 
Section 7 presents the study results comprising a set of cost estimates for a range of BMT related 
services undertaken in NSW.  The total cost of BMT services by transplant type and adult and 
paediatric hospital is shown in the table below.  The total annual cost of BMT services (allogeneic 
and autologous; adult and paediatric; inpatient and outpatient) for the study dataset is 
$30,882,930.  The average cost per BMT in paediatric hospitals is approximately double the 
average cost per BMT in adult hospitals.  The cost per allogeneic BMT is approximately twice as 
much as the cost per autologous BMT in both adult and paediatric facilities. 
 
Ward costs account for approximately 40% of the inpatient component of transplant episodes for 
both adult and paediatric transplants.  Pharmacy costs are the second highest cost bucket 
representing approximately 30% in adult hospitals and 25% in paediatric hospitals.  Across the 
adult hospitals in the study dataset, ICU costs contributed 7% of total costs for allogeneic 
transplant episodes and 11% in paediatric hospitals.   
 
Table 1 below shows the total annual cost of both allogeneic and autologous transplant services 
for each hospital that participated in the study.  Total cost is $30.88 m annually for 134 allogeneic 
and 153 autologous transplants undertaken across the eight hospitals.  Total costs range from 
$610,020 at St George Hospital which undertakes 11 autologous transplants, to $7.95m at 
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Westmead Hospital which undertakes an average of 57 allogeneic and 26 autologous transplants 
annually. 
Table 1 Total annual costs of allogeneic and autologous BMT – study dataset 
Hospital Cost Per 
Allogeneic 
Transplant 


















$120,510 27 $71,905 23 50 $4,907,576 
Westmead Hospital  $117,569 57 $48,263 26 83 $7,956,278 
Royal North Shore 
Hospital  
$93,571 17 $67,581 39 56 $4,226,365 
Prince of Wales 
Hospital 
 $0 0 $69,440 9 9 $624,956 
St George Hospital  $0 0 $55,456 11 11 $610,020 
Nepean Hospital   $0 0 $63,183 12 12 $758,191 
Adult Hospitals $114,316 101 $62,812 120 221 $19,083,386 
              
Sydney Children's 
Hospital 
$237,407 15 $104,346 16 31 $5,230,632 
Children's Hospital 
Westmead 
$218,851 18 $154,681 17 35 $6,568,895 
Paediatric 
Hospitals 
$227,286 33 $119,367 33 66 $11,799,536 
     
Total $142,137 134 $75,010 153 287 $30,882,930 
 
The financial implications of the projected increase in BMT activity in NSW are an increased in 
Statewide expenditure to $46.49m by 2011 and $53.58m by 2016. 
 
A set of key messages arising from the study follows.  
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Key Messages 
• There are few published costing studies on BMT and those that are available usually include 
insufficient detail to facilitate comparison between studies. 
  
• It is inherently difficult to cost BMT services because of the issue of determining the point at 
which BMT treatment commences and treatment of the underlying disease ends.  For this 
study, it was decided to cost a window of services commencing 60 days prior to transplant and 
ending 365 days post transplant. 
 
• The average (mean) cost of a BMT episode including inpatient and outpatient services in NSW 
was found to be: 
o adult allogeneic transplant: $114,316 
o adult autologous transplant: $62,812 
o paediatric allogeneic transplant: $227,286 
o paediatric autologous transplant: $119,367 
 
• Costing studies inevitably require a trade-off between what is desirable and what is feasible.  
This study sought to capture cost data on the major elements of BMT recognising that it was 
not possible to identify all costs.  
 
• The projected cost of BMT services (all inpatient and outpatient) in NSW will increase from its 
current level to $46.49m in 2011 and $53.58m in 2016.   
 
• In this study, there were 508 transplant episodes, which we consider to be an appropriate 
sample size.  Of these 60% were autologous and 40% allogeneic.  The ratio is consistent with 
levels of activity reported elsewhere.  
 
• The cost of paediatric BMT services is significantly higher than the cost of adult BMT services.  
The difference in cost is less for the transplant episode component of the BMT, but is still large 
enough to support an argument for the AR-DRG classification system to separate adult and 
paediatric BMT transplant episodes.  
 
• Overall, the higher cost of paediatric services aligns with the views expressed by clinicians 
during the clinical consultations.  In part, this may be a reflection of the higher proportion of 
unrelated donor transplants and the growing number of cord blood transplants undertaken at 
these facilities. 
 
• There is considerable variation in the cost of individual episodes within both allogeneic and 
autologous patients.  This is a function of the variation in clinical condition between patients 
and is reflected in the large difference between the mean and median costs across hospitals. 
 
• For adult hospitals providing unrelated allogeneic transplants (St Vincent’s and Westmead), the 
costs are consistent with a slightly lower cost for Royal North Shore Hospital which undertakes 
only sibling related allogeneic transplants. 
   
• There is no evidence to suggest that autologous transplants are more or less expensive at 
hospitals that undertake only autologous transplants regardless of the number of transplants 
undertaken.  This may have implications in a planning context. 
 
• There may be growing demand for transplants due to the widening indications such as non 
malignant conditions in children; transplant genetics; availability of cord blood and capacity for 
reduced intensity conditioning to be used with older patients.  Greater use of reduced-intensity 
conditioning regimens, increasing worldwide donor availability and the availability of alternative 
drug treatments were noted as significant trends likely to lead to increasing use of transplant 
for a range of indications. 
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1 Introduction 
This is the final report of a study undertaken by the Centre for Health Service Development 
(CHSD), University of Wollongong.  The study was commissioned by the NSW Department of 
Health to provide a costing of blood and marrow transplantation services in NSW.  An interim 
report was issued in September 2008 and circulated to stakeholders for comment.  The major 
principles set out in the interim report were acceptable to all parties.  This report incorporates 
modifications based on stakeholder feedback and data received from hospitals and provides cost 
results for BMT services in NSW.   
 
This study was commissioned in recognition of the importance of developing an understanding of 
current cost structures associated with blood and marrow transplantation (BMT) services.  The 
outputs of this study will be used to inform the “NSW Blood & Marrow Transplantation Service 
Plan” currently under development by the NSW BMT Service Plan Development Working Group.  It 
is hoped that this will in turn provide valuable information to feed into future policy and planning 
processes.  
 
The scope of this study encompassed both inpatient and related outpatient BMT services.   
Currently, fifteen hospitals deliver BMT services across NSW as shown in Table 2 below.  The 
work of these transplant centres is supported by specialty blood and marrow laboratories.  There 
are eight BMT laboratories servicing NSW located at: Royal North Shore Hospital, Royal Prince 
Alfred Hospital, St Vincent’s Hospital, Westmead Hospital, Liverpool Hospital, Newcastle Mater, 
Prince of Wales Hospital and St George Hospital. 
Table 2:  Number of BMT transplants in NSW 2007 
Adult Allogeneic and Autologous Transplants Number of Transplants  
St. Vincent’s Hospital (incl. Private) 60 
Westmead Hospital  79 
Royal North Shore Hospital  42 
Royal Prince Alfred Hospital  37 
Paediatric Allogeneic and Autologous Transplants  
Sydney Children’s Hospital 29 
Children’s Hospital Westmead 27 
Adult Autologous Transplant Services   
Concord Hospital  13 
Gosford Hospital  7 
Liverpool Hospital  18 
Nepean Hospital  12 
Newcastle Mater Hospital  12 
Prince of Wales Hospital 8 
St George Hospital  11 
Wollongong Hospital  18 
Paediatric Autologous Transplants  
John Hunter Children’s* 3 
  
Total 376 
Source:  Australasian BMT Recipient Registry, March 2008.   
*John Hunter Children’s Hospital manages autologous transplants in collaboration with Newcastle Mater and Sydney 
Children’s Hospital.   
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1.1   Study objectives 
 The primary questions addressed in this study, as identified in the project brief are as follows:  
• What is the average per patient cost of autologous and allogeneic BMT? 
• What is the breakdown of costs for each of these, in terms of the inpatient and ambulatory 
phase of treatment? 
• Are there available costings from other States in Australia with which to compare, and if 
significantly different, why? 
• What proportion of BMT costs do pharmaceuticals represent? 
• What, if any, difference is there between costs for adult patients and paediatric BMT? 
• What are the financial implications of the projected increase in BMT activity in NSW by 2011? 
 
This study has developed a set of cost results in relation to each of the above questions.  A range 
of associated cost results are included to provide a more detailed breakdown of various BMT cost 
structures.  The results are presented in the context of the NSW health system and the current 
funding arrangements that operate within that context.  In doing so, the study aims to identify the 
major costs associated with BMT services in NSW.     
1.2   Structure of this report 
This report is structured to reflect the activities undertaken during the study.  
 
• Section 2 provides a summary of the consultation process undertaken at the commencement 
of the study;  
 
• Section 3 provides summary results of a targeted literature review undertaken to identify any 
relevant previous costing studies of BMT services.  The full results are provided in Appendix 2 
 
• Section 4 presents an overview of the clinical processes associated with the BMT process 
developed from a series of consultations conducted with clinicians throughout the project;  
 
• Sections 5 and 6 describe the process for developing the study data collection protocol, 
corresponding dataset and costing methodology;   
 
• Section 7 presents the study results comprising a set of cost estimates for a range of BMT 
related services undertaken in NSW;  
 
• Section 8 provides a discussion of the results in the context of implications for the planning 
and delivery of BMT services in NSW in the future.  
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1.3   The study dataset 
We raise this issue at the outset as it was identified in the early stages of the study and impacted 
on the subsequent data collection and costing methodology.  This issue is outlined in detail in 
Section 5 and relates to the availability of activity and cost data from the fifteen BMT hospitals.    
 
The models of care and treatment protocols vary to some extent between hospitals.  Some key 
areas of difference include drug regimens, methods of harvesting stem cells and the mixture of 
services provided on an inpatient versus outpatient basis.  As these differences potentially result in 
variations in cost, it would have been ideal to obtain data from all fifteen BMT hospitals.   
 
However, the information systems required to extract relevant data do not routinely operate at 
each site.  For this reason, it was necessary to restrict the data collection to hospitals that operate 
‘clinical costing’ systems and could therefore produce ‘episode level’ cost data for BMT patients.   
 
This comprised eight of the fifteen BMT hospitals.  These hospitals provided cost data for all 
transplant and related inpatient episodes for a one, two or three year period between 2004/05 and 
2006/07.  In most cases, data were available for either two or three years during this time.  
Similarly, all but one of these hospitals could provide outpatient data for some or all of this period.  
The one hospital that did not provide outpatient data undertakes only a small number of 
autologous transplants each year.   
 
Data from these eight hospitals formed what is referred to during the remainder of this report as 
the ‘study dataset’.  Details of the number of episodes and outpatient occasions of service are 
provided in Section 6.6.  We have compared the volume of activity in the study dataset with activity 
data reported by the NSW Department of Health in its annual hospital cost data collection.  This 
shows that the study dataset represents approximately 90.1% of allogeneic and 58.1% of all 
autologous BMT transplant episodes undertaken annually in NSW.  For paediatric services, it 
represents of 96% of allogeneic transplants and 97% of autologous transplants undertaken 
annually in NSW.  On this basis, we are confident that the study is representative of BMT services 
across the State.   
1.3.1 The NSW and annual cost data collection  
We note here that the NSW Department of Health undertakes an annual hospital costing process 
involving all NSW public hospitals including the fifteen BMT hospitals.  The NSW cost study 
produces cost results at the AR-DRG level.  The cost data provided for this BMT study is 
essentially the same data that was used in the NSW cost study.  As such, the results for transplant 
episodes at the eight hospitals are likely to be similar across the two studies.  The key element of 
our study that is additional to the NSW study is the inclusion of cost estimates for non-transplant 
related inpatient episodes and outpatient services.  Non-transplant inpatient episodes related to 
BMT cannot be identified in the NSW study as they are assigned to potentially any AR-DRG and 
cannot be separated from other episodes in that AR-DRG.  Outpatient episodes are not in scope 
for the NSW study.   
 
We utilised the results of the NSW study to obtain costs for the three BMT AR-DRGs from the 
seven hospitals that do not operate clinical costing systems.  We have also included the results of 
the NSW study for all hospitals in Appendix 5. 
 
1.3.2 The National hospital cost data collection 
We also note that the Commonwealth Department of Health and Ageing conducts a national 
hospital cost data collection (NHCDC).  This study involves all States and Territories and produces 
cost results at the AR-DRG level.  Again, for NSW services the AR-DRG level data obtained for 
this BMT study is essentially the same data submitted by NSW public hospitals to the NHCDC.  As 
such, the results for transplant AR-DRGs at the eight hospitals are likely to be similar between this 
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study and the NHCDC.  The NHCDC results do however allow a comparison of the cost of BMT 
AR-DRGs in NSW with other States.  For this reason, at Appendix 6 we have included a 
breakdown of the BMT AR-DRGs reported in the NHCDC.  
 
1.4   Costing versus funding – an important distinction  
It is important to distinguish between studies that deal with costing issues on the one hand and 
studies that deal primarily with funding models.  Whilst the two are closely related, the terms of 
reference for this project are explicit in that issues relating to funding are out of scope.   
 
We would note our understanding that Statewide and Selected Specialty Services (such as BMT) 
receive enhancement funding from the NSW Department of Health.  This funding is allocated to 
the host Area Health Service to be passed on to the Statewide service.  There is also an allowance 
in the Resource Distribution Formula to ensure the host Area's target share of funding reflects the 
fact that it hosts a Statewide service. 
 
The primary objective of this study was to identify and cost the core services associated with 
providing BMT services.  During the clinical consultation process, a range of issues were raised in 
relation to costs that are incurred by hospitals providing BMT services.  In some cases, it was 
suggested that current funding arrangements do not adequately reimburse hospitals for providing 
these services.   
 
To ensure that we have accurately and thoroughly represented the views expressed during the 
consultations, we have included these issues in our summary of the clinical consultation process in 
4 and in the discussion of costing issues in 7.4.  We would suggest, however, that many of these 
issues are more appropriately dealt with in a consideration of the broader funding issues 
associated with BMT services.     
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2 Consultations with stakeholders 
The starting point for this study is to understand the patient journey for autologous and allogeneic 
BMT as it applies in practice for both adults and children.  This process assists in defining the 
‘episodes of care’ that most accurately represent current clinical practice in blood & marrow 
transplantation.  A series of consultations have occurred with clinicians to ensure CHSD has a 
comprehensive understanding of this process.  These consultations have centred on four key 
stakeholder groups: clinicians, casemix and costing staff, executive leaders and other agencies 
with a major interest in BMT.  A list of consultations completed to date is provided at Appendix 1. 
 
2.1   Clinical 
An important objective of the clinical consultations is to ensure that the costing process accurately 
reflects the range of clinical processes that are associated with BMT services.  Consultations have 
been undertaken with twenty-eight clinicians including senior medical officers, clinical nurse 
consultants, hospital scientists and pharmacists.  Consultations have also been undertaken with 
representatives from the three Children’s Hospitals in NSW to identify any differences between 
paediatric and adult BMT.  The CHSD team has consulted with personnel from twelve hospitals, 
(all four facilities delivering adult allogeneic transplants have been consulted).   
2.2   Casemix and costing 
Obtaining appropriate service utilisation and financial/costing data is a critical input for this project.  
Consultations with costing staff from nine hospitals have been undertaken.  In some cases, these 
staff have been able to provide data for several hospitals within an Area Health Service.  As 
expected, the consultation process has revealed considerable variation between facilities in terms 
of their capacity to contribute cost data to the study.  This issue is discussed in more detail in 
Section 5.1 of this report.  However, there has been a high degree of consistency across facilities 
in terms of the various costing processes that are routinely undertaken.  This has improved the 
capacity to combine cost data across facilities to produce overall BMT cost estimates.  
2.3   Executive 
The proposed approach to the costing study has been outlined to the Director, Clinical Operations 
from South Eastern Sydney Illawarra, (this Area Health Service has five BMT sites, including adult, 
paediatric, autologous and allogeneic services) and to the Director, Clinical Services at Sydney 
Children’s Hospital.  This has been helpful in providing a broader strategic perspective in relation 
to BMT services and in advising Statewide Services Development Branch (SSDB) about a 
potential “validation” process for data obtained from Area Health Services. 
2.4   Other agencies 
Interviews have occurred with the Executive Officer and the Principal Scientist from the Australian 
Bone Marrow Donor Registry.  This has provided useful insights into the costs associated with the 
procurement of stem cells both within Australia and internationally.  Statewide Services 
Development Branch (SSDB) has informed the NSW Cancer Institute of the progress of this study.   
In addition, a preliminary presentation outlining the approach to this costing study was delivered to 
the NSW BMT Service Plan Development Working Group in late September 2008. 
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3 Literature review summary 
A key question for this study was to determine the availability of cost data for BMT services from 
other studies which might be compared with the results of this study.  To this end, a targeted 
literature review was undertaken at the outset of the study.  The results are provided in  
Appendix 2.  This section provides an overview of methodology and the key findings of the 
literature review.  It identifies various cost drivers and a range of cost estimates found in the 
Australian and international literature.   
 
As was expected, one of the major difficulties in identifying relevant work is the widely varying 
objectives and methodologies used in previous studies.  In particular, many studies examined the 
cost of particular components of BMT, such as certain types of pharmaceuticals or a particular 
method of stem cell harvesting.  Whilst these results provide useful background information, they 
often are of limited value in seeking to develop an understanding of the overall cost of BMT 
services.   
3.1   Defining blood and marrow transplantation 
Whilst the acronym BMT is commonly thought to stand for “bone marrow transplant” it actually 
refers to the term “blood and marrow transplant”.  Bradstock et al. (2006:7) note that: 
 
“BMT is a general term used to cover all types of transplants using haematopoietic stem cells: 
cord blood transplant (CBT), peripheral blood stem cell transplant (PBSCT), haematopoietic 
stem cell transplant (HSCT) and bone marrow transplant.” 
 
Blood and marrow transplantation is used to treat a range of diseases including haematological 
(blood) diseases such as leukaemia, lymphoma and multiple myeloma, as well as some immune 
disorders and, occasionally solid tumours.  There are two main types of stem cell transplants 
autologous and allogeneic.   
 
“In autologous stem cell transplants, the patient is their own stem cell donor.  The patient’s 
blood stem cells are collected in advance (while they are in remission) and then returned to 
them after they receive high-doses of chemotherapy…In allogeneic stem cell transplants the 
stem cells are donated by another person.  Allogeneic transplants are more complex and carry 
more risks than autologous transplants.”  (Daly 2006:15) 
 
In allogeneic transplant, stem cells may be donated by a family member or unrelated donor, 
including cord blood. 
3.2   Introduction 
The NSW BMT Service Plan Development Working Group provided the starting point for the 
literature review.  State government officials from the relevant departments in Victoria, 
Queensland, South Australia and Western Australia were contacted regarding the existence of any 
documented costing studies in those states.  Only two studies were discovered – a very small 
scale study undertaken in Queensland in 2004, and a study undertaken by the Royal Melbourne 
Hospital.  Permission to include details of the latter study was not granted.  
3.3   Search strategy 
Relevant papers were identified by searching the electronic databases Medline, EconLit, Science 
Direct, Cinahl and Cochrane databases using combinations of the search terms transplant$, blood, 
bone marrow, stem cell, cord, umbilical, cost$ and method, costing, costing method$, costing 
model$, cost accounting, and case-mix.  Key journals such as Bone Marrow Transplantation, 
Blood, Clinical and Laboratory Haematology as well as Cancer Treatment Reviews and the 
European Journal of Cancer were also searched separately to ensure all references were found.  
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The resulting citations were culled to exclude those that did not focus on either costing or 
economic evaluation of blood and bone marrow transplantation.  Only English language citations 
were retained.  Additional citations were identified by internet searching, reviewing reference lists 
in recently published work and searching for recent publications by key researchers in the field.  A 
second round of culling was undertaken based on reading the abstract or executive summary of 
each paper or report.  Full text copies of the remaining 34 papers/reports were then reviewed. 
3.4   Overview 
The literature on costing blood and bone marrow transplants comprises only a small number of 
studies, with the main work undertaken in the USA and Europe, in particular Scandinavia and the 
Netherlands.  The studies are limited in scope, most are targeted to particular indications and 
underlying disease, and few provide detailed costing of the stages of transplant.   
 
While about a third of the papers were published in the last 5 years, many refer to research 
undertaken more than a decade ago.  Each of two recent systematic reviews (of the health 
economics of managing multiple myeloma, and of the comparative costs of high-dose 
chemotherapy and autologous stem cell transplantation vs. conventional chemotherapy), reported 
on only five studies examining the cost of BMT services (Moeremans and Annemans 2006, 
Simnett et al. 2000).   
 
Several economic evaluations of blood and marrow transplantation were found.   Whilst economic 
evaluation was outside the scope of this project the studies were reviewed for details of the costing 
methodologies employed.  In most such studies, the costing methodologies were not fully 
explained, nor were costing details reported, but they were useful for the purposes of shedding 
light on the overall magnitude of costs of different BMT service types.   
 
Very little economic analyses of BMT services that take account of recent changes in clinical 
practice and/or advances in new technology and diagnostics in the past few years, in particular in 
relation to gene therapy and sources of donor stem cells are available.  Thus, in terms of informing 
the development of costings for BMT service components, most of the literature was of marginal 
value.   
 
The terminology used to refer to the economic aspects of BMT services differs throughout the 
literature, at times affecting interpretation.  It was important to distinguish, for example, between 
charges and costs, in particular in regard to studies undertaken in the United States, since studies 
reporting the hospital charge for BMT services and products, may not necessarily report the actual 
costs of services.   
 
A major difficulty in costing BMT services is that widely differing assumptions and a variety of 
different inputs may be used to derive costings.  This is particularly the case because there are 
many different treatment methodologies covering both autologous and allogeneic transplants, a 
variety of donor stem cells, and an increasing range of indications and clinical practice modalities.  
Moreover, costs do not remain static and, because of the complexity of treatments and indications, 
even small changes in protocol can lead to a large difference in cost (Freeman et al 1996).  Most 
studies refer to this matter, in keeping with the general principle that robust cost comparisons can 
only be made when cost measurement is in reasonable compliance with a standardised costing 
methodology (Smith and Mogyorosy 2005).   
 
The pace of change in BMT is rapid so that conclusions regarding changes in clinical practice and 
emerging technologies that may impact on service provision, if based on retrospective studies, 
may already be out of date with practices and technologies well-established.   
 
In a recent paper that aimed to identify trends in Europe in BMT patient numbers and to anticipate 
transplant rates for the next 5 years, estimates of activity and expected changes in practice were 
used to estimate likely costs (Tan et al. 2007).  Greater use of reduced-intensity conditioning 
regimens followed by transplantation (RIC-HSCT) and increasing worldwide donor availability were 
noted as significant trends likely to lead to increasing use of transplant for a range of indications.  
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The availability of alternative drug treatments was another key factor expected to influence trends 
in transplantation.  The study predicted an increase in autologous transplantation in Europe of 6% 
between 2005-2010, with particular reference to the treatment of acute leukaemia and auto-
immune diseases.  An even greater increase of about 20% in allogeneic transplantation was 
predicted, with rises in use for all indications except chronic myeloid leukaemia, due mainly to the 
expected increased use of RIC-HSCT in older patients and in patients with co-morbidities.   
 
Changes in the characteristics of BMT service delivery and consequent changes in costs and shifts 
in cost distribution are the subject of discussion in a number of papers.   
 
In terms of disaggregated costing data, the most comprehensive analyses found were: 
• a 2002 Dutch study of a cost analysis for HLA-identical sibling and voluntary unrelated 
allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute 
myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL) (van Agthoven et al. 
2002); and  
• a 2005 report prepared for the Technology Assessment Unit of the McGill University Health 
Centre (Canada) on allogeneic transplantation in adults of stem cells from unrelated 
donors.   
 
A study by Prajogo (2004) reporting the results of a cost comparison of high-dose chemotherapy 
and autologous bone marrow transplantation vs. standard dose chemotherapy for patients with 
non-Hodgkin’s lymphoma at the Calvary Mater Misericordiae Hospital in Newcastle (NMMH) 
provided the most relevant Australian analysis.   
3.5   Cost drivers 
Many of the studies identified factors that have an important impact on costs.  The cost drivers 
depended partly on the type(s) of BMT services being studied, the aim of the study, the country in 
which the study was undertaken, data availability and the study methodology.   
 
A number of studies noted the fundamental structural differences between the United States and 
Europe in terms of health service delivery, resulting in different cost drivers for BMT services 
depending on where studies are conducted.   
 
For studies of autologous BMT, examples of cost drivers include: 
• number of hospital days and blood products (for the period from hospital admission to 
discharge only)  
• stem cell mobilisation costs (harvest phase), nursing costs and pharmacy  
• room costs, laboratory, pharmacy, medical consultant fees; radiology and supportive care  
• conditioning regimens, number of hospital days, blood products, antibiotic and supportive 
care  
• induction chemotherapy (and within this, the number of cycles to achieve remission); post-
induction: blood products, inpatient costs (medical staff and accommodation), 
laboratory/radiology and pharmacy  
• number of hospital days, number of stem cells collected, phase and type of disease, 
whether patient is a child or adult. 
 
For allogeneic transplants, examples of cost drivers include: 
• tissue typing and donor stem cell collection costs, medical and nursing staff costs, 
pharmacy, blood products and laboratory costs  
• pharmacy, number of hospital days 
• total body irradiation (TBI)  
• number of hospital days, medical and nursing staff costs  
• GVHD prophylaxis 
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• number of hospital days, post-transplant complications including infections, veno-occlusive 
disease, GVHD, death.. 
 
3.6  Detailed cost analyses by stage of transplant 
A Dutch cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and 
peripheral blood stem cell transplantation in adults with AML or ALL between 1994 and 1999 
included costs for patients prepared for, but who did not undergo, transplantation, and covered all 
stages from pre-transplant tissue typing up to 24 months after transplantation.  Costs were 
separately identified for three transplant types (bone marrow transplant (BMT), matched unrelated 
donor (MUD) and peripheral blood stem cell transplant (PBSCT)) and allocated either to the 
pre-transplant phase, transplantation phase, or to one of the three follow-up phases (that is, 1-6 
months, 6-12 months and 12-24 months after transplantation).  Total costs per living patient were 
estimated to be approximately $195,6001 for BMT, $301,9002 (MUD) and $196,9003 (PBSCT). 
 
A Canadian comparison of the costs of allogeneic transplantation in 17 adults in 2004, using either 
cord blood or PBSCT from unrelated donors, included costs for the transplantation procedure and 
estimates of costs for up to 10 years after transplantation.  Based on possible relapses, infections 
and chronic GVHD, the total cost of an allogeneic stem cell transplantation including a 10-year 
follow-up (excluding the cost of procurement of stem cells) in an adult patient was estimated at 
approximately $A65,5004 and $A69,5005 for bone marrow and cord blood transplantation 
respectively.   
3.7   Previous cost estimates 
In 2004, a study at the Royal Brisbane and Women’s Hospital estimated the approximate total cost 
of bone marrow transplants, by transplant type, at that hospital.  It should be noted that only two 
patients were enrolled in each costing type.  The study suggested benchmark mean costs of 
approximately $54,500 for autologous transplants and $130,500 for allogeneic transplants6.  
 
Prajogo (2004) investigated the costs of high-dose chemotherapy and autologous bone marrow 
transplantation vs. standard chemotherapy in patients with relapsed non-Hodgkin’s lymphoma 
treated at Newcastle Mater Misericordiae Hospital from January 1995 to June 2002.  The study 
covered the period from induction chemotherapy to conditioning and transplant only.  Non-
pharmaceuticals comprised the largest overall cost (61%), with the cost of inpatient stay the major 
factor within the non-pharmaceuticals component (40% of total).  The estimated total mean cost 
per patient of $37,490 (in 2001) was compared with the cost of autologous transplantation in 
patients with either lymphoma or acute leukaemia ($A70,769), or non-Hodgkin’s lymphoma 
($A59,500) in the Netherlands.  It was suggested that the differences related to factors including 
use of total body irradiation before transplantation, service utilisation rates and the costs of 
hospitalisation and blood products in the two countries, the proportion of total costs of 
pharmaceuticals, and whether the transplant was PBSCT or autologous bone marrow 
transplantation (ABMT). 
                                                
1 $A2007 – costs converted from Euro 2002 to A$ and escalated using Reserve Bank of Australia Inflation Calculator (RBA) 
www.rba.gov.au 
2 $A2007 – costs converted from Euro 2002 to A$ and escalated using Reserve Bank of Australia Inflation Calculator (RBA) 
www.rba.gov.au 
3 $A2007 – costs converted from Euro 2002 to A$ and escalated using Reserve Bank of Australia Inflation Calculator (RBA) 
www.rba.gov.au 
4 $A2007 – costs converted from CDN to A$ and escalated using Reserve Bank of Australia Inflation Calculator (RBA) www.rba.gov.au 
5 $A2007 – costs converted from CDN to A$ and escalated using Reserve Bank of Australia Inflation Calculator (RBA) www.rba.gov.au 
6 $A2007 – costs escalated using Reserve Bank of Australia Inflation Calculator (RBA) www.rba.gov.au 
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4 An overview of the BMT clinical process 
An understanding of the clinical process of BMT was fundamental in undertaking this costing 
study.  Clinicians assisted in flowcharting the patient journey to identify the key stages of the BMT 
process from the clinical care or service delivery perspective. This section provides an overview of 
the BMT process identified by clinicians.     
 
An important element of the consultation process was to form a view regarding start and end 
points of the BMT process for the costing process.  A consistent view was expressed that BMT 
physicians and other staff are involved in treating patient’s at several stages before and after 
transplantation.  At the same time, however, views on the detail of this involvement differed 
between clinicians as well as between adult and paediatric services.   
 
During the consultation, various hypotheses were generated that were tested with clinical activity 
data provided by hospitals to determine appropriate ‘start’ and ‘end’ points in this context.  Based 
on this, business rules were developed and applied in the costing process.  These are presented in 
Section 6.2 for inpatient episodes and Section 6.5 for outpatient activity.   
 
The remainder of this section set outs ‘patient journey’ flowcharts, and a discussion of clinical and 
related issues that were raised during the consultation process.  In the discussion, an emphasis 
has been placed on the issue of determining start and end points in the BMT process.  Separate 
flowcharts are provided for allogeneic and autologous transplants as well as for adult and 
paediatric transplants.   
4.1   Adult autologous blood and marrow transplant  
The stages of the adult autologous BMT patient journey are depicted below in Figure 1. 
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4.1.1 BMT Physician accepts patient for transplant 
Autologous transplantation can be done if a patient is in remission or with responsive disease.  The 
patient is ideally clinically stable and the timing of the transplant is disease specific.  Peripheral 
blood stem cells are the most common source of stem cells for autologous BMT in adults (Eden et 
al. 2007). 
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Three views emerged on the “start” point or beginning of the patient journey: 
• The BMT journey starts when a decision is made to transplant the patient; this is reflected 
in practice by the BMT Physician or BMT team accepting the patient. 
• The BMT journey starts when there is an intention to transplant the patient. 
• The BMT journey starts from when a patient is diagnosed with a condition in which BMT 
may be indicated. 
 
The distinction between the “decision to transplant” and the “intention to transplant” has been 
made particularly by clinicians working with children.  Using “intention to transplant” as the starting 
point will ensure that the activity related to patients who are intended for transplant and therefore 
placed on certain treatment regimes, counselled and potentially “worked up” but never actually 
proceed to transplant, are captured.   
 
The course of the underlying disease may result in the period from intention to transplant to 
decision to transplant ranging from as short as two weeks through to several years.  Using this 
definition as the “start” of BMT would make costing virtually impossible as the ability to distinguish 
between costs relating to the underlying disease and costs relating to a future transplant would 
become blurred.  The same can be said for a start point coinciding with diagnosis of a condition 
that may be an indication for BMT.   
 
An option presented in our interim report suggested that for costing purposes, the BMT process 
could be deemed to start at the point when the BMT Physician accepts a patient for transplant.  
This is usually reflected in practice by a series of outpatient visits as the patient is assessed and 
subsequently worked up for transplant.  It is recognised that in practice, this process is not clear 
cut.  Patients who have an underlying cancer that indicates BMT may have been managed by the 
hospital or treating haematologist/oncologist for some time prior to the transplant episode.  
However, in generating an accurate cost of BMT it is necessary to exclude episodes of care that 
can be attributed to the underlying disease as opposed to the transplant.  
4.1.2 Work up 
The consultation process confirmed the view expressed by key stakeholders, that there is a high 
level of consistency in the range of tests performed in the work up phase.  Most routine medical 
tests occur on an outpatient basis before the patient is admitted to hospital for BMT.  The range of 
tests performed depends on the type of underlying disease but the aim is to determine if the 
patient is fit enough to endure the physical stresses of BMT.  Heart function may be tested by a 
gated heart pool scan and/or cardiac echo; kidney function is measured as well as lung function.   
 
A chest or sinus x-ray may be indicated and some patients may require computerised tomography 
(CT or CAT) or Positron Emission Tomography (PET) scan.  A number of blood tests are taken 
and these may screen for viral and bacterial infections, iron levels, blood glucose, clotting, thyroid 
and liver function.  The patient will have a full blood count and blood group identified.  Some 
patients may require a lumbar puncture and a bone marrow biopsy.  Patients are also encouraged 
to have a dental check up and to maintain good nutrition prior to transplant (Eden et al. 2007 and 
Daly 2006). 
4.1.3 Mobilisation 
Eden et al. (2007:25) note that: 
 
“Mobilisation occurs when the bone marrow increases production of stem cells, which then spill 
out into the circulating blood so they can be collected.  Your BMT doctor will decide on the best 
regimen to mobilise your peripheral blood stem cells.  The regimen will depend on your 
diagnosis, previous chemotherapy and radiotherapy, and your general health.” 
 
Mobilisation usually includes chemotherapy (one dose) and G-CSF (Granulocyte colony 
stimulating factor) a synthetic version of a naturally occurring hormone, which is administered daily 
by injection for 8-10 days.  G-CSF stimulates the growth of bone marrow stem cells and also 
 
Centre for Health Service Development 
 
Page 16    Final Report: A Costing Study of Blood & Marrow Transplantation Services in NSW 
causes the mobilisation of peripheral stem cells.  If the patient is well enough, many facilities 
provide this care on an outpatient basis.  If the hospital has an appropriate outreach team, it is 
possible on occasion, for this process to occur in the patient’s home.  Some facilities prefer to 
admit the patient for anywhere from one to three days, depending on their level of wellness; status 
of their underlying disease and prescribed mobilisation regimen. 
4.1.4 Stem cell harvest (cell processing and storage) 
Stem cell harvest occurs when the circulating peripheral blood stem cells are deemed to have 
reached a certain level.  Daily blood tests occur from mobilisation to the date of harvest to allow 
the BMT team to identify the optimal time for harvest.  Stem cells are collected using an apheresis 
machine and this procedure usually occurs on an outpatient basis or in some cases as a day only 
admission.   
 
The amount of blood processed during the harvest depends on the practice of the hospital.  Two 
hospitals use large volume collection and process a minimum of 20 litres of blood during the stem 
cell harvest.  This requires the patient to stay in hospital for an extended period of 6 – 8 hours.  
Most hospitals process a smaller volume of blood and if an inadequate number of stem cells are 
collected, ask the patient to return a couple of days later for a second collection.  Should the 
source of stem cells be from bone marrow then a day only admission to hospital is required as 
bone marrow harvests are performed in the operating theatre under general anaesthesia. 
 
After collection, the stem cells must be transported to an appropriate laboratory for processing.  
Major BMT sites have a laboratory on site.  In NSW eight of the fifteen sites providing BMT have 
laboratory capacity.  However smaller facilities transport the collected stem cells to an off-site for 
processing and storage until they are required.  Transport costs are usually met by the hospital 
sending the stem cells, for example, if Wollongong Hospital sends stem cells to Westmead 
Hospital for processing and storage, Wollongong Hospital meets these costs.  However when 
Westmead Hospital transports the cells back to Wollongong Hospital for the transplant procedure, 
Westmead Hospital pays the transport costs. 
 
We note here that the scope of this study prevented a separate costing of the BMT laboratories 
from being undertaken.  The issue is discussed further in Section 7.4.  
4.1.5 Transplant (including conditioning) 
The patient is admitted prior to transplant for the conditioning process.  Usually a central venous 
catheter will be inserted and the patient will receive several days of chemotherapy and/or 
radiotherapy to destroy bone marrow and cancerous cells and make space in the bone marrow for 
the new stem cells.  Whilst some facilities may provide this stage of the patient journey on an 
outpatient basis, our consultation process found that almost without exception this stage is 
provided on an inpatient basis as part of the “transplantation” admission.   
 
“There are many different types of conditioning therapies used in autologous stem cell 
transplantation but as a general rule they involve between five and eight days of high-dose 
chemotherapy…Occasionally, chemotherapy is given with radiation therapy in the form of total 
body irradiation (TBI).  The kind of conditioning therapy…will depend on several factors 
including the type of disease…age and general health and the type of transplant…” (Daly 
2006:32). 
 
Eden et al. (2007:11) reports that the doses of chemotherapy and/or radiotherapy given to patients 
during conditioning are much stronger than doses given to patients with the same disease who are 
not having a BMT. 
 
The transplant proceeds a couple of days after this conditioning treatment and consists of an 
infusion of the previously collected stem cells.  This occurs in a hospital room rather than an 
operating theatre.  The patient remains in hospital while engraftment occurs – in the period prior to 
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this the patient is at high risk of infection.  A range of drug therapy will be required at this time and 
the patient typically spends 2 - 4 weeks in hospital (Eden et al. 2007). 
   
The mean average length of stay (ALOS) for an adult autologous transplant is 26 days based on 
the data analysis undertaken in this study.  A relatively small proportion of autologous transplant 
patients require admission to ICU during the transplant episode.  
 
Some hospitals are implementing early discharge practices for adult autologous patients, 
particularly those with multiple myeloma.  However, this requires an effective outreach or early 
discharge program to be in place and in practice, occurs only rarely.  These patients are visited 
daily for 10 days.  A major barrier to early discharge is the lack of available week-end outreach 
services.   
4.1.6 Post transplant management 
This stage commences from the end of the transplantation episode.  Clinicians indicated that 
patients are normally seen once or twice per week immediately following transplantation and then 
with decreasing frequency.  If the patient is progressing well he or she will return for review 
monthly for approximately six months, then revert to two-monthly visits for the remainder of the 
twelve month period post transplant.  Practice of course varies in individual cases based on clinical 
judgement.  If the patient has travelled from a rural area to a metropolitan centre for BMT he or she 
will return home, usually at the six week mark, with their referring haematologist or oncologist 
resuming care.  There is a high requirement for prophylactic medication post transplant such as 
anti-viral and anti-biotic medications.   
 
During the post transplant period, patients may be readmitted to hospital.  The most common 
reasons for readmission cited during the consultations included: infection, fever and dehydration.  
In the case of autologous transplants readmissions are often due to the underlying disease.  The 
inpatient data sourced from facilities has provided greater detail about the frequency and cause of 
readmissions and this is discussed in Section 7.2. 
 
The views expressed regarding identifying an end point has been relatively consistent.  Most 
clinicians agreed that the BMT process has usually ended by twelve months post transplant.  
Clinical management by the BMT team may finish earlier than this, with the patient referred back to 
their treating haematologist or oncologist.  This discussion has been important in establishing the 
‘end’ point of the transplant process for costing purposes.   
 
Data provided by hospitals has been analysed in conjunction with the advice received during the 
consultation process to determine when the BMT process will be considered to have commenced 
and ended for costing purposes.  The results of this process is outlined in Section 6. 
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4.2   Paediatric autologous blood and marrow transplant 
The stages of the paediatric autologous BMT patient journey are depicted below in Figure 2. 
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The paediatric patient journey in autologous BMT mirrors the stages of the adult patient journey.  
Whilst there are no major differences in the transplant process, several issues identified during the 
consultation process are discussed for each stage. 
4.2.1 BMT Physician accepts patient for transplant 
During the consultation process, paediatric clinicians pointed out that the patient may not be in 
remission prior to transplant.  This may be related to the growing use of BMT in the management 
of non-malignant disease.  It has also been emphasised that there is a significant amount of 
counselling and discussion that occurs with the patient’s family - and often extended family - prior 
to the decision to transplant being made.  In the case of children the transplant team have 
additional issues to manage.  For example, if the family lives some distance from the treating 
hospital, they may all move to the metropolitan centre for the period of the patient’s hospitalisation.  
This generates various support needs such as accommodation, financial assistance, counselling 
and schooling for siblings.  This support is co-ordinated by the transplant team.  The family often 
requires significant amounts of face to face time with the BMT Physician to understand the 
transplantation process.  A proportion of families choose not to proceed with the transplant after 
this period of discussion and education. 
 
Clinicians working in paediatric transplant centres recognise that time is invested in counselling the 
adult patient and family prior to the patient deciding to proceed to transplant.  However, the 
dependent nature of the child does generate a greater degree of clinical and allied health input at 
this stage of the patient journey.  This view is supported by the volume of outpatient activity 
reported by the paediatric facilities.    
 
4.2.2 Work up 
Where possible the patient work up occurs on an outpatient basis, however certain underlying 
diseases (e.g. acute leukaemia) may mean that the child is already hospitalised and the transplant 
work up occurs on an inpatient basis.  Some patients require additional investigations  
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e.g. neuroblastoma patients, but as this need is driven by the diagnosis it does not materially 
impact the BMT costing process.   
 
Clinicians identified that there is a cost associated with preparing paediatric patients for transplant 
who do not then proceed to transplant.  We recognise that this a legitimate cost and that it has not 
been included in this study.  The reason for its exclusion relates to data availability and the fact 
that the study dataset is based on patients who had received a transplant during the study period.  
As such, it was not possible to identify the range of costs incurred by patients that did not progress 
to transplantation.       
4.2.3 Mobilisation 
The major difference identified in this stage of paediatric autologous BMT is that stem cells are 
often mobilised ‘off the back’ of a course of chemotherapy that is being given to manage the 
underlying disease.  The paediatric patient is more often an inpatient than an outpatient.  The costs 
relating to mobilisation are captured through the inpatient episodes. 
4.2.4 Stem cell harvest (cell processing and storage) 
In the paediatric patient journey the primary source of stem cells is peripheral blood rather than 
bone marrow.  This means that the child may require a visit to operating theatre and a general 
anaesthetic.  The patient is always admitted in this situation.  In children, stem cells may be stored 
for long periods as the course of the underlying disease can be unpredictable.  In addition, it may 
be thought that a second transplant may be indicated at a future time.   
4.2.5 Transplant (including conditioning) 
The conditioning and transplant process is similar for adults - noting that conditioning regimens are 
clearly tailored for each paediatric patient.  Chemotherapy is usually given for several days and the 
patient given two days break prior to the stem cell infusion.  Patients who have myeloblative 
conditioning therapy will be very ill and highly immunosuppressed.  Anecdotal advice suggests the 
average length of stay is longer for children than adults.  An analysis of the data supplied resulted 
in an average length of stay (mean=25 days) that is similar to that for adult autologous transplant 
patients. (Refer to Section 7.1). 
4.2.6 Post transplant management 
Based on feedback provided during consultations, it appears that monitoring in the immediate post 
transplant phase is more frequent in paediatric patients.  Initial discussions suggested that the 
period of post transplant management extends for 24 months.  However, subsequent advice from 
paediatric BMT clinicians has confirmed that 12 months post transplant reflects actual practice.  As 
children often do not have the comorbidities that may generate further readmissions post 
transplant, it is likely that most readmissions are due to the underlying disease as opposed to 
BMT. 
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4.3   Adult allogeneic blood and marrow transplant  
The stages of the adult allogeneic BMT patient journey are depicted below in Figure 3. 
 








































































As many stages of care are similar to the autologous BMT patient journey, these are not restated 
in detail.  Comment is provided on aspects unique to allogeneic BMT. 
 
Clinicians emphasised the differences in the patient journey for autologous and allogeneic patients.  
The varying levels of complexity within the allogeneic transplant group have been consistently 
raised during interview and concerns expressed that the one AR DRG may not accurately capture 
the variations amongst allogeneic transplant patients. 
 
The major determinants of complexity are three-fold: 
• Donor status (related or unrelated; matched or unmatched); 
• Source of stem cells (bone, peripheral blood or cord blood); 
• Acuity of patient’s underlying disease. 
4.3.1 BMT Physician accepts patient for transplant 
Allogeneic transplant uses stem cells donated by another person (a donor).  Bradstock et al. 
(2006:8) describe two types of allogeneic transplants: 
 
“Myeloblative or full allo: the aim is to destroy the patient’s marrow and kill the cancer 
cells.  Non-myeloblative (“mini” allo): the aim is to suppress the patient’s marrow and 
allow the donor cells to grow and attack the cancer cells.  This is the graft-versus-tumour 
effect.” 
 
With use of reduced intensity conditioning regimens in allogeneic transplantation, the age limit has 
increased, permitting the inclusion of older patients.  This patient group may have a range of 
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comorbidities associated with advancing age and/or underlying disease.  The patient is usually in 
remission and must be clinically stable for transplant.  The timing of the transplant is always 
determined by each patient’s underlying condition. 
4.3.2 Tissue typing and virology markers 
The BMT Physician accepts the patient for transplant recognising that tissue typing and virology 
markers are required.  Unless a suitable donor can be found then it is not possible to proceed to 
transplant.  The donor may be related or unrelated; matched or unmatched and the source of stem 
cells may be from peripheral blood, bone marrow or cord blood.  In Australia in 2004, allogeneic 
related donor transplants comprised 56% of all allogeneic transplants and allogeneic unrelated 
donor transplants approximately 44%. (Nivison-Smith, Bradstock and Dodds et al. 2007) 
 
Tissue typing is carried out by the Australian Red Cross.  It is done to check how closely the 
patient’s cells match the potential donor’s cells.  HLA (human leukocyte antigen) markers are 
found on almost all the cells in the body and they are one of the main ways the immune system 
can tell the difference between the patient’s own cells and foreign cells.  The closer the match in 
HLA types, the better the chance of a successful transplant. (Bradstock et al. 2006:25). 
 
Both the donor and patient are tissue typed - this occurs on an outpatient basis.  How the process 
proceeds depends on the nature (related or unrelated) of the donor and the location of the 
donor/and or stem cells.  Whilst the most suitable donor for a stem cell transplant is a fully 
matched (tissue typed) family member, only about one person in three has such a donor.  This 
means that several family members will need to be tissue typed and, if a donor is not found in the 
immediate family, a wider family search and/or unrelated donor search may be needed.  
(Bradstock et al. 2006).  The search for a donor starts with the hospital who works in conjunction 
with the NSW Search Co-ordinator from the Australian Red Cross to try to find a related donor. 
The search may then be passed to the Australian Bone Marrow Donor Registry (ABMDR), should 
an unrelated donor be required. 
 
Costs related to tissue typing have not been separately identified in this study.  It should be 
recognised that costs relating to tissue typing have increased significantly in recent years due to 
the rapid advancements in tissue typing technology.  Hospitals are only funded for Low Resolution 
Class 1 typing.  High Resolution typing is now standard practice.   
4.3.3 Work up 
The work up process is similar to that described for autologous BMT and usually occurs on an 
outpatient basis. 
4.3.4 Donor collection (cell processing and storage) 
The donor collection stage is unique to allogeneic BMT, however the actual process of stem cell 
collection is similar to that described in Section 4.1.4.  If the donor is unrelated, the collection 
process will occur in a separate facility to ensure patient confidentiality.  Most transplants from 
unrelated donors use bone marrow cells.  The donor may be managed as an outpatient or 
admitted.  If for any reason the donor is admitted this is for a maximum of one to two days.  The 
patient receiving the transplant is always admitted prior to donor collection to ensure their 
readiness for conditioning. 
 
If the donor is related and resides within NSW they will normally travel to the hospital where the 
patient will have the transplant.  This means that the donor or family of the transplant recipient will 
normally meet the costs related to the donor’s travel, whilst the hospital stay would normally 
covered by Medicare.  In these cases, it is possible that the NSW Isolated Patients Travel and 
Accommodation Assistance Scheme (IPTAAS) may offer some financial assistance.  IPTAAS is a 
transport and accommodation subsidy scheme that assists people in isolated and rural 
communities to gain access to specialist medical treatment not available in their own area. 
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While donors outside NSW may choose to have their donor collection process in a transplant 
facility in their own state, any donor to a NSW resident who is an Australian resident is eligible to 
access the NSW IPTAAS.    Usually collection of stem cells occurs from peripheral blood and this 
can be done via apheresis as an outpatient.  The hospital treating the transplant recipient then 
arranges for collection and transport of the stem cells.  The costs of this collection are met by the 
NSW based hospital that will provide the transplant. 
 
If the donor is overseas then the Commonwealth funds the costs of stem cell collection and 
transport.  International unrelated donor searches and cell procurement are managed by the 
ABMDR.  If a NSW donor is a match for another international patient requiring a BMT than the 
assessment, work up and stem cell collection is done by a NSW hospital.  The Commonwealth 
reimburses the NSW hospital for these costs up to a maximum of $2000 per patient, (this fee has 
apparently remained the same since 1992).  If however a NSW donor is a match for another 
Australian patient requiring a BMT then the NSW hospital has to assess, work up the donor and 
collect the required stem cells at the cost of the hospital.  According to the ABMDR, in NSW an 
estimated 25 patients per annum (international and national) are admitted for donor collection.    
 
Cord blood donations require specific attention as obtaining these from overseas cord blood banks 
is very expensive, although the cost is usually mostly met by the Commonwealth.  The ABMDR 
currently have a contract with the Commonwealth and a parallel contract with State Cord Blood 
Banks. 
 
It has been suggested during consultation that there are higher costs of storage with allogeneic 
transplant patients – this is related to the use of donor cells that may require more complex 
processing and longer periods of storage.  
4.3.5 Transplant (including conditioning) 
The conditioning process is a critical part of the transplant process.  For allogeneic transplant 
patients this will include chemotherapy and frequently Total Body Irradiation (TBI).  In TBI, 
radiotherapy is given to the entire body to kill cancer cells and suppress the immune system to 
allow the transplanted cells to engraft.  It is usually given in six treatment sessions over three days 
within the Radiation Oncology Department.   
 
Often additional consultations are needed with other sub-specialists to manage any pre-existing 
co-morbidities or anticipated complications.  The most complex type of allograft is that which uses 
a matched unrelated donor.  These patients have a much higher incidence of admission to an 
Intensive Care Unit post transplant and a longer average length of stay.    Figure 3 provides the 
mean ALOS for allogeneic transplants (all types) which is 34 days.  Clinician advice suggests that 
the ALOS for matched unrelated donors is usually substantially longer than that for matched sibling 
donors. 
4.3.6 Post transplant management 
In the case of allogeneic transplants, whilst these patients are customarily followed up for longer 
than twelve months, most of the major costs “post transplant” are likely to occur in the first year 
post BMT.  The post transplant stage follows a similar trajectory to that described for the 
autologous BMT patient recognising that periodic monitoring may extend for at least 24 months. 
 
In the post transplant period, patients may be readmitted to hospital.  The major difference with 
allografts is that the patient may develop Graft versus Host Disease (GVHD).  This is a very 
serious complication of allogeneic BMT.  It occurs when the donor marrow cells begin to engraft 
and multiply and the donor T lymphocytes see the patient’s own body as foreign and try to destroy 
tissues and organs.  The conditioning therapy has suppressed or eliminated the patient’s immune 
system to stop their body rejecting the donor marrow.  Acute GVHD occurs within 100 days after a 
BMT and may be mild through to life threatening.  Chronic GVHD develops more than 100 days 
after BMT.  Chronic GVHD is more common in people whose donor is unrelated or whose marrow 
is not perfectly matched (Bradstock et al. 2006:87-92).   
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The inpatient data sourced from facilities enumerates the major causes of readmission including 
those linked to GVHD.  GVHD arose as a major concern during the consultation process due to the 
extraordinarily high costs of managing both acute and particularly chronic patients with this 
condition.  It was suggested that the multi-drug therapy required by these patients post transplant 
for extended periods, has a significant cost impact, particularly anti-fungal therapy.  Patients will 
also need to be re-immunised twelve months post transplant. 
4.4   Paediatric allogeneic blood and marrow transplant 
The stages of the paediatric allogeneic BMT patient journey are depicted below in Figure 4. 
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Evidence gathered during consultations indicates that a higher proportion of unrelated donor 
transplants are done in paediatric BMT patients.  In addition, the majority of cord blood transplants 
occur in paediatrics and these stem cells take longer to engraft therefore carrying higher risk and 
resulting in a longer length of stay.  The mismatched cord blood transplant is deemed the most 
clinically difficult and costly. 
4.4.1 BMT Physician accepts patient for transplant 
This stage occurs in the same way that has been described for the paediatric autologous BMT 
patient.  However paediatric clinicians have highlighted the diversity of underlying conditions for 
paediatric allograft patients and the fact that for complex non-malignant immunodeficiency or 
metabolic indications, there may be a much higher level of sub-specialty consultant input require 
both pre and post transplant. 
4.4.2 Tissue typing and virology markers 
The tissue typing stage is similar to that described for the adult allogeneic BMT patient journey.  As 
with adults, several family members may be tissue typed to find an appropriate related donor. 
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4.4.3 Work up 
Where possible the patient work up occurs on an outpatient basis.  However as is the case in 
paediatric autologous BMT, certain underlying diseases (e.g. acute leukaemia) may mean that the 
child is already hospitalised and the transplant work up occurs on an inpatient basis.  Anecdotal 
advice suggests that approximately 10% of paediatric patients may not survive or not go into 
remission and therefore do not proceed to transplant.  Clinicians felt that if possible, these costs 
should be captured.  However, as identified in Section 7.4, the study was limited to those patients 
who actually proceeded to transplant.   
4.4.4 Donor collection (cell processing and storage) 
There is no significant difference to the donor collection process except for the fact that the 
majority of donor cells used in paediatric BMT are sourced from bone marrow.  The donor will be 
admitted for this bone marrow harvest.  The transplant recipient is usually an inpatient at the time 
of donor collection. 
 
With children, some stem cells may be stored for future transplants, particularly if their underlying 
disease makes them prone to relapse.  As there are a higher proportion of unrelated transplants in 
children, this can increase demand for additional cell processing measures.  These measures are 
high cost and are met by the treating hospital e.g. CD34 selection which filters out T cells from the 
stem cell graft reducing the risk of GVHD. 
 
A proportion of donor collections will incur additional costs for the transplanting hospital, 
associated with stem cell procurement and transport. 
4.4.5 Transplant (including conditioning) 
The conditioning and transplant occur in the same episode.  As conditioning is usually aggressive 
it is provided on an inpatient basis.  In paediatric allogeneic BMT, children with malignant disease 
usually receive TBI unless they are younger than two years and/or have an existing developmental 
problem. 
 
As the indications for non-myeloblative conditioning are increasing, the potential for a second 
transplant is becoming more common.  Higher risk may be associated with paediatric patients 
having a second transplant.  Data analysis reveals that the mean average length of stay for 
allogeneic paediatric patients is approximately 65 days.  This longer length of stay is due in part to 
the acuity of children who have had intensive chemotherapy prior to transplant (for example whilst 
there has been some improvement in upfront treatment for leukaemia patients, these regimens are 
more intensive so if the child does have to progress to transplant they are often sicker).  The 
higher proportion of unrelated donor transplants and the growing proportion of cord blood 
transplants (the latter taking longer to engraft) also impact on average length of stay.   
4.4.6 Post transplant management 
The paediatric allograft patient is seen up to two to three times per week for the first three months 
post transplant.  Outpatient visits then reduce to weekly after three months post transplant and by 
the six month mark, the child is usually seen once per month.  A variety of allied health 
professionals may be involved during the post transplant period, most often social work, dietetics, 
physiotherapy and occupational therapy.  Whilst the GP is kept informed throughout the course of 
treatment, at the six month mark the BMT Physician actively tries to involve the child’s GP in 
ongoing patient management. 
 
Whilst the immediate transplant related complications occur in the first twelve months post BMT, 
the use of myeloblative conditioning protocols and associated risk of GVHD can lead to 
complications up to 24 months post transplant.  The management of chronic GVHD can be 
particularly resource intensive, even though it occurs less often than in adults.  With children there 
is the added complication of the potential impact of toxicity (from the high dose chemotherapy) on 
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future growth and development e.g. children may require a cardiac echo every two years to 
monitor risk of cardiac failure post high dose chemotherapy.  This leads to a longer period of follow 
up and periodic monitoring for children, with six monthly monitoring often occurring for up to five 
years post transplant, with the patient then reverting to annual review. 
 
Whilst it is recognised that paediatric patients do require follow up for longer periods than adults, 
data analysis demonstrates that the vast majority of related inpatient episodes occur in the 12 
months immediately post transplant (as discussed in Section 7.2). 
 
Another major challenge for paediatric BMT services is transitioning adolescents to adult 
haematology/oncology services.  This is difficult as families often have a long association with their 
respective Children’s Hospital and many are reluctant to transfer their child’s care to an adult 
facility.  Whilst adult patients can often be directed by the BMT Physician back to the referring 
haematologist/oncologist, this is more difficult with children who may have been referred by a 
generalist paediatrician.  This means that paediatric haematologists/oncologists often manage the 
general follow up of children on an ongoing basis until the patient transitions to an adult service.  
 
There continues to be high drug use during the post transplant stage with immunosuppressants, 
antifungals and antibiotics required.  Patients will also need to re re-immunised twelve months post 
transplant.  Most readmissions (if not related to the child’s underlying disease) are due to BMT as 
these patients rarely have comorbidities. 
 
4.5   Differing clinical practices 
In developing the costing methodology it is necessary to distil other clinical issues from the 
consultations that may impact on BMT.  These issues were “reality tested” with the Cost Study 
Reference Group. 
 
Generally there is a high level of consistency in the management of BMT patients.  The Greater 
Metropolitan Clinical Taskforce (GMCT) Bone Marrow Transplant Network has been highly 
effective in ensuring there are agreed indications for BMT and a standardised approach to the 
investigations required during the “work-up” stage pre transplant.  If a patient has had extensive 
treatment of their underlying disease prior to transplant, more tests may be indicated.  There are 
also common treatment protocols. 
 
During the course of consultation very few differences in clinical practice have emerged.  None of 
these differences were seen to have a material impact on this study. 
 
• Extended Family Donor Search: When a related donor is being sought tissue typing 
usually occurs of immediate family members.  One facility pursues extended family 
searches with as many as 20 – 30 persons tissue typed instead of the more common 3 – 4 
persons.  Tissue typing is recognised as an expensive process. 
 
• Mobilisation:  Whilst varying stages of the patient journey occur in the outpatient setting 
only one facility provides outreach services for BMT patients.  This hospital has two Clinical 
Nurse Consultants who manage a cohort of haematology patients, including those who are 
to have, or have had BMT.  These nurses assist suitable patients to manage the 
mobilisation process at home and assist with injections if necessary and collection of blood 
samples to monitor the CD34 cell count and predict the day of stem cell harvest.  They will 
also administer blood and platelet transfusions in the home, should they be indicated. 
 
• Stem Cell Harvest:  A couple of hospitals use large volume collection and process a 
minimum of 20 litres of blood during the stem cell harvest.  This requires the patient to stay 
in hospital (usually an outpatient setting) for an extended period of 6 – 8 hours.  Best 
practice of stem cell collections needs to be validated, that is, large volume versus small 
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volume blood processing.  For hospitals that perform small volume harvests, if inadequate 
stem cells are collected, the patient returns the very next day for another collection. 
 
• Interval from Harvest to Transplant: This period can vary significantly from weeks to 
months and is driven by the patient’s underlying disease.  In children there may be a much 
longer period as stem cells may be required years later, this impacts on cell storage 
capacity and costs. 
 
• Rainy Day Harvest:  Most BMT teams treating adult patients try not to do rainy day 
harvests because of the additional costs and ongoing cell storage issues.  However 
paediatric patients that are expected to have an allogeneic transplant have their own 
peripheral blood stem cells collected and these are routinely processed and stored as 
backup if the allogeneic transplant fails. 
 
• Use of PET scan: Some clinicians advise that a PET (Positron Emission Tomography) 
scan is completed pre and post transplant for most lymphoma patients.  (Patients are sent 
to either Royal Prince Alfred or Liverpool Hospital). 
 
• Post Transplant Care:  A few hospitals are trying to implement early discharge practices 
for adult autologous patients, particularly those with multiple myeloma, (there are strict 
criteria for eligibility for early discharge).  In practice this occurs rarely and is only possible 
where there is an effective outreach or early discharge program.  These patients are visited 
daily for 10 days; a major barrier to early discharge is the lack of week-end outreach 
services. 
 
• Extracorporeal Phosphoresis: ECP may be a treatment of choice in patients with GVHD.  
Treatment occurs on consecutive days every two weeks for up to three months.  Each 
treatment is costly.  ECP in Australia is currently only accessible in Victoria. 
 
4.6   Clinical issues that impact on BMT costs  
Most clinical issues relevant in autologous and allogeneic BMT have been covered during the 
description of the respective adult and paediatric patient journeys.  Some clinical issues were 
identified that may have an impact on the cost of providing BMT services and are therefore 
outlined here.   
 
Firstly, it was noted that the growth in technology for tissue typing has increased the accessibility 
and utility of extended tissue typing (high resolution or molecular tissue typing).  The indication for 
high resolution typing (HR Class 1) is becoming more standard and has cost implications.  
 
The cost of donor stem cell procurement is borne by the transplanting hospital for related donors 
that reside within Australia.  This can result in travel costs to collect stem cells and lost productivity 
or staff time as highly trained nursing personnel are those most often sent from hospitals to collect 
stem cells. 
 
Haematology/Oncology Units in large rural centres often meet the costs of work-up and the costs 
of post transplant management (particularly drug costs) even though the transplant episode may 
not have occurred in this facility.  This issue was raised particularly by Newcastle Mater and John 
Hunter Hospital who send all allogeneic transplant patients to Sydney.  This occurs also in smaller 
BMT centres that may only do autografts yet assist with pre and post management of patients 
requiring allografts.  NSW Health policy currently states that after one year post treatment the cost 
of drugs will be met by the patient’s area of residence.     
 
In paediatric care, the transplant team often needs to manage the entire family through the 
transplant process.  This requires significant time from senior clinicians and allied health 
personnel.  Paediatric cancer patients tend to have ongoing involvement of their paediatric 
oncologist or haematologist and there are challenges in transitioning these patients to adult 
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services.  This is driving an emerging trend to ‘shared care models’ between paediatric oncologists 
and adult oncologists.   
 
In the case of Sydney Children’s Hospital (SCH), children sometimes travel from South Australia 
for a BMT.  In these cases, SCH may only meet a proportion of the costs because the pre and post 
transplant management occurs in the child’s home state.  The converse experience occurs with 
children referred from the ACT, as all stages of the patient journey are managed at SCH. 
 
The development of pre transplant genetics may extend the potential for unrelated donor 
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5 Data collection and the development of a BMT study dataset 
The primary aim of this project was to develop cost estimates for the various care processes 
involved in the delivery of BMT services.  As such, it was important to obtain data relating to the 
cost of BMT episodes, related inpatient episodes and a range of outpatient BMT services.   
 
The scope and timeframe of the study precluded a prospective costing study being undertaken.  
Instead, the data collection protocol developed for the study was based around retrospective data 
available from hospitals that provide BMT services.   
 
Each of the eight hospitals with clinical cost data was contacted to discuss their capacity to provide 
data.  Three types of data were potentially required: 
• Costs of inpatient and outpatient services provided to BMT patients; 
• Service utilisation data in relation to outpatient services provided to BMT patients;    
• Clinical information comprising diagnosis and procedure data for BMT inpatient episodes. 
 
The study team worked with each facility to obtain the range of required information related to BMT 
services.  This process took many weeks and often involved several iterations of data being 
provided to the study team.  During this process, several methodological issues arose in relation to 
the structure of the study dataset and the proposed data analysis approach.  The key issues and 
the agreed outcome are discussed briefly below.   
5.1   Inpatient cost data - clinical costing versus cost modelling data  
This issue was identified in our project proposal and subsequently discussed in our Interim Report.  
NSW public hospitals routinely participate in an annual hospital inpatient cost data collection that 
involves an annual submission of cost data to NSW Health.  The outcome of this process is the 
development of AR-DRG costs for separations that occurred in the previous financial year. 
 
Hospitals rely on two basic types of costing systems to produce data for this annual hospital cost 
data collection.  Firstly, an increasing number of hospitals have implemented what are referred to 
as ‘clinical costing’ systems.  Other hospitals rely on what is referred to as a ‘cost modelling’ 
approach to producing costing information.   
 
In the current study, we are aiming to produce costs for two types of inpatient episode: 
• BMT episodes;  
• Other inpatient episodes related to the BMT treatment.   
 
In the context of this study, there is an important difference in the capacity to use data extracted 
from each type of costing system.  Clinical costing systems produce a cost for individual episodes 
of care by costing the various elements of care provided during an episode.  These costs can be 
analysed individually or rolled up to produce an average AR-DRG cost.  Importantly, it is 
straightforward to identify and obtain cost data for related inpatient episodes provided to BMT 
patients.   
 
Cost modelling systems produce cost estimates through a ‘top down’ process in which costs are 
allocated to AR-DRGs using a set of existing relativities.  The end result of the cost modelling 
process is an average cost for each AR-DRG.  The process does not produce costs at the 
individual episode level.   
 
The key issue in the context of this study is that cost modelling systems do not allow the costs of 
BMT related episodes to be identified.  Data from these hospitals can only be used to analyse the 
cost of BMT episodes.  This is because a BMT related episode could be assigned to virtually any 
AR-DRG.  BMT patients would comprise only a small proportion of the patients contributing data to 
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that AR-DRG.  As such, the average AR-DRG cost would be meaningless in terms of 
understanding costs of episodes related to the BMT.   
 
Given the limitation of data extracted from cost modelling systems, it was agreed to utilise data 
from hospitals with clinical costing systems as the primary data source for inpatient cost data for 
the study.  Clinical costing data were available from eight of the fifteen hospitals that provide BMT 
services.  These facilities therefore formed the basis of the study dataset.       
 
Importantly, of the six hospitals that undertake allogeneic BMT, Royal Prince Alfred Hospital is the 
only facility that could not provide clinical costing data.  As noted earlier, based on the average 
number of BMT episodes currently undertaken in NSW annually for adults, the study captured data 
on 90.1% of allogeneic transplants and 58.1% of autologous transplants.  We are confident that 
this is a representative sample of BMT episodes across NSW. 
 
Table 3 below shows fifteen BMT hospitals and which of these have the type of costing system in 
use during the study period at each of the BMT hospitals.  
Table 3:  Types of costing systems in NSW BMT hospitals 
Hospital  Type of Costing System  Type of BMT Provided 
St Vincent's Hospital*  Clinical costing  Allogeneic and autologous 
Westmead Hospital* Clinical costing Allogeneic and autologous 
Royal North Shore Hospital* Clinical costing Allogeneic and autologous 
Royal Prince Alfred Hospital Cost modelling Allogeneic and autologous 
Sydney Children's Hospital* Clinical costing Allogeneic and autologous 
Children's Hospital Westmead* Clinical costing Allogeneic and autologous 
Concord Hospital Cost modelling Autologous 
Gosford Hospital Cost modelling Autologous 
John Hunter Hospital Cost modelling Autologous 
Liverpool Hospital Cost modelling Autologous 
Nepean Hospital* Clinical costing Autologous 
Newcastle Mater Hospital Cost modelling Autologous 
Prince of Wales Hospital* Clinical costing Autologous 
St George Hospital* Clinical costing Autologous 
Wollongong Hospital Cost modelling Autologous 
   
* Contributed data to the study dataset 
5.2   Use of costing data from a different number of years 
As noted, eight hospitals contributed data to the study dataset.  These hospitals were able to 
provide data for one, two or three financial years.  The differing capacity to provide data between 
hospitals was largely determined by the period of time that each hospital has been operating a 
clinical costing system.     
 
Four hospitals provided three years of data (2004/05,2005/06 and 2006/07), one hospital provided 
two years of data (2005/06 and 2006/07) and three hospitals provided one year of cost data 
(2006/07) as shown in Table 4 below.  It was agreed not to consider using data from periods 
earlier than 2004/05 because of the cost implications of changes that may have occurred in clinical 
practice since that time.  
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Table 4:  Available inpatient cost data from hospitals in study dataset 
Hospital Available Inpatient Cost Data 
St Vincent’s Hospital* 2005/06, 2006/07 
Westmead Hospital  2006/07 
Royal North Shore Hospital  2006/07 
Prince of Wales Hospital 2004/05, 2005/06, 2006/07 
St George Hospital 2004/05, 2005/06, 2006/07 
Nepean Hospital  2006/07 
Sydney Children’s Hospital 2004/05, 2005/06, 2006/07 
Children’s Hospital Westmead 2004/05, 2005/06, 2006/07 
* St Vincent’s also provided clinical data for 2007/08 
 
A methodological issue that arose was whether to include data for a different time period from 
different hospitals in the study dataset.  At one level, it could be argued that a simple approach 
would be to limit the study dataset to one year.  However, BMT services are clearly a high cost/low 
volume activity.  As such, obtaining a sufficient sample size to derive reliable cost estimates was a 
critical concern for the study.   
 
Further, the hospitals that could provide three years of data tended also to be hospitals that 
provided a small number of BMT episodes on an annual basis.  In some cases, it would not have 
been possible to produce meaningful cost estimates at the hospital level based on only one year’s 
data.     
 
For this reason, it was decided to include all available data from each facility between 2004/05 and 
2006/07.  Data from 2004/05 and 2005/06 were inflated to 2006/07 terms using rates provided by 
the NSW Department of Health.  In adopting this approach, it was important to ensure that 
hospital’s with two or three year’s data were not over represented when calculating average BMT 
costs across multiple hospitals.   
 
The method adopted for the analysis was to calculate any multiple hospital average cost as the 
average cost of those hospitals that contributed to that average weighted by each hospital’s 
average number of BMT episodes per year.  Clearly, it was not necessary to apply this weighting 
when averages were being calculated for individual hospitals.  
 
A final point is worth noting in relation to this issue.  As both of the paediatric facilities were able to 
provide three years of cost data, any averages calculated only for these facilities will not be 
affected by the weighting approach.  Similarly, for the three adult hospitals, as two provided one 
year’s data and one provided two year’s data, the impact of the weighting approach will be 
minimal.  The only circumstance when the weighting will have an effect is if combined average 
costs are produced across both paediatric and adult hospitals.    
 
Overall, in our view, the approach adopted represents the most appropriate method to maximise 
the available data whilst ensuring that each hospital is appropriately represented in the calculation 
of average costs. 
5.3   Collection of inpatient cost data 
As noted, the primary source of inpatient cost data for the study was clinical cost data produced by 
each of the eight hospitals as part of the NSW Health annual hospital cost data collection process.   
 
Each hospital was asked to provide a dataset that contained episode level cost data for the 
following two types of inpatient episodes: 
• BMT episodes where the separation date was in the financial year/s being costed by that 
hospital; 
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• Any other inpatient episode for these patients that occurred in any of the financial year/s for 
which cost data were being provided by that hospital.        
 
Relevant details such as episode dates and AR-DRG together with cost data for each episode 
broken into the following cost buckets was provided by each hospital:  
• Clinical (medical) costs 
• Ward (nursing) costs 
• Allied health costs 
• Pharmacy costs 
• Intensive care unit costs 
• Imaging costs 
• Pathology costs 
• Operating room costs 
• Emergency department costs 
• On costs 
• Depreciation costs 
• Total costs 
 
As outlined in Section 6.1, on receipt of each dataset, a range of edit checks were undertaken to 
identify any potential anomalies in the data.  Where necessary, hospitals were contacted to clarify 
issues and any necessary re-submisson of data was arranged.  
5.3.1 Pharmacy cost data 
The importance of identifying the cost of pharmaceuticals was raised at each consultation as it 
represents a significant proportion of both inpatient and outpatient BMT services.   
 
For inpatients, sites provided patient level drug costs for patients in the study cohort.  An issue was 
identified by hospital pharmacists and other staff about the capacity to cost ‘imprest’ drugs (drugs 
not dispensed to individual patients).  In costing systems, a share of the cost of these drugs is 
allocated to BMT patients on a per diem basis using AR-DRG based relative value scales.  This 
issue was discussed with each site’s costing staff (and pharmacy staff where necessary), during 
the data preparation process.  As a result of these discussions, we are confident that the cost of 
imprest drugs has been accurately allocated to BMT patients.   
 
In relation to outpatients, it was equally important to obtain patient level costs for drugs dispensed 
to BMT patients.  In this case, the issue of imprest drugs did not arise as all outpatient drugs are 
dispensed on an individual patient basis.  Here, an effort has been made to identify drugs that fall 
under the Section 100 scheme as well as any drugs that are dispensed through the PBS.   
 
At an initial meeting of the Study Reference Group, it was suggested that the process of costing 
BMT drugs may be expedited by identifying the top 10 to 20 high cost BMT drugs.  To this end, 
several hospitals were able to provide separate cost data on the high volume drugs dispensed to 
BMT patients.  This information has been compiled and is presented in Section 7.3.2. 
5.4   Collection of inpatient clinical data 
Each of the eight hospitals provided ICD 10 diagnosis and procedure data for each of the years for 
which financial data were provided.  In one case, clinical data were provided for a year (2007/08) 
for which cost data were not available.  The clinical data included several (ranging from 3 to 10) 
ICD 10 diagnoses codes and one procedure code.   
 
These data were used for several purposes in the preparatory analysis process as discussed in 
Section 6.2.  Most notably, this information provided an important clinical profile of inpatient 
services provided to BMT patients before and after their transplantation episode.  
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5.5   Collection of outpatient data 
During the consultation process, BMT clinicians and other staff were asked to provide a profile of 
the range of pre and post transplantation services that are provided to BMT patients on an 
outpatient basis.  Some differences were identified in models of care between hospitals that impact 
on the type and level of outpatient services that are typically provided.  
 
The availability of outpatient activity and corresponding cost data was substantially less than for 
inpatient services.  This finding was expected given that the systems required to routinely generate 
this information are not generally in place.  This issue was flagged at the outset of the study.  It 
was agreed that where data were not available, cost estimates would be developed based on a 
combination of service utilisation and the best available financial information.  
 
A study protocol was developed and hospital’s asked to provide the details shown in Table 5 below 
in relation to outpatient activity: 
Table 5:  Outpatient data collection 
Outpatient Clinics Drugs Pathology  
MRN MRN MRN 
Date of service Date dispensed Date of test 
Duration of service Drug name Test type  
Clinic description Drug cost Cost of test 
Clinician seen   
Cost of service   
   
Imaging  Radiotherapy Other Outpatient Services 
MRN MRN MRN 
Date of test Date of service Date of service 
Test type  Cost of service Description of service 
Cost of test  Cost of service 
 
In practice, some hospitals were able to provide costed activity data for most of the outpatient 
services identified above.  However, most hospitals were able to provide activity data for only 
some of the above services and very few hospitals were able to provide detailed cost data.   
 
The exception to this was in the area of drugs where all but one hospital, (that provides a low 
volume of adult autologous transplants), was able to provide the required drug data.    This is 
important as it represents the most expensive element of BMT outpatient services.  For the 
remaining services, cost estimates were developed base on the data that were available in each 
area.  The results are provided in Section 7.3.  We stress that the areas in which data were not 
available represent a relatively small component of the total cost of providing BMT services.   
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5.6   Data quality  
We have accepted data provided to us by each hospital as being both accurate and representing 
the best data available for the purposes of the study.  In our view, the quality of the data provided 
by hospitals is of a high standard.  We have not been given any reason to form the view that the 
financial information is not an accurate reflection of each hospital’s current cost structures.   
 
The validity of the inpatient data is supported by the fact that the inpatient cost data are costed as 
part of the NSW Department of Health’s Program and Product Data Collection.   Further, each 
hospital is required to account for all expenses by an identified Program in the Unaudited Annual 
Return and an appropriate reconciliation is undertaken as part of this process.   
 
We recognise that some of the outpatient cost estimates are not as robust as the equivalent 
inpatient costs.  This is a function of the fact that outpatient costing systems and processes are not 
as sophisticated as inpatient systems.  However, we believe that these results are more than 
adequate for the purposes of the current study and note that these estimates represent a relatively 
small component of the total cost of BMT services.   
 
Centre for Health Service Development 
 
Page 34    Final Report: A Costing Study of Blood & Marrow Transplantation Services in NSW 
 
6 Preparatory data analysis 
Prior to the analysis, a series of preparatory data analysis tasks were undertaken.  An outline of 
these tasks is provided below.  The end result was an edited study dataset that formed the basis of 
the costing analysis.   
6.1   Data edit checking  
On receipt of data from each hospital, a set of edit checks were undertaken to identify systematic 
data inconsistencies.  In several cases, anomalies were detected and revised data were submitted 
by the hospital concerned.     
 
In addition, an edit check was undertaken to identify any individual episodes that appeared to be 
outliers from a cost perspective.  This process identified considerable variation in the average cost 
of both transplant and related inpatient episodes.  Where individual episodes were significantly 
higher than the average, advice was sought from the hospital about whether to include these 
episodes in the study dataset.  As a result, no individual episode was excluded from the analysis 
on the basis of cost.   
6.2   Identifying inpatient episodes that are related to the BMT 
An important methodological issue was to determine which non-BMT inpatient episodes to include 
in the costing analysis.  A total of 3,663 non-BMT inpatient episodes were submitted by the eight 
hospitals.  The number of episodes by hospital, BMT type and pre and post transplant episode is 
shown in Table 6 below.  

















St Vincent’s Hospital 29 302 204 164 
Westmead Hospital  48 51 32 16 
Royal North Shore Hospital  30 15 66 23 
Prince of Wales Hospital 0 0 243 155 
St George Hospital 0 0 133 32 
Nepean Hospital  0 0 53 9 
Sydney Children’s Hospital 303 189 312 204 
Children’s Hospital Westmead 180 106 453 282 
Total 590 663 1496 885 
 
This issue essentially revolves around forming a clinical view about whether an inpatient episode is 
sufficiently related to the BMT to be included in the analysis of BMT costs.  Ideally, each inpatient 
episode could be considered individually and a decision made about whether it should be included.  
In practice, however, this would require a detailed clinical review that was clearly beyond the scope 
of this study.  Instead, we were guided by the clinical consultation process and a data analysis of 
inpatient episodes submitted by the eight hospitals.     
 
During the clinical consultation (refer Section 2), advice was sought in relation to patterns of clinical 
care and the number of inpatient episodes that would typically occur before and after a 
transplantation episode.   
 
In summary, the predominant view was that for adult allogeneic transplant patients, most pre-
transplant related episodes occur in a 30-60 day window prior to the transplant.  Following the 
transplant episode, most related acute admissions will occur within a twelve month period.  
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For paediatric allogeneic transplants, it was suggested that children are managed by the transplant 
team from the time a transplant is indicated.  It was suggested that in some cases (such as 
neuroblastoma), this would occur from the point of initial diagnosis, even though the treatment 
pathway may extend for some time prior to transplant.  This philosophy was quite different to that 
found in adult hospitals.  A key difference appears to be that with adults, virtually all patients are 
referred to the transplant physician from a haematologist or oncologist who was already treating 
the patient’s underlying disease.   
 
As children do not usually have the comorbidities of adults, related inpatient episodes post 
transplant are usually due to the underlying disease or the BMT and occur most frequently in the 
12 months post transplant.  Whilst children are followed up for much longer than 12 months, 
particularly to identify the effects of chemotherapy toxicity on their development, this usually occurs 
relatively infrequently on an outpatient basis. 
 
In relation to autologous BMT’s, the adult services indicated that most services are typically 
provided in the 30 days prior to transplant to ensure the patient’s readiness for transplant.  Work 
up, mobilisation and stem cell harvest and processing primarily occur on an outpatient basis.  
However, inpatient admissions do occur for mobilisation in some cases in the two weeks prior to 
transplant.  In terms of post-transplant services, the clinicians suggested that most admissions 
occur within a three month period.  Following this, the patient is referred back to their original 
treating haematologist/oncologist.   
 
For paediatric autologous transplants, our advice was that related inpatient episodes do occur pre 
transplant particularly for mobilisation and stem cell harvest (the latter requires general 
anaesthetic).  No distinct pattern of activity was identified during the consultation process.  Post 
transplant most related readmissions and/or outpatient services were reported as occurring in a 
one to six months period.  
 
Following receipt of data from each hospital, a detailed analysis of transplant episodes and other 
inpatient episodes was undertaken.  The analysis examined the frequency of days by time periods 
before and after a BMT episode.  In addition, the ICD 10 diagnoses associated with these 
episodes were analysed to assess the likelihood that an episode was related to the BMT.   
 
The following key findings emerged from this analysis: 
• Across all hospitals, the vast majority of days occurred during the BMT episode;  
• For adult hospitals, the vast majority of non-BMT inpatient days occurred within 60 days prior 
to and 90 days following the BMT episode; 
• For paediatric hospitals, although a larger proportion of non-BMT inpatient days occurred prior 
to 60 days pre transplant than did for the adult hospitals a large majority of days still occurred 
within 60 days prior to and 90 days following the BMT episode;   
• There was lower incidence of inpatient episodes associated with GVHD that had been 
expected; 
• The majority of post transplant inpatient episodes related to infections than were demonstrably 
related to the BMT. 
 
Based on the clinical consultation and data analysis, we formed the view that at one level, this 
issue can perhaps be considered as a philosophical issue about the point at which BMT services 
commence.  There were clearly differing views on this matter between clinicians and between adult 
and paediatric services.   
 
In the context of this study, we would stress that our objective was simply to develop a business 
rule that would allow BMT costs to be reasonably estimated.  On this basis, the business rule 
below was developed in relation to the inclusion of non-BMT inpatient episodes for both adult and 




Centre for Health Service Development 
 
Page 36    Final Report: A Costing Study of Blood & Marrow Transplantation Services in NSW 
Business rule for inclusion of inpatient episodes in the costing analysis 
 
The following inpatient episodes were excluded from the costing analysis: 
 
• episodes  where the separation date was more than 60 days earlier than the admission date 
for the BMT episode; and 
• episodes where both the admission date was more than 90 days after the separation date from 
the BMT episode and the diagnoses for the episode were not related to the BMT; and  
• any episodes where the admission date was more than 12 months after the separation date 
from the BMT. 
 
Overall, it is our view that the business rule we have applied is appropriate in the context of the 
current study.  
6.3   Grouping of related inpatient episodes for costing purposes 
This is a technical issue that is outlined here as it was considered during the preparatory analysis 
phase of the project.   
 
Inpatient episodes related to a BMT may occur in the same year as the BMT or in a previous or 
subsequent year.  That is, for a given year, the estimated cost of related BMT episodes will 
include:  
 
• Inpatient episodes related to a BMT that occurred in that year; 
• Inpatient episodes related to a BMT that occurred in the previous year; 
• Inpatient episodes related to a BMT that occurred in the following year. 
 
For example, 2005/06 datasets will include related inpatient episodes where the transplant 
occurred in 2004/05 but will also include related inpatient episodes where the transplant did not 
occur until 2006/07.  The same applies to both 2005/06 and 2006/07 datasets.   
 
This data structure needs to be borne in mind when looking at results in this report that relate to 
cost estimates for a particular year.  That is, we have reported the cost of related inpatients 
episodes that occurred in a particular year regardless of when that transplant occurred.  In our 
view, it is sensible to produce annual cost estimates in this way as it allows for planning and 
funding processes to be based around the annual cost of BMT activity.   
 
A related issue arises as we have used data from one, two and three years from different 
hospitals.  Specifically, hospitals that have provided three years data will have provided a complete 
dataset for 2005/06 (i.e. the middle year).  A proportion of prior episodes that occurred in 2003/04 
and a proportion of subsequent episodes that occurred in 2007/08 will not be included.  Hospitals 
that have provided one year of data will not include a proportion of episodes from both the previous 
(2004/05) and subsequent year (2007/08).  The hospital that provided two years data (2005/06 and 
2006/07) will not include a proportion of data from 2004/05 and 2007/08.  The overall effect is that 
the hospitals with more than one year’s data will be missing a smaller proportion of related 
inpatient episode data.  We have carefully considered this issue in the context of its likely impact 
on the study results.  Our proposed approach is not to make any adjustments in the primary cost 
results that are reported.  
6.4   Treatment of incomplete inpatient episodes for costing purposes 
The study dataset comprised three subsets of episodes as shown in Figure 5 below.  It is 
theoretically possible that episodes that commenced prior to the study start may not have ended 
by the study end.  However, we are aware of no such episodes occurring at any of the study 
hospitals.  
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Study Start Study End  
 
For costing purposes, it was necessary to apply a set of business rules regarding the treatment of 
the small number of inpatient episodes that straddled the study period.  This was necessary for 
both BMT episodes and related inpatient episodes.  Further, it was necessary regardless of 
whether data were provided for a one, two or three year period.   
 
In this study, three types of cost results are of primary interest: 
 
• Episode level costs such as the average cost per allogeneic BMT; 
 
• Per diem costs such as the average daily cost of an allogeneic transplant patient; 
 
• Annual costs such as total expenditure on BMT in a financial year by a given hospital.  
 
No cost data were available for episodes in the starting cohort.  For this reason it was necessary to 
exclude them from all analyses.  This will not impact on the calculation of episode level or per diem 
costs other than by slightly reducing the overall sample size.  However, it will have a small impact 
on the calculation of annual costs for the study period. 
 
The remaining two episode subsets were included in the analyses as follows: 
 
The complete cohort 
 
These are episodes that started and ended within the study period.  Cost data were available for 
the whole episode.  These episodes were used in all analyses.  Importantly, this subset represents 
the vast majority of episodes in the study dataset.  
 
The ending cohort 
 
These are episodes that commenced prior to study start but ended during the study period.  Cost 
data were available for days after the study start but are not available for days prior to the study 
start.   With this subset, episodes where 90% or more of the episode fell in the study period were 
used to calculate average per diem and average episode costs.  
 
As shown in Table 7 below, the ending episodes represent only a small percentage of all episodes 
and therefore only a minor proportion of costs have been estimated.  This proportion is slightly 
higher for hospitals which provided a single year of inpatient data (Nepean Hospital, Royal North 
Shore Hospital and Westmead Hospital). 
 
Annual costs were then calculated by multiplying the average episode costs by the number of 
episodes per year.  This is equivalent to estimating the costs of ending episodes using the 
complete episodes. 
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St Vincent's Hospital 98.0% 2.0% 
Westmead Hospital 89.2% 10.8% 
Royal North Shore Hospital 92.9% 7.1% 
Prince of Wales Hospital 96.4% 3.6% 
Nepean Hospital 91.7% 8.3% 
St George Hospital 100.0% 0.0% 
Sydney Children's 96.8% 3.2% 
Children's Hospital Westmead 99.0% 1.0% 
All 95.8% 4.2% 
 
 
6.5   Inclusion of outpatient data in the study dataset 
The advice received during the clinical consultation process enabled a profile to be developed of 
typical patterns of outpatient care for BMT services (see Section 4).  Whilst minor variations were 
noted between hospitals, an overall high level of consistency was reported.   
 
For the costing process, a business rule was required around the period before and after 
transplantation that would determine which outpatient data would be included in the study dataset.  
This issue was discussed with the Study Reference Group and the NSW BMT Service Plan 
Development Working Party.  It was agreed that subject to an analysis of the relevant data, a 
period of twelve months would be applied.  The data received by hospitals confirmed that the vast 
majority of outpatient activity did occur within a twelve month period.   
 
The study dataset for outpatient services was therefore developed on this basis.  In applying this 
business rule, we recognise that the data provided by hospitals will not include all outpatient 
services for a twelve month period for all transplant patients.  The same issues arise for outpatient 
services that were discussed in relation to related inpatient episodes in Section 6.3.   
 
Again, we have considered this issue in the context of its likely impact on the study results.  Our 
proposed approach is not to make any adjustments in the primary cost results that are reported.  
We have estimated a cost for that proportion of activity that is not available from the sites that have 
one and two year’s data and have included this in the results reported in Section 7.3. 
6.6   The final study data set 
After the adjustments described above, the final study dataset comprised 16,960 records made up 
of: 
 
• 508 BMT episodes 
• 2,258 related inpatient episodes 
• 7,485 outpatient medical, nursing and allied health clinic occasions of service 
• 6,272 outpatient dispensed drugs 
• 435 other outpatient treatments.  
 
This dataset formed the basis of the cost estimates that are presented in the following section.  
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7 Analysis and results 
As noted earlier, the project brief required the following questions to be addressed in relation to the 
cost of providing BMT services in NSW: 
• What is the average per patient cost of autologous and allogeneic BMT? 
• What is the breakdown of costs for each of these, in terms of the inpatient and ambulatory 
phase of treatment? 
• Are there available costings from other States in Australia with which to compare, and if 
significantly different, why? 
• What proportion of BMT costs do pharmaceuticals represent? 
• What, if any, difference is there between costs for adult patients and paediatric BMT? 
• What are the financial implications of the projected increase in BMT activity in NSW by 2011? 
 
The study dataset contained a large volume of data with which to consider these questions.  The 
results are set out below as follows: 
 
Section 7.1 - Presents a profile and cost results for the 508 BMT transplant episodes in the study 
 dataset; 
 
Section 7.2 - Presents a profile and cost results for the 2,258 related inpatient episodes in the    
study dataset; 
  
Section 7.3 - Presents a profile and related results for the 14,192 outpatient records included in the 
study dataset; 
 
Section 7.4 - Discusses a set of costing issues that were identified during the study.  
 
Section 7.5 - Presents a set of cost projections for NSW BMT services based on activity projection 
data provided by the NSW Department of Health  
 
Section 7.6 - Combines all of the study results to present an overall profile of the cost of BMT 
          services in NSW. 
7.1  BMT episodes 
A total of 508 transplant episodes were included in the BMT inpatient study dataset.  We are 
confident this sample of transplant episodes is large enough to base the cost estimates that follow.  
As discussed in Section 5.2, we have adjusted the data to reflect the fact that data from different 
periods have been included in the dataset.  These adjustments are noted in the remainder of this 
section where relevant.     
 
The breakdown of the 508 episodes is shown in Table 8 below.  This table shows episodes for all 
years for which data were provided by the eight hospitals.  Of these 508 episodes, 60% were 
autologous and 40% allogeneic.  The ratio of autologous to allogeneic transplants is consistent 
with levels of activity reported elsewhere.  
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Table 8:  Number of transplant episodes in the study dataset 
Hospital Autologous Allogeneic Total 
Transplant 
Episodes 
Number of Years 
of Source Data 
St Vincent's Hospital 45 53 98 2 
Westmead Hospital 26 57 83 1 
Royal North Shore Hospital 39 17 56 1 
Prince of Wales Hospital 28 0 28 3 
St George Hospital 32 0 32 3 
Nepean Hospital 12 0 12 1 
Sydney Children's Hospital 48 45 93 3 
Children's Hospital Westmead 52 54 106 3 
Total 282 226 508 17 
7.1.1 Allogeneic transplant episodes 
Table 9 below presents length of stay data for the 226 allogeneic transplant episodes from the five 
hospitals that contributed to the study dataset.     
Table 9:  Allogeneic transplants - average length of stay  









St Vincent's Hospital 53 35 26 19 177 
Westmead Hospital 57 37 31 4 90 
Royal North Shore Hospital 17 23 21 16 35 
Adult Hospitals* 127 34 28 4 177 
            
Sydney Children's Hospital 45 54 42 4 202 
Children's Hospital Westmead 54 82 62 16 254 
Paediatric Hospitals 99 69.49 47 4 254 
*Has been weighted to adjust for the number of year’s data submitted by each hospital. 
 
There is considerable variation in length of stay both within and between facilities which reflects 
variations in the clinical profile of patients.  The considerably longer length of stay at the two 
paediatric facilities is notable but is consistent with the issues raised during the clinical consultation 
and discussed in Section 4.4.  The longer length of stay at the paediatric hospitals confirms the 
view that the conditioning regime for children can be aggressive and is predominantly undertaken 
on an inpatient process and reflects the longer engraftment period associated with cord blood 
transplants. 
 
Table 10 below shows the costs of allogeneic BMTs from the five hospitals that contributed to the 
study dataset.  The most notable result is that for each hospital there is a large variation in cost 
between the least and most expensive episode.  This finding was supported by the views 
expressed during the consultation about the clinical variation between individual BMT patients.   
 
For this reason, it is sensible to examine the median, as well as the mean cost.  For the adult 
hospitals, this shows a consistent result between the two hospitals that undertake unrelated 
transplants (St Vincent’s and Westmead) and a slightly lower cost for Royal North Shore Hospital 
which undertakes only sibling related allogeneic transplants.  The lower average cost per 
allogeneic transplant at Royal North Shore Hospital was expected.  For the paediatric hospitals, 
the median cost is considerably higher that for the adult hospitals, but quite similar between the 
two hospitals.   
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St Vincent's Hospital $85,853 $68,303 $56,404 $51,886 $403,549 
Westmead Hospital $92,440 $70,120 $73,816 $11,461 $402,035 
Royal North Shore Hospital# $65,368 $62,589 $22,730 $14,551 $116,207 
Adult Hospitals* $86,124 $68,367 $61,942 $11,461 $403,549 
            
Sydney Children's Hospital $144,184 $106,050 $125,161 $9,181 $679,370 
Children's Hospital Westmead $176,955 $115,956 $135,892 $41,571 $626,656 
Paediatric Hospitals $161,986 $110,610 $131,320 $9,181 $679,370 
* Has been weighted to adjust for the number of year’s data submitted by each hospital. 
# Royal North Shore does not undertake unrelated BMTs. 
 
As total episode costs are largely a function of length of stay, it is useful to examine costs on a per 
diem basis.  Table 11 shows per diem costs for allogeneic transplants for the five hospitals that 
contributed to the study dataset.  Again, for all hospitals, the considerable variation between the 
least and most expensive patient is consistent with comments provided during the clinical 
consultation.  However, the median per diem cost is quite consistent across the five hospitals.  The 
significant difference between adult and paediatric facilities is not evident here.  Royal North Shore 
Hospital has a slightly higher median per diem cost than the other hospitals.  
 
Table 11:  Allogeneic transplants - per diem costs 








St Vincent's Hospital $2,582 $2,566 $284 $2,132 $4,090 
Westmead Hospital $2,408 $2,372 $921 $782 $5,507 
Royal North Shore Hospital# $2,842 $2,956 $638 $728 $3,498 
Adult Hospitals* $2,527 $2,522 $695 $728 $5,507 
            
Sydney Children's Hospital $2,616 $2,587 $1,017 $1,358 $7,098 
Children's Hospital Westmead $2,340 $2,325 $467 $904 $3,575 
Paediatric Hospitals $2,466 $2,447 $776 $904 $7,098 
* Has been weighted to adjust for the number of year’s data submitted by each hospital. 
** Royal North Shore does not undertake unrelated BMTs. 
 
Table 12 below shows the average cost of each cost bucket across all five hospitals that 
contributed episodes to the study dataset.  The cost buckets are the standard ‘buckets’ used in 
costing studies undertaken by the NSW Department of Health.  This information is provided for 
each hospital individually in Appendix 3.  Ward costs account for 36% of costs in adult hospitals 
and 37% of costs in paediatric hospitals.  Pharmacy costs account for the second highest “bucket” 
of costs with 33% in adult hospitals and 25% in paediatric hospitals.   
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Table 12:  Allogeneic transplants – average cost by cost bucket all hospitals 
  Adult Hospitals* Paediatric Hospitals 
 Cost bucket Mean  % of 
Total 
Mean % of 
Total 
Ward costs $31,232 36% $60,623 37% 
Pharmacy costs $28,045 33% $40,701 25% 
ICU costs $5,867 7% $19,199 12% 
Pathology costs $5,748 7% $9,629 6% 
Medical costs $5,435 6% $12,840 8% 
Oncosts $3,849 4% $6,010 4% 
Allied health costs $2,666 3% $3,548 2% 
Other costs $2,626 3% $7,570 5% 
Imaging costs $639 0.7% $1,840 1% 
Emergency dept costs $17 0.02% $26 0.02% 
Total costs $86,124 100.00% $161,986 100.00% 
*Has been weighted to adjust for the number of year’s data submitted by each hospital. 
 
We note that transportation costs related to specimens sent from a hospital without an appropriate 
laboratory and donor costs are not included in the cost buckets in Table 12 above.  These costs 
would be very small relative to the overall cost of the episode.   It is recognised however, that there 
remains a cost to the facilities affected.  A donor may be managed as an outpatient or admitted, 
the collection may occur in a NSW hospital or outside of this State.  As there is no unique DRG for 
admission of a stem cell donor it has not been possible to capture data relating specifically to 
donor collection in NSW hospitals. 
 
7.1.2 Cost of ‘matched sibling’ versus ‘other’ BMT episodes 
In addition to the above results, we examined cost differences between ‘matched sibling’ and 
‘other’ transplant episodes.  We note that we have compared ‘matched sibling’ episodes with ‘all 
other’ episodes rather than comparing ‘related’ and ‘unrelated’ episodes.  The rationale for this was 
based on clinical advice that mismatched related donor episodes (such as haploidentical 
transplants) are more similar in terms of clinical complexity (and therefore cost) to unrelated 
transplants that matched sibling transplants.  However, we also note that the proportion of 
mismatched related episodes in the ‘other’ group is very low. 
 
Table 13 below shows the cost of matched sibling versus other transplants for each hospital.  In 
terms of the mean cost per episode, the most notable finding is the significant difference between 
‘matched sibling’ and ‘other’ transplant episodes in the two paediatric hospitals.  The cost 
differential is similar for each hospital.  There is a smaller, but noticeable mean cost difference 
between two of the adult hospitals.  This cost difference for the adult hospitals is much less when 
the median cost per episode is compared. 
 




Final Report: A Costing Study of Blood & Marrow Transplantation Services in NSW  Page 43 
 




Table 14 below presents the same comparison based on per diem costs.  The results here suggest 
that there is very little difference in cost between matched sibling and other episodes on a per diem 
basis for any of the five hospitals.  Similarly, there is also little difference in the mean or median per 
diem cost across the five hospitals.  This is consistent with the results above and suggests that 
differences in cost primarily reflect variation in length of stay both between matched sibling and 
other transplant episodes and also between hospitals.  
 
Table 14 ‘Matched sibling’ versus ‘other’ transplant per diem costs 
 
 
7.1.3 Autologous transplants 
Table 15 below shows length of stay statistics for the 282 autologous transplant episodes from the  
eight hospitals that contributed to the study dataset.  Again, there is considerable variation 
between minimum and maximum average lengths of stay within each hospital.  Whilst there is less 
variation in length of stay between hospitals than for allogeneic transplants, it is notable that 
Sydney Children’s Hospital has a shorter median length of stay than any other hospital.   
 
An analysis of the data from this hospital has identified a different length of stay distribution with a 
larger proportion of patients having a length of stay of between 1 and 3 days than at other 
hospitals.  Our discussions suggest that this may result from differing coding practices whereby 
Hospital Sample size Mean cost Median cost Min cost Max cost 
 Matched 
sibling 











n = 14 n = 3 $65,199 $66,157 $61,930 $67,713 $47,186 $14,551 $95,268 $116,207 
Westmead n = 28 n = 24 $85,913 $100,055 $69,538 $71,522 $21,112 $11,461 $402,035 $329,067 
St Vincent's  n = 17 n = 31 $69,472 $94,835 $65,196 $69,459 $52,130 $51,886 $100,621 $403,549 
Adult  n=59 n=58 $76,261 $95,512 $65,758 $69,962 $21,112 $11,461 $402,035 $403,549 
           
Children's 
Westmead 
n = 16 n = 28 $86,561 $228,609 $79,959 $160,860 $41,571 $82,316 $232,844 $626,656 
Sydney 
Chilrdren's  
n = 16 n = 21 $79,622 $193,374 $65,732 $169,860 $9,181 $45,483 $167,949 $679,370 
Paediatric  n=32 n=49 $83,092 $213,508 $79,541 $167,277 $9,181 $45,483 $232,844 $679,370 
Hospital Sample size Mean per diem Median per diem  Min per diem  Max per diem  
 Matched 
sibling 











n = 14 n = 3 $3,000 $2,102 $2,960 $2,257 $2,273 $728 $3,498 $3,320 
Westmead n = 28 n = 24 $2,299 $2,533 $2,275 $2,642 $782 $1,169 $5,507 $3,664 
St Vincent's n = 17 n = 31 $2,603 $2,563 $2,570 $2,550 $2,360 $2,132 $2,874 $4,090 
Adult  n=59 n=58 $2,553 $2,527 $2,570 $2,557 $782 $728 $5,507 $4,090 
           
Children's 
Westmead 
n = 16 n = 28 $2,206 $2,439 $2,321 $2,392 $924 $1,486 $2,677 $3,575 
Sydney 
Chilrdren's  
N = 16 n = 21 $2,162 $2,962 $2,236 $2,745 $1,358 $1,487 $2,838 $7,098 
Paediatric   n=32 n=49 $2,184 $2,663 $2,278 $2,587 $924 $1,486 $2,677 $7,098 
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episodes being assigned to the autologous AR-DRG at Sydney Children’s Hospital are not being 
assigned to a BMT AR-DRG at other hospitals.  This requires review as if this is the case this 
presents a confounding factor in this study.  This will require clarification with possible follow-up 
action by NSW Health. 
Table 15:  Autologous transplants - average length of stay   







St Vincent's Hospital 45 25 24 4 85 
Westmead Hospital 26 27 22 3 98 
Royal North Shore Hospital 39 29 21 3 185 
Prince of Wales Hospital 28 21 19 2 56 
St George Hospital 32 23 24 1 43 
Nepean Hospital 12 22 20 12 35 
Adult Hospitals* 182 26 22 1 185 
            
Sydney Children's Hospital 48 16 5 1 86 
Children's Hospital Westmead 52 20 11 1 88 
Paediatric Hospitals* 100 18 6.5 1 88 
* Has been weighted to adjust for the number of year’s data submitted by each hospital. 
 
Table 16 below shows the cost of autologous BMTs from the eight hospitals that contributed to the 
study dataset.   









St Vincent's Hospital $47,818 $39,739 $37,336 $10,279 $258,147 
Westmead Hospital $36,688 $32,344 $22,810 $9,622 $89,650 
Royal North Shore Hospital $48,892 $45,574 $24,464 $11,909 $128,039 
Prince of Wales Hospital $53,011 $41,674 $38,268 $4,066 $216,821 
St George Hospital $33,133 $35,081 $16,820 $3,330 $75,902 
Nepean Hospital $34,415 $28,252 $16,326 $14,804 $61,459 
Adult Hospitals* $43,496 $38,616 $29,657 $3,330 $258,147 
            
Sydney Children's Hospital $36,841 $12,026 $56,975 $1,076 $244,576 
Children's Hospital Westmead $38,117 $18,617 $34,733 $2,528 $151,782 
Paediatric Hospitals* $37,505 $13,691 $46,479 $1,076 $244,576 
* Has been weighted to adjust for the number of year’s data submitted by each hospital. 
 
As expected, autologous transplants are considerably less expensive than allogeneic transplants.  
As some autologous patients have very short lengths of stay (1-2 days), there is again a large 
variation between the least and most expensive patient.      
 
The median cost for autologous transplants actually shows more variation between hospitals than 
the allogeneic transplants.  This will be caused partly by the fact that there are more hospitals in 
this group.  The shorter mean length of stay at Sydney Children’s Hospital is reflected in a 
correspondingly lower median cost here than at other hospitals, although this difference is not 
evident in the mean cost per transplant at this hospital.    
 
There is no clear pattern to suggest that autologous transplants are more (or less) expensive in 




Table 17 below shows the per diem costs of autologous transplant episodes from the eight 
hospitals that contributed to the study dataset.   
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St Vincent's Hospital $1,815 $1,862 $356 $1,381 $3,037 
Westmead Hospital $1,558 $1,638 $710 $655 $3,207 
Royal North Shore Hospital $2,117 $2,051 $518 $1,169 $3,970 
Prince of Wales Hospital $2,519 $2,303 $833 $1,731 $5,599 
St George Hospital $1,519 $1,452 $408 $1,028 $3,330 
Nepean Hospital $1,541 $1,729 $326 $1,188 $2,028 
Adult Hospitals* $1,859 $1,859 $645 $655 $5,599 
            
Sydney Children's Hospital $2,222 $2,189 $639 $1,076 $4,322 
Children's Hospital Westmead $2,143 $2,023 $572 $1,191 $4,769 
Paediatric Hospitals* $2,181 $2,062 $603 $1,076 $4,769 
* Has been weighted to adjust for the number of year’s data submitted by each hospital. 
 
It can be seen that there is still considerable (but less than for allogeneic transplants) variation 
between the least and most expensive patient within hospitals.  Between hospitals, there is greater 
variation in per diem cost than for allogeneic transplants.  It is difficult to identify any particular 
pattern that could reasonably be explained by the range of BMT services provided at each 
hospital.   
 
The two children’s hospitals are very similar in terms of per diem cost.  This confirms the lower 
median episode cost at Sydney Children’s Hospital is a function of its shorter length of stay for 
autologous transplant patients.  Prince of Wales has the highest per diem cost for autologous 
transplant patients.  This may be the result of the coding issue raised above.  At  Prince of Wales 
Hospital only 4% of patients had a length of stay of less than 14 days, compared with Sydney 
Children’s Hospital, for example, where 36% had a length of stay of less than 14 days.   
 
Table 18 and Table 19 below show the cost of autologous transplants broken down by the two  
BMT AR-DRGs.  As would be expected AR-DRG A08A (Autologous BMT with catastrophic 
complications or comorbidities) has a higher mean and median cost for all hospitals than AR-DRG 
A08B.  Again, the cost of paediatric hospitals is higher than for the adult hospitals.  There is no 
particular difference in the cost of autologous transplants at the three hospitals that also undertake 
allogeneic transplants.  In fact, the cost at Prince of Wales is higher than at any other adult 
hospital.   
Table 18:   Autologous transplant costs - AR-DRG AO8A** 






St Vincent's Hospital $59,123 $48,503 $45,509 $37,152 $258,147 
Westmead Hospital $38,563 $20,540 $27,715 $9,622 $89,650 
Royal North Shore Hospital $57,605 $51,541 $24,330 $21,791 $128,039 
Prince of Wales Hospital $68,086 $51,866 $47,530 $33,700 $216,821 
St George Hospital $40,510 $38,621 $13,954 $22,130 $75,902 
Nepean Hospital $46,375 $47,081 $12,185 $28,252 $61,459 
Adult Hospitals* $51,913 $42,649 $33,882 $9,622 $258,147 
            
Sydney Children's Hospital $102,023 $76,723 $74,885 $13,562 $244,576 
Children's Hospital Westmead $60,012 $66,980 $28,968 $8,034 $100,600 
Paediatric Hospitals* $80,240 $69,939 $58,867 $8,034 $244,576 
*Has been weighted to adjust for the number of year’s data submitted by each hospital. 
**AR-DRG AO8A = Autologous Bone Marrow Transplant with catastrophic complications or comorbidities. 
 
 
Centre for Health Service Development 
 
Page 46    Final Report: A Costing Study of Blood & Marrow Transplantation Services in NSW 
For AR-DRG AO8B (no complications of comorbidities), Table 19 shows a high level of 
consistency in terms of mean cost and median cost across the adult hospitals.  Here, both the 
paediatric hospitals have a lower median cost than the adult hospitals.  We would suggest that the 
noticeable difference in mean cost between the paediatric hospitals is a reflection of the higher 
proportion of patients with a very low length of stay at Sydney Children’s Hospital that would 
mostly be assigned to this AR-DRG.    
 
Table 19:  Autologous transplant costs - AR-DRG AO8B** 






St Vincent's Hospital $34,817 $30,350 $18,730 $10,279 $109,043 
Westmead Hospital $34,251 $32,572 $15,363 $11,135 $57,331 
Royal North Shore Hospital $29,883 $30,177 $9,687 $11,909 $49,471 
Prince of Wales Hospital $36,777 $38,000 $13,226 $4,066 $59,468 
St George Hospital $22,352 $27,416 $15,056 $3,330 $42,726 
Nepean Hospital $20,063 $21,384 $2,952 $14,804 $21,719 
Adult Hospitals $30,643 $30,212 $15,472 $3,330 $109,043 
            
Sydney Children's Hospital $11,164 $9,380 $7,479 $1,076 $34,189 
Children's Hospital Westmead $29,602 $13,131 $33,331 $2,528 $151,782 
Paediatric Hospitals $39,640 $11,820 $26,157 $1,076 $151,782 
*Has been weighted to adjust for the number of year’s data submitted by each hospital. 
**AR-DRG AO8B = Autologous Bone Marrow Transplant without catastrophic complications or comorbidities   
 
Table 20 below shows the average cost of each cost bucket across all five hospitals that 
contributed episodes to the study dataset.  This information is provided for each hospital 
individually in Appendix 4. 
 
The results show that ward and pharmacy costs comprise the vast majority of total costs.  As was 
expected, pharmacy costs represent a higher proportion of total costs than most other AR-DRGs.  
The relatively small proportion of costs (4%) related to intensive care services in adult hospitals 
confirms the expectations expressed in the clinical consultations.  This proportion was 11% in 
paediatric hospitals, which was also in line with expectations expressed in the clinical 





Table 20:  Autologous transplants - cost by cost bucket  
Hospital Adult hospitals* Paediatric hospitals 
  Mean  % of 
Total  
Mean  % of 
Total  
Ward costs $18,360 42% $14,636 39% 
Pharmacy cost $13,240 30% $8,071 22% 
Pathology costs $2,640 6% $2,103 6% 
Medical cost $2,087 5% $3,522 9% 
Oncosts $1,840 4% $1,327 4% 
ICU costs $1,648 4% $4,058 11% 
Other costs $1,573 4% $2,252 6% 
Allied Health costs $1,331 3% $953 3% 
Imaging costs $725 2% $584 2% 
Total cost $43,496 100% $37,505 100% 
*Has been weighted to adjust for the number of year’s data submitted by each hospital. 
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7.1.4 Estimated annual cost of transplant episodes 
The annual cost of transplantation episodes (allogeneic and autologous) is presented in Table 21 
and Table 22.  The average number of transplants per year is multiplied by the average cost per 
transplant (values in Table 21) to produce an estimate of the total cost of transplants as shown in 
Table 22.  It shows that total annual expenditure on BMT transplants at the study hospital’s is 
$19.67m per annum comprising $12.62m spent on allogeneic transplants and $7.05m spent on 
autologous transplants.  
 


















St Vincent's Hospital 27 23 $85,853 $47,818 
Westmead Hospital  57 26 $92,440 $36,688 
Royal North Shore Hospital  17 39 $65,368 $48,892 
Prince of Wales Hospital 0 9 $0 $53,011 
St George Hospital 0 11 $0 $33,133 
Nepean Hospital  0 12 $0 $34,415 
Sydney Children's Hospital 15 16 $144,184 $36,841 
Children's Hospital Westmead 18 17 $176,955 $38,117 
*Average here refers to the mean cost per transplant and not than the median cost. 
 
Table 22:  Total annual cost of transplant episodes 
Hospital Total Annual 
Cost Allogeneic 
Transplants 






St Vincent's Hospital $2,318,031 $1,099,814 $3,417,845 
Westmead Hospital $5,269,080 $953,888 $6,222,968 
Royal North Shore Hospital $1,111,256 $1,906,788 $3,018,044 
Prince of Wales Hospital $0 $477,099 $477,099 
St George Hospital $0 $364,463 $364,463 
Nepean Hospital $0 $412,980 $412,980 
Sydney Children's Hospital $2,162,760 $589,456 $2,752,216 
Children's Hospital Westmead $3,185,190 $660,695 $3,845,885 
Total $14,046,317 $6,465,183 $20,511,500 
7.2 Related inpatient episodes 
A total of 3,663 episodes were included in the initial related inpatient episode dataset.  Of these, 
1,405 episodes were excluded from further analysis in line with the adjustments discussed in 
Sections 5 and 6.  This left 2,258 related inpatient episodes in the study dataset.  
 
Table 23 below shows the total number of related inpatient episodes relative to the number of 
transplant episodes.  The numbers in this table have not been adjusted for the fact that different 
hospitals contributed data for different periods.  The frequency of related inpatient episodes per 
transplant is higher at both paediatric hospitals as well as being very similar between these 
hospitals.  This finding is consistent with advice received during the clinical consultation process 
about the need for a greater proportion of services to be provided to children on an inpatient basis.   
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Table 23:  Number of related inpatient episodes 





St Vincent's Hospital 98 527 
Westmead Hospital 83 119 
Royal North Shore Hospital 56 85 
Prince of Wales Hospital 28 216 
St George Hospital 32 74 
Nepean Hospital 12 30 
Sydney Children's Hospital 93 638 
Children's Hospital Westmead 106 569 
Total 508 2258 
 
 
Table 24 below shows the average number of related inpatient episodes per patient.  The 
proportion of patients that had at least one related inpatient episode varied from 58% at Westmead 
Hospital to 92% at Nepean Hospital.  The number of related inpatient episodes per patient is also 
greater at the two paediatric hospitals.   













St Vincent's Hospital 98 76 6.9 
Westmead Hospital 83 48 2.5 
Royal North Shore Hospital 56 35 2.4 
Prince of Wales Hospital 28 24 9.0 
St George Hospital 32 28 2.6 
Nepean Hospital 12 11 2.7 
Sydney Children's Hospital 93 68 9.4 
Children's Hospital Westmead 106 82 6.9 
All 508 365 6.5 
As discussed in Section 6.3, the annual cost and number of episodes are slightly underestimated for hospitals 
that submitted data for one year as they are missing a higher proportion of episodes outside the reporting period. 
 
Table 25 below shows the average length of stay, including and excluding sameday episodes by 
hospital.  This shows a surprising variation in the proportion of sameday related inpatient episodes 
across adult hospitals.  This may be a reflection of administrative practices and/or clinical 
management preferences.  The particularly high proportion of sameday episodes at St Vincent’s 
Hospital is partly due to one patient with renal failure that had a large number of same day 
episodes during the study period.  The paediatric hospitals have less variation in their respective 
proportions of same day episodes. 
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Table 25:  Average length of stay - related inpatient episodes 
Facility Average Length of 
Stay All Episodes 
Average Length of 
Stay Excluding Same 
Day Episodes 
Percentage of Same 
Day Episodes 
St Vincent's Hospital 3.5 14.0 81 
Westmead Hospital 6.3 10.2 42 
Royal North Shore Hospital 8.5 9.6 13 
Prince of Wales Hospital 2.0 5.3 76 
St George Hospital 4.9 5.4 11 
Nepean Hospital 7.8 9.9 23 
Sydney Children's Hospital 5.4 9.1 46 
Children's Hospital Westmead 5.6 8.4 38 
All 5.1 10.1 51.4 
 
 
7.2.1 Annual cost of related inpatient episodes 
The above results highlight the importance of examining the casemix of related episodes to 
understand their associated costs.  Table 26 below show the twenty most expensive AR-DRGs in 
terms of total cost across all hospitals.  Here, episode costs have been adjusted to reflect the 
average annual cost of related inpatient episodes.  It can be seen that the most expensive  
AR-DRG was Q60A Reticuloendothelial and Immunity Disorders W Catastrophic or Severe CC.  
Advice from clinical and casemix staff confirm that this DRG is where episodes related to GVHD 
are most commonly recorded.     provides the same information for all AR-DRGs.   
 
 
Table 26:   Related inpatient episodes - Top 20 AR-DRGs by cost  
DRG DRG Description Number of 
Episodes 






Q60A Reticuloendothelial and Immunity Disorders 
W Catastrophic or Severe CC 
45.3 $912,264 $1,415 14.22 
R60A Acute Leukaemia W Catastrophic CC 14.8 $741,796 $2,111 23.7 
R60C Acute Leukaemia W/O Catastrophic or 
Severe CC 
181.8 $665,420 $1,644 2.2 
R61B Lymphoma and Non-Acute Leukaemia W/O 
Catastrophic CC 
86.3 $594,017 $1,513 4.5 
A06Z Tracheostomy or Ventilation >95 hours 4.2 $362,841 $2,452 35.5 
T60A Septicaemia W Catastrophic or Severe CC 23.5 $326,041 $1,672 8.3 
R61A Lymphoma and Non-Acute Leukaemia W 
Catastrophic CC 
11.3 $310,478 $1,568 17.5 
R60B Acute Leukaemia W Severe CC 19.8 $266,755 $1,524 8.8 
T62A Fever of Unknown Origin W CC 29.0 $244,690 $1,537 5.5 
R03A Lymphoma and Leukaemia with other OR 
procedures W catastrophic or severe CC 
4.2 $181,917 $1,487 29.4 
B66B Nervous System Neoplasm W/O 
Catastrophic or Severe CC 
31.0 $140,497 $1,489 3.0 
B60B Established Paraplegia/Quadriplegia W or 
W/O O.R. Procs W/O Catastrophic CC 
1.0 $136,776 $1,169 117.0 
B02A Craniotomy W Catastrophic CC 1.0 $124,249 $2,845 43.7 
B66A Nervous System Neoplasm W Catastrophic 
or Severe CC 
11.0 $119,202 $1,568 6.9 
F75B Other Circulatory System Diagnoses W 
Severe CC 
9.3 $97,569 $1,517 6.9 
E62B Respiratory Infections/Inflammations W 
Severe or Moderate CC 
6.5 $79,850 $1,369 9.0 
Q60B Reticuloendothelial and Immunity Disorders 9.0 $76,778 $1,525 5.6 
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DRG DRG Description Number of 
Episodes 






W/O Cat or Severe CC W Malignancy 
R61C Lymphoma and Non-Acute Leukaemia, 
Same Day 
128.7 $71,729 $557 1.0 
G02A Major Small and Large Bowel Procedures W 
Catastrophic CC 
1.0 $70,473 $1,499 47.0 
Other 
DRGs 
 377.8 $2,305,165 $796 7.8 
All  996.5 $7,828,507 $1,538 4.9 
 
The number of related inpatient episodes per transplant was slightly less than anecdotal estimates.  
Our analysis of the ICD 10 diagnosis data suggests that many of the complications arising from 
transplantation are actually dealt with during the BMT episode.  This appears to be the case with 
acute GVHD.  Nevertheless, after the data were adjusted, there were still a total 996 related 
inpatient episodes during the study period representing a cost of $7.82m.  The top twenty  
AR-DRGs accounted for $5.52m or 71% of this amount.   
 
The information on related inpatient episodes is consolidated in Table 27 below to provide an 
estimate of the annual cost of related inpatient episodes at each hospital.  This has been 
calculated as the average number of episodes per year at each hospital multiplied by the average 
cost per patient of a related inpatient episode at that hospital.   
 
Table 27:  Annual cost of related inpatient episodes   
Hospital Average Number of 
Related Inpatient 
Episodes per Year 
Average Cost per 
Related Inpatient 
Episode 
Average Annual Cost 
of Related Inpatient 
Episodes 
St Vincent's Hospital 264 $4,435 $1,168,626 
Westmead Hospital 119 $9,247 $1,100,357 
Royal North Shore Hospital 85 $10,176 $864,954 
Prince of Wales Hospital 72 $2,063 $148,544 
St George Hospital 25 $7,031 $173,437 
Nepean Hospital 30 $9,373 $281,182 
Sydney Children's Hospital 213 $9,770 $2,077,682 
Children's Hospital Westmead 190 $10,375 $1,967,792 
* As discussed in Section 6.3, the annual cost and number of episodes are slightly underestimated for hospitals 
that submitted data for one year as they are missing a higher proportion of episodes outside the reporting period.  
 
The number of related inpatient episodes per year and the average cost of these episodes varies 
between hospitals.  This is not surprising given the differences in length of stay (including the 
proportion of same day episodes) noted above.  Overall, however, the results show a very 
consistent result by type of hospital and BMT service provided.  The average annual cost of related 
inpatient episodes is very similar at St Vincent’s and Westmead Hospitals, the two hospitals that 
provide adult unrelated allogeneic transplants.  This similarity was also evident in the cost of 
allogeneic transplants at these hospitals.   
 
Further, the cost of related inpatient episodes is similarly less at Royal North Shore Hospital, which 
does not undertake unrelated BMTs.  As would be expected, the annual cost of related inpatient 
episodes at the three adult hospitals that provide only autologous transplant is significantly less 
than for the other hospitals.   
 
The annual cost of related inpatient episodes at the two paediatric hospitals is significantly higher 
that for the adult hospitals.  Again, this mirrors the experience of the transplant episodes.  Costs 
are also very similar at each hospital in terms of total annual cost, number of annual episodes and 
average cost per episode. 
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7.3   Outpatient analysis and results 
Outpatient services play a critical part in the process of providing BMT services.  Whilst they 
represent a smaller proportion of total costs than inpatient services, they are often provided over a 
longer period of time.  In some cases, such as drugs, they can also represent an ongoing cost to 
hospitals. 
 
A range of services are provided in outpatient clinics.  Whilst these clinics predominantly involve 
patients being seen by BMT Physicians, services are also provided by allied health and nursing 
staff.  In some cases, clinics operate specifically for BMT patients.  In other cases, BMT patients 
are seen in general outpatient clinics.   
 
Hospitals were asked to provide activity and cost data on the range of outpatient services provided 
to BMT patients (as outlined in Section 5.5).  Seven of the eight hospitals provided data to form a 
study dataset that comprised 7,485 outpatient clinic attendances, 6,272 dispensed drugs, 1,087 
diagnostic tests and 435 other outpatient treatments.  As was the case with inpatient data, different 
hospitals also provided outpatient data across different time periods.  In most cases, this covered 
the same period as the inpatient data.  
 
All but one hospital (that provides a low volume of adult autologous transplants) provided costed 
patient level data for drugs dispensed in the outpatient setting.  This is important as it represents a 
large outpatient cost and potentially varies significantly between hospitals.  For the other services, 
the availability of outpatient data was substantially less than for inpatient services.  A small number 
of hospitals were able to provide costed activity data for most outpatient services identified above.  
However, most hospitals were able to provide activity data for only some of the above services and 
very few hospitals were able to provide detailed cost data.     
 
The following is a summary of the data that were obtained for each outpatient service area and the 




The cost of each outpatient drug dispensed to each BMT patient during the study period was 
available for inclusion in the study dataset.  Data from each hospital were collated into a single 
data set and records which occurred outside of the reporting period were removed.  Records were 
kept if the date that a drug was dispensed occurred either within 60 days prior to transplant or 
within 365 days post transplant.  Any records that fell during a transplant episode or a related 
inpatient episode as well as records which could not be linked by MRN with a transplant episode 
were excluded.   
 
Outpatient clinic costs 
 
Six of the eight hospitals were able to provide details of the number of occasions of service, 
duration of service and relevant clinic details.  However, only two hospitals were able to provide 
cost estimates at the occasion of service level.   
 
For one hospital, the cost data were based only on the hourly salary rate of the clinician attending 
the clinic.  For the other hospital, the cost data were based on the hourly salary rate of the clinician 
plus the overhead costs of the relevant clinical department.  The data from the second hospital 
clearly represented a more comprehensive estimate of the total cost of operating an outpatient 
clinic.   
 
This information was used to develop hourly rates for medical, nursing and allied health outpatient 
clinic attendances.  These rates were discussed with staff from the other hospitals to determine if 
they could reasonably be applied across all hospitals.  The emerging view was that this would be a 
reasonable approach given the lack of routinely available cost data.  
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On this basis, an hourly rate of $78 for nursing and allied health and $301 for medical occasions of 




The outpatient data received from hospitals included a relatively small number of treatment 
services such as intravenous drug infusions that were provided in an outpatient setting.  The 
duration of these treatments was not provided.  For costing purposes, we have applied a duration 
of 60 minutes and used the nursing hourly rate, as clinical advice indicated that these treatments 
would normally be undertaken by nursing staff.  These treatments represent less that $50,000 in 




Three of the eight hospitals were able to provide details of pathology and/or diagnostic imaging 
services provided to BMT patients on an outpatient basis.  The data from these facilities confirms 
that this does not represent a large cost component for BMT patients. 
 
The method developed to cost diagnostic tests (as a component of outpatient services) was 
derived from a review of these data and advice provided during clinical consultations regarding the 
likely range of diagnostic tests that a BMT patient would receive.  We note that clinicians 
consistently advised that whilst there was an accepted range of tests required during the “work up” 
phase pre BMT, the additional diagnostic tests required by patients’ pre transplant would be 
dependent on the clinical status and underlying condition of each patient.   
 
In addition, whilst most routine post transplant outpatient visits would generate a similar range of 
diagnostic tests, each patient may require more complex diagnostic procedures based on clinical 
progress and their underlying condition.  It was suggested however, that all BMT patients would 
have a more comprehensive review of their progress (which means potentially more diagnostic 
investigations) at least once within the twelve month period post BMT.   
 
Based on the data received from hospitals and the clinical advice received during the consultation, 
diagnostic profiles were developed for each of the following: 
 
• Routine pre transplant outpatient occasion of service 
• Pre transplant work up outpatient occasion of service 
• Routine post transplant outpatient occasion of service 
• Extended post transplant outpatient occasion of service 
 
In the absence of reliable cost data from a sufficient sample of hospitals, the Commonwealth 
Medical Benefits Schedule was used as a proxy for cost.  Where service utilisation data was 
available from hospitals, it was used to form a template for the number of diagnostic tests in each 
of the above categories of activity.  This resulted in an estimated total cost of outpatient diagnostic 
tests for each hospital.  As this methodology is less robust than other elements of the study, they 
are deliberately conservative in terms of over estimating the range and number of diagnostic tests 
likely to be undertaken.  
 
Further, as this approach involves some assumptions, we have not attempted to separately cost 
adults and children or allogeneic and autologous transplants.  It is recognised that paediatric 
patients (particularly those who have myeloblative conditioning protocols), may require more 
frequent and complex diagnostic tests post transplant to assess the impact of chemotherapy 
toxicity on their growth and development.   
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7.3.1 Outpatient cost results 
The results of the outpatient costing process are presented in Table 28 and Table 29 below for 
allogeneic and autologous patients respectively.  Overall, the results are consistent with anecdotal 
expectations - with total cost at each facility largely reflecting the volume of activity that is 
undertaken.   
 
There is some variation in the annual cost of outpatient clinics between the two paediatric 
hospitals.   This may reflect a higher volume of clinic activity at Children’s Hospital Westmead or 
may suggest that the outpatient clinic data from Sydney Children’s Hospital is incomplete.  
 
Table 28:  Average annual cost of outpatient services - allogeneic transplant patients 
 









St Vincent's Hospital Data 
unavailable  
$103,246 $89,032 $192,278 
Westmead Hospital  $63,634 $243,063 $191,503 $498,200 




Adult hospitals $160,730 $346,309 $337,650 $844,689 
Sydney Children's Hospital $36,726 $175,937 
  
$50,396 $263,059 
Children's Hospital Westmead $49,643 $68,478 $33,597 $151,718 
Paediatric hospitals $86,369 $244,415 $83,993 $414,777 
 
 
Table 29:  Average annual cost of outpatient services - autologous transplant patients 
 









St Vincent's Hospital  Data 
unavailable 
 
$57,669 $75,593 $133,262 
Westmead Hospital  $9,643 $47,005 $87,352 $144,000 




St George Hospital $9,829 $28,798 $35,837 $74,464 
Nepean Hospital  $15,134 $8,579 $40,316 $64,029 
Adult Hospitals $102,909 $142,051 $370,126 $615,086 
          
Sydney Children's Hospital $22,283 $81,177 
 
$53,755 $157,215 
Children's Hospital Westmead $94,506 $71,726 $77,273 $243,505 
Paediatric Hospitals $116,789 $152,903 $131,028 $400,720 
 
7.3.2 Pharmaceutical costs 
Pharmaceuticals represent a significant component of the cost of BMT services.  For this reason, 
in addition to the data used for the primary costing, hospitals were asked to provide a breakdown 
of individuals prescriptions issued to patients that received a BMT during the study period and any 
available documentation relating to BMT regimen’ that are routinely used.   
 
As expected, only some hospitals were able to provide the very detailed information required to 
undertake an analysis by individual drugs.  However, we have undertaken an exploration of the 
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available data.  Drugs are grouped into pharmacological categories and Table 30 below shows the 
proportion of annual inpatient and outpatient drug expenditure by hospital and category for the four 
hospitals that provided data in this area.  We would note the following points in relation to this 
analysis: 
 
• The data includes both inpatient and outpatient drugs; 
• The results reported here do not include any drugs dispensed through a hospital imprest 
system; 
• The analysis here includes all drug records provided by hospitals.  That is, no records have 
been excluded on the basis of the business rules used in the primary costing;  
• Only the top 20 most expensive drugs were categorised - other drugs are included in the other 
category; 
• Where hospitals provided data for more than one year, the proportions have been averaged to 
reflect an annual amount.   
• The number of years data provided by hospitals may have a slight impact on the distribution 
between categories.     
 
Table 30:  Drug cost by type by hospital 










Antifungals 22% 39% 26% 27% 
Antivirals 5% 9% 17% 11% 
Antibiotics 1% 4% 12% 2% 
Immunosuppressants 18% 15% 13% 5% 
Colony Stimulating Factors 15% 13% 7% 22% 
Monoclonal Antibodies 5% 7% 5% 0% 
Chemotherapy Drugs 28% 6% 5% 17% 
Nutrition 0% 0% 10% 2% 
Others 6% 7% 6% 13% 
Total 100% 100% 100% 100% 
 
 
The following points summarise the key findings that arose from this analysis: 
 
Adult hospitals 
• There are significant differences in the use of antifungals (Westmead) and chemotherapy 
agents (St Vincent’s) otherwise there is reasonable similarity on a per patient basis; 
• The high cost of antifungal agents is heavily influenced by the liposomal delivery of 
amphotericin as well as the general expense of triazole drugs; 
• The use of the chemotherapy drugs is relatively inexpensive in comparison with anti 
infective agents; 
• Parenteral Nutrition is rarely listed in the adult hospitals;  
• A lower than expected proportion of drugs were listed under Section 100.  
 
Paediatric  
• The two paediatric hospitals are similar in antifungal drug use; 
• According to the data provided monoclonal antibodies are rarely used at the Children’s 
Hospital Westmead while colony stimulating factors are three times more significant than at 
Sydney Children’s Hospital.  
• A lower than expected proportion of drugs were listed under Section 100.  
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7.3.3 BMT Laboratory costs 
As noted previously there are eight specialist BMT laboratories servicing the fifteen hospitals that 
provide blood and marrow transplants.  These laboratories process and store the stem cells used 
in BMT.   To formulate a costing methodology for this cost component, advice was sought from the 
Blood and Marrow Transplantation Cost Study Reference Group.  This group supplied a copy of 
information collated by the BMT Network NSW Executive Group in 2003 which provided an 
estimated costing for ‘processing and cryopreservation of autologous PBCS’. This information was 
subsequently revised using 2007 dollar values. 
 
Further information was obtained from the NSW Blood and Marrow Transplantation Service Plan 
(Working Draft – Sep 2008) on the number of stem cell collections per transplant per hospital, 
performed by each respective BMT laboratory during 2007.  Information was also gathered on the 
relevant Medicare item numbers for common procedures performed by all eight BMT laboratories 
in NSW, and information on the associated fee obtained from a search of the Commonwealth 
Medical Benefits Schedule, (this is summarised in Table 31 below). 
 
Table 31  Medicare items for procedures commonly performed in NSW BMT laboratories 
Item Number Description MBS Fee 
13760 In vitro processing (and cryopreservation) of bone marrow or peripheral blood for 
autologous stem cell transplantation 
$ 704.60 
71146 Enumeration of CD34+ cells, only for the purposes of autologous or allogeneic 
haemopoietic stem cell transplantation, including a total white cell count on the 
aphaeresis collection* 
$ 105.85 
* This test is performed 3 times per patient (morning PB CD34 test, bag CD34 count and thawed pilot vial CD34 
counts)=$317.55 
 
This information shows that a laboratory performing one common autologous cryopreservation 
procedure would be eligible for approximately $ 1022.15 from Medicare.  This fee does not 
represent the full cost of staff time needed to process a product, storage and maintenance of cells 
in liquid nitrogen tanks, other compulsory tests required to be performed on each product like 
microbial studies, confirmatory blood group testing, colony assays etc. 
 
Additional expert advice was sourced from the Scientific Director, Sydney Cellular Therapies 
Laboratory at Westmead Hospital as this laboratory receives the highest number of stem cell 
products for processing, manipulation and storage per year in NSW.   
 
The Sydney Cellular Therapies Laboratory at Westmead Hospital represents the spectrum of 
laboratory work required in BMT.  For example: 
 
• Products collected are use in autologous, allogeneic and unrelated transplants 
• Products used for transplantation include bone marrow, peripheral blood stem cells and cord 
blood 
• Products used are specifically intended for adults and paediatric transplant patients in NSW 
• Procedures performed in this laboratory include routine and specialised procedures (such as 
CD34+ selection procedures) 
• A full time BMT Laboratory service is provided for other BMT hospitals in NSW (other than an 
on-site service) 
 
Data were examined for this laboratory for the previous three years, demonstrating consistent cost 
patterns.  The cost information supplied incorporated the running costs of the laboratory such as: 
staff, consumables and reagents, equipment and maintenance as well as the routine tests 
performed on each product.   
 
The laboratory cost per product was calculated to be $2085 for the Sydney Cellular Therapies 
Laboratory at Westmead Hospital for 2007/08.  This figure is considered a realistic estimate of the 
current cost of cell processing across NSW BMT laboratories.  On this basis, it has been used to 
generate current cost estimates.  Activity data from 2007 has been used in this calculation.  The 
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results are shown in Table 32 by hospital and by laboratory.  It shows the annual BMT laboratory 
costs for NSW as being $1.651M.  We note that all eight BMT laboratories have been included in 
this Table.     
 
Table 32 BMT laboratory costs estimated by volume of products processed in 2007 




 Total cost per 
annum 
 
  Per Hospital Total per 
laboratory 
Per Hospital Total per 
laboratory 
Westmead Children's Hospital  65  $135,532  
 Westmead 105  $218,936  
 Nepean 15  $31,277  
 Wollongong 41 226 $85,489 $471,233 
      
St Vincent's St Vincent's 118  $246,042  
 Gosford 14 132 $29,191 $275,233 
      
Royal Prince Alfred Royal Prince Alfred 63  $131,361  
 Concord 24 87 $50,042 $181,404 
      
Sydney Children's Sydney Children's 57  $118,851  
 Prince of Wales 19 76 $39,617 $158,468 
      
Royal North Shore Royal North Shore 155 155 $323,191 $323,191 
      
Liverpool Liverpool 51 51 $106,340 $106,340 
      
St George St George 20 20 $41,702 $41,702 
      
Calvary Mater 
Newcastle 
Calvary Mater Newcastle 42  $87,574  
 John Hunter Children's 3 45 $6,255 $93,830 
      
Total  792 792  $1,651,399 
 
 
7.4    Costs not included in this study 
This study has aimed to cost the primary activities associated with the provision of BMT services in 
NSW.  As the study had a limited scope and timeframe, it was not possible to capture data on the 
full range of activities associated with BMT services.  In particular some indirect services have not 
been included.  We have identified these services below.  We would note, however, that there was 
a wide range of views expressed during the study about whether it is appropriate to include these 
activities in a costing study of BMT services.   
 
Services on which cost data was not captured in this study: 
 
• costs attributable to cell processing, transport and storage borne by the treating hospital; 
• costs associated with pre transplant genetics and/or research; 
• family members who travel and stay close to the patient for long periods of time in 
accommodation that may be provided in association with hospitals; 
• blood and blood products; 
• tissue typing (particularly extended tissue typing); 
• costs associated with donor stem cell collection (for NSW, national and international 
transplant recipients); 
• ‘rainy day harvests’; 
• patients prepared for transplant who do not then proceed to transplant; 
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• Haematology/oncology units in large rural centres which have met the costs of work-up and 
the costs of post transplant management (particularly drug costs) even though the 
transplant episode may not have occurred in this facility;   
• parts of the patient journey for selected interstate patients; 
• outpatient consultations or community outreach services provided by non BMT 
physicians/clinicians; 
• additional patient education and support programs; 
• specialty bone marrow services that may be unique to one facility e.g. the Australasian 
Bone Marrow Transplant Recipient Registry at St. Vincent’s Hospital;  
• service development elements of  bone marrow services that are provided by NSW Health 
e.g. the Greater Metropolitan Clinical Taskforce Bone Marrow Transplant Network; 
• treatment that may be provided interstate e.g. provision of extracorporeal phosphoresis by 
the Peter McCallum Cancer Centre; 
• costs involved in the ongoing treatment of chronic GVHD post 365 days transplant which 
applies to a significant proportion of allogeneic transplant patients long term treatment. 
7.4.1 Revenue 
We have not undertaken a detailed review of sources of revenue associated with BMT services as 
this was outside the terms of reference for this project.  We would, however note the following two 
points that were identified during the consultation stage of the project.  
 
• All BMT hospitals indicated that the vast majority of outpatient services provided to BMT 
patients are billed to Medicare.  Further, some hospitals indicated that at some point following 
transplantation, patients may be seen in doctor’s private rooms.  In this latter case, both the 
cost and the activity would have been excluded from this study.  
 
• Very few patients that receive a BMT are treated as private inpatients.  While this proportion is 
much lower than the actual proportion in the population, it is not uncommon for persons 
requiring expensive and long-standing health care to elect non-chargeable status. 
7.5   Estimated cost of BMT projections in NSW  
The NSW Department of Health is currently working with the NSW BMT Service Plan Development 
Working Group to develop a Statewide plan for BMT services.  We have applied the results of this 
study to produce cost estimates base on the current projections developed by this group.  
 
 In producing these estimates, we would make the following points: 
 
• Our costing is based on the projections set out on page 49 of the NSW Blood and Marrow 
Transplantation Service Plan dated September 2008.     
 
• We have not attempted to adjust the average cost per patient other than keeping constant 
dollars.  The Service Plan document indicates that costs can be expected to rise with new 
technology but quantification of the effect of that technology is not provided. It was also 
beyond the scope of our study to attempt to cost these potential changes.  
 
• The projections indicate an increase in unrelated BMT relative to related donors.  This 
implies a higher cost because of the higher price of the unrelated transplants.  This change 
has not been factored into our costing.   
 
• The projections imply but do not explicitly state that both autologous and allogeneic BMT 
for paediatric cases are expected to be constant over time. 
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Table 33 below provides an estimate of the cost of BMT services in NSW based on constant 2007 
dollars and constant real cost per patient.  Estimated costs for 2011 are $46.84m which will 
increase in 2016 to $53.92m. 
 
 
Table 33:  Projections for BMT for NSW residents 
 
Transplant Type 2006/07 Cost per 
transplant 
2011 NSW Total 
cost 
2016 NSW Total 
cost 
Adult Allogeneic $114,316 
 
$16,118,556 $18,747,824 
Adult Autologous $62,812 $18,843,600 $23,303,252 
Paediatric Allogeneic $227,286 
 
$7,955,010 $7,955,010 
Paediatric Autologous $119,367 
 
$3,581,010 $3,581,010 
TOTAL  $46,498,176 $53,587,096 
 
7.6  Summary of results  
This section consolidates the earlier results to provide an overall estimate of the current cost of 
BMT services in NSW.  These results are presented separately for allogeneic and autologous 
services and for adult and paediatric hospitals. 
 
Firstly, Table 34 shows the total annual cost for allogeneic transplants including the transplant 
episode, related inpatient episodes and outpatient services.  The average number of BMTs at each 
hospital and the cost per BMT is also shown.  Total expenditure on the 134 allogeneic transplants 
undertaken annually is $19.04m of which $14.04m is spent on transplant episodes, $3.74m on 
related inpatient episodes and $1.26 m on outpatient services.   
 
The average cost of an adult allogeneic transplant is $114,316 compared with a paediatric 
transplant with an average cost of $227,286.  In our view, the large difference in cost between 
adult and paediatric transplants means that there is little value in considering the overall average 
cost of an allogeneic transplant.  However, it is shown here ($142,137) for the sake of 
completeness.   
 
Table 34:  Total annual costs of allogeneic transplant – study dataset 
 








St Vincent's Hospital $2,318,031 $743,452 $192,278 $3,253,761 27 $120,510 
Westmead Hospital $5,269,080 $934,157 $498,200 $6,701,437 57 $117,569 
Royal North Shore 
Hospital 
$1,111,256 $325,234 $154,211 $1,590,701 17 $93,571 
Adult Hospitals $8,698,367 $2,002,843 $844,689 $11,545,899 101 $114,316 
             
Sydney Children's 
Hospital 
$2,162,760 $1,135,285 $263,059 $3,561,104 15 $237,407 
Children's Hospital at 
Westmead 
$3,185,190 $602,415 $151,719 $3,939,324 18 $218,851 
Paediatric Hospitals $5,347,950 $1,737,700 $414,777 $7,500,428 33 $227,286 
         
All $14,046,317 $3,740,543 $1,259,466 $19,046,327 134 $142,137 
BMT = Transplant episode.  RIE = Related inpatient episode 
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Table 35 shows the equivalent information for autologous transplants.  Total expenditure on the 
159 transplants undertaken annually is $11.98m of which $7.05m is spent on transplant episodes, 
$3.90m on related inpatient episodes and $1.0 m on outpatient services.   
 
The average cost of an adult autologous transplant is $62,812 compared with a paediatric 
transplant with an average cost of $113,812.  Again, in our view, there is little value in considering 
the overall average cost of an autologous transplant, but it is shown here ($75,322) for the sake of 
completeness.   
 
Table 35:  Total annual costs of autologous transplant – study dataset 
 








St Vincent's Hospital $1,099,814 $420,739 $133,262 $1,653,815 23 $71,905 
Westmead Hospital $953,888 $156,953 $144,000 $1,254,841 26 $48,263 
Royal North Shore 
Hospital 
$1,906,788 $529,545 $199,332 $2,635,664 39 $67,581 
Prince of Wales Hospital $477,099 $147,857   $624,956 9 $69,440 
St George Hospital $364,463 $171,093 $74,464 $610,020 11 $55,456 
Nepean Hospital $412,980 $281,182 $64,029 $758,191 12 $63,183 
Adult Hospitals $5,215,032 $1,707,369 $615,087 $7,537,487 120 $62,812 
              
Sydney Children's 
Hospital 
$589,456 $922,857 $157,215 $1,669,528 16 $104,346 
Children's Hospital 
Westmead 
$660,695 $1,365,385 $243,505 $2,629,585 17 $154,681 
Paediatric Hospitals $1,250,151 $2,288,242 $400,720 $3,939,113 33 $119,367 
          
All $6,465,183 995,611 $1,015,807 $11,476,601 153 $75,010 
BMT = Transplant episode.  RIE = Related inpatient episode 
 
 
Finally, Table 36 shows the total annual cost of both allogeneic and autologous transplant services 
for each hospital that participated in the study.  Total cost is $30.88m annually for 134 allogeneic 
and 153 autologous transplants undertaken across the eight hospitals.  Total costs range from 
$610,020 at St George Hospital which undertakes 11 autologous transplants, to $7.95m at 
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Table 36:  Total annual cost of allogeneic and autologous transplants – study dataset 
 
Hospital Cost Per 
Allogeneic 
Transplant 


















$120,510 27 $71,905 23 50 $4,907,576 
Westmead Hospital  $117,569 57 $48,263 26 83 $7,956,278 
Royal North Shore 
Hospital  
$93,571 17 $67,581 39 56 $4,226,365 
Prince of Wales 
Hospital 
 $0 0 $69,440 9 9 $624,956 
St George Hospital  $0 0 $55,456 11 11 $610,020 
Nepean Hospital   $0 0 $63,183 12 12 $758,191 
Adult Hospitals $114,316 101 $62,812 120 221 $19,083,386 
              
Sydney Children's 
Hospital 
$237,407 15 $104,346 16 31 $5,230,632 
Children's Hospital 
Westmead 
$218,851 18 $154,681 17 35 $6,568,895 
Paediatric 
Hospitals 
$227,286 33 $119,367 33 66 $11,799,536 
      
Total $142,137 134 $75,010 153 287 $30,882,930 
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Appendix 1 Consultation Summary  
 
Name Position / Department Area Health Service Facility 
Clinical Consultations    
Associate Professor Tony Dodds Director Haematology/BMT, Co-Chair of 
BMT Network Executive 
South Eastern Sydney/Illawarra St Vincent’s Hospital 
Annabelle Horne BMT Transplant Coordinator South Eastern Sydney/Illawarra St Vincent’s Hospital 
Associate Professor Ken Bradstock Director BMT Sydney West Westmead Hospital 
Dr Warwick Benson Director Clinical Haematology Sydney West Westmead Hospital 
Leng Leng Yee  Acting BMT Transplant Coordinator Sydney West Westmead Hospital 
Professor Peter Shaw Director Haematology/Oncology Sydney West Children’s Hospital, Westmead 
Dr Chris Arthur Director Haematology and BMT Northern Sydney/Central Coast Royal North Shore Hospital 
Cassandra Reid BMT Transplant Coordinator Northern Sydney/Central Coast Royal North Shore Hospital 
Dr Stephen Larson Haematologist Sydney South West Royal Prince Alfred Hospital 
Jon Sanders BMT Transplant Coordinator Sydney South West Royal Prince Alfred Hospital 
Dr Sundra Ramanathan Head of Cancer Services South Eastern Sydney/Illawarra St George Hospital 
Dr David Rosenfeld Director Haematology/BMT Sydney South West Liverpool Hospital 
Patricia Ryan Acting Transplant Coordinator Sydney South West Liverpool Hospital 
Dr Tracey O’Brien Head, Cord and Marrow Transplant 
Program 
South Eastern Sydney/Illawarra Sydney Children’s Hospital 
Dr Carol Cheung Staff Specialist, Haematology South Eastern Sydney/Illawarra Prince of Wales Hospital 
Alison Read Clinical Nurse Consultant South Eastern Sydney/Illawarra St George Hospital 
Cassandra Hobbs Clinical Nurse Consultant South Eastern Sydney/Illawarra St George Hospital 
Vicki Antonenas Head Scientist, BMT Laboratory, Co-chair of 
BMT Network Executive, Chair BMT 
Network Laboratory Services Working 
Group 
Sydney West Westmead Hospital 
Dr David Gottlieb Medical Director, BMT Laboratory Sydney West Westmead Hospital 
Dr Stephen Larsen Haematologist Sydney South West Royal Prince Alfred Hospital 
Jon Sanders BMT Transplant Coordinator Sydney South West Royal Prince Alfred Hospital 
Genevieve Daly Senior Pharmacist South Eastern Sydney/Illawarra Prince of Wales/ 
Sydney Children’s Hospital 
Tom Fong Acting Deputy Director, Pharmacy South Eastern Sydney/Illawarra Prince of Wales/ 
Sydney Children’s Hospital 
Rebecca Walsh Senior Pharmacy Technician South Eastern Sydney/Illawarra Prince of Wales/Sydney 
Children’s Hospital 
Conducted by Teleconference    
Associate Professor Phillp Rowlings Senior Staff Specialist Haematologist Hunter/New England Calvary Mater Newcastle 
Louisa Bray Transplant Coordinator Hunter/New England Calvary Mater Newcastle 
Dr Frank Alvaro Paediatric Haematologist/Oncologist Hunter/New England John Hunter Children’s Hospital 
Dianne Cotterell Clinical Nurse Consultant Hunter/New England John Hunter Children’s Hospital 
Costing/Casemix/Finance 
Personnel 
   
Melita Howes Casemix Manager South Eastern Sydney/Illawarra St Vincent’s Hospital 
Sue-Ellen Fletcher Senior Costing Analyst Sydney West Westmead Hospital 
Winston Piddington Senior Clinical Costing Officer Northern Sydney/Central Coast Royal North Shore Hospital 
Penny Ison Clinical Costing Offier Northern Sydney/Central Coast Royal North Shore Hospital 
Christine Fan  Clinical Costing Manager Sydney West Children’s Hospital, Westmead 
Micheline Hanna Clinical Costing Officer Sydney West Children’s Hospital, Westmead 
Jenny McNamee Casemix Manager South Eastern Sydney/Illawarra Sydney Children’s Hospital 
Chris Ellery Manager, Performance Information South Eastern Sydney/Illawarra Prince of Wales Hospital 
Robert Siu Cancer Service Network Manager Sydney West Westmead & Nepean Hospitals 
Jenna Balding Finance and Information Resource Manager Sydney West Westmead Hospital 
Cara Dickson Senior Costing Officer South Eastern Sydney/Illawarra St George Hospital 
Alison Cochrane  
 
Performance Analyst SESIHS Northern Hospital 
Network 
Prince of Wales Hospital 
Vineet Makhija Casemix Policy Unit, Intergovernment & 
Funding Strategies Branch 
NSW Health Intergovernment & Funding 
Strategies Branch 
Executive    
Elizabeth Koff Director Clinical Operations South Eastern Sydney/Illawarra Area Administration 
Dr Michael Brydon Director, Clinical Services South Eastern Sydney/Illawarra Sydney Children’s Hospital 
Kathy Meleady Director, Statewide Services Development 
Branch 
NSW Health Statewide Services Development 
Branch 
Cristalyn DaCunha Manager, Casemix Policy Unit, 
Intergovernment & Funding Strategies 
NSW Health Intergovernment & Funding 
Strategies Branch 
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Name Position / Department Area Health Service Facility 
Branch 
Bart Cavalletto Manager, Clinical Services Planning Unit, 
Statewide Services 
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Appendix 2 Literature review 
 
A1 Search strategy 
 
The NSW BMT Service Plan Development Working Group (the Working Group) was the starting 
point for the literature review.  The Working Group provided background to the current delivery of 
blood and marrow transplant (BMT) services in New South Wales including information on: 
• trends in service use and expected future service requirements based on population 
projections for Area Health Services throughout NSW 
• research underway and the potential for future research and diagnostic opportunities 
involving BMT 
• the potential for increased demand for BMT services both for new indications, and arising 
from improvements in practice, technologies and pharmacological products 
• the increasing availability of donor stem cells and the resulting impetus for significant 
increase in some forms of BMT, in particular, alternative donor allogeneic transplants 
• changes in clinical practice affecting demand, including different types of service delivery 
such as early discharge and greater use of outpatient facilities and 
• the infrastructure and personnel requirements of BMT services - in particular, laboratory 
requirements (including for stem cell storage and processing), facilities needed by each 
BMT unit (including design, operational and data collection requirements) and workforce 
needs appropriate to the delivery of BMT services.    
 
With this background, the literature review focussed on costing studies that might shed light on 
these and other issues affecting BMT services in NSW.    
Relevant papers were identified by searching the electronic databases Medline, EconLit, Science 
Direct, Cinahl and Cochrane databases using combinations of the search terms transplant$, blood, 
bone marrow, stem cell, cord, umbilical, cost$ and method, costing, costing method$, costing 
model$, cost accounting, and case-mix.  Key journals such as Bone Marrow Transplantation, 
Blood, Clinical and Laboratory Haematology as well as Cancer Treatment Reviews and the 
European Journal of Cancer were also searched separately to ensure all references were found.  
The resulting citations were culled to exclude those that did not focus on either costing or 
economic evaluation of blood and bone marrow transplantation.  Only English language citations 
were retained.  Additional citations were identified by internet searching, reviewing reference lists 
in recently published work and searching for recent publications by key researchers in the field.  A 
second round of culling was undertaken based on reading the abstract or executive summary of 




The literature on costing blood and bone marrow transplants comprises only a small number of 
studies, with the main work undertaken in the USA and Europe, in particular Scandinavia and the 
Netherlands.  The studies are limited in scope, most are targeted to particular indications and 
underlying disease, and few provide detailed costing of the stages of transplant.   
 
While about a third of the papers were published in the last 5 years, many refer to research 
undertaken more than a decade ago.  For example, a UK study published in 2004 reviewing the 
costs and cost-effectiveness of new interventions for the treatment of aggressive non-Hodgkin’s 
lymphoma summarised information gathered between 1987 and 1999 (Beard et al 2004).  Each of 
two recent systemic reviews (of the health economics of managing multiple myeloma, and of the 
comparative costs of high-dose chemotherapy and autologous stem cell transplantation vs. 
conventional chemotherapy), reported on only five studies examining the cost of BMT services 
(Moeremans and Annemans 2006, Simnett et al 2000).  Another review of economic analyses of 
acute myeloid leukaemia found only five studies that estimated per patient BMT costs, with only 
two of these costing different components of BMT (Redaelli et al 2004). 
 
Very little economic analysis of BMT services in light of recent changes in clinical practice and/or 
advances in new technology and diagnostics in the past few years, in particular in relation to gene 
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therapy and sources of donor stem cells, is available.  A recent systematic review of ‘trends and 
prospects’ in stem cell transplantation in Europe between 2005 and 2010 contained no costing 
detail.  Instead, it relied on estimates of activity based on trends in use for different indications and 
expected developments in practice, to suggest possible expansions in budget (Tan et al 2007).  In 
terms of informing the development of costings for BMT service components, most of the literature 
was of marginal value.   
The terminology used to refer to the economic aspects of BMT services differs throughout the 
literature, at times affecting interpretation.  The terms costs, charges, expenditures, payments and 
reimbursement can all be found.  It was important to distinguish, for example, between charges 
and costs, in particular in regard to studies undertaken in the United States.  Studies reporting the 
hospital charge for BMT services and products, are not necessarily reporting the actual costs of 
services.  For example, charges in some hospitals may be inflated to cover costs from other 
departments and third-party payer costs may need to be taken into account (Westerman and 
Bennett 1996). 
 
The literature review identified several economic evaluations of blood and marrow transplantation.   
Whilst economic evaluation was outside the scope of this project the studies were reviewed for 
details of the costing methodologies employed.  In most such studies, the costing methodologies 
were not fully explained, nor were costing details reported, but they were useful for the purposes of 
shedding light on the overall magnitude of costs of different BMT service types.  In general, they 
took a pragmatic approach, in keeping with the literature.  “Analysts and decision makers must 
consider whether the benefits of more accurate and detailed cost information justify the additional 
costs incurred in obtaining that information.” (Smith and Mogyorosy 2005) 
 
A major difficulty in costing BMT services is that widely differing assumptions and a variety of 
different inputs may be used to derive costings.  This is particularly the case because there are 
many different treatment methodologies covering both autologous and allogeneic transplants, a 
variety of donor stem cells, and an increasing range of indications and clinical practice modalities.  
Moreover, costs do not remain static and, because of the complexity of treatments and indications, 
even small changes in protocol can lead to a large difference in cost (Freeman et al 1996).  This 
issue is compounded when methodologies reported lack detail, or are ambiguous.  Therefore, any 
comparison of reported costings is difficult.  Most studies refer to this matter, in keeping with the 
general principle that robust cost comparisons can only be made when cost measurement is in 
reasonable compliance with a standardised costing methodology (Smith and Mogyorosy 2005).   
 
Some of the many possible sources of differences between studies that might lead to bias and/or 
discrepancies are: 
• the type and complexity of the service, for example, service settings, admission practice 
• the availability of data and its validity 
• the sample size and design - for example, whether randomised, prospective or 
retrospective (typically, sample size is very small with most studies based on < 50 patients) 
• the costing methodology – for example, (i) use of direct and/or indirect costs, whether 
standard unit costs or fees, charges and/or market prices are used; and (ii) the 
assumptions underlying cost estimation and/or extrapolation  
• the time horizon for a study and the consequent technologies, diagnostics and level of 
knowledge and sophistication of BMT services available at that time 
• the stages or components of BMT included and the practices considered (for example, 
conditioning regimens)  
• the range of items that may or may not be included in costs 
• the large variation in unit costs that is possible, particularly between countries 
• the variations in price levels between treatment alternatives and treatment items, 
particularly between countries 
• assumptions regarding the static nature of costs (for example, for cycles of chemotherapy)  
• whether donor costs are taken into account  
• the duration of follow-up period, if any, that is covered in a study 




Final Report: A Costing Study of Blood & Marrow Transplantation Services in NSW  Page 65 
• the indications and type and severity of disease covered by a study (for example, 
Westerman and Bennett (1996) found that the main cost driver for severe combined 
immunodeficiency was nursing care, while laboratory and radiology costs were the main 
drivers for acute myeloid leukaemia, severe aplastic leukaemia and chronic granulocytic 
leukaemia) 
• the study perspective and country in which it was undertaken  
• (as already noted) whether reimbursement costs for procedures are reasonable estimates 
of the real costs borne by the treating facility. 
 
(Beard et al 199, van Agthoven et al 2002, Moeremans and Annemans 2006, Mishra et al 2003, 
Westerman and Bennett 1996). 
 
The pace of change in BMT is rapid so that conclusions regarding changes in clinical practice and 
emerging technologies that may impact on service provision, if they are based on retrospective 
studies, may already be out of date with practices and technologies well-established.  For 
example, several studies refer to the use of high-dose chemotherapy with stem-cell support vs. 
standard conventional chemotherapy for managing different conditions.  Beard et al (2004) 
referred to ‘a definite trend towards reduced costs for high-dose therapy {for patients with 
aggressive non-Hodgkin’s lymphoma}, possibly reflecting increasing technical excellence and 
improved bone marrow recovery through the use of stem cell transplantation and growth factors’.  
Moeremans and Annemans (2006) note that the former practice ‘has clearly improved disease-free 
survival’ for patients with multiple myeloma.  They also note that ‘new promising agents…with 
improved response rates, progression-free and potentially overall survival in different stages of 
multiple myeloma’ are available, but that their acquisition costs are very high compared with some 
established treatments.  Mishra et al (2005) noted that high dose chemotherapy with autologous 
peripheral blood stem cell support (PBSCT) was ‘an established treatment strategy for 
poor-prognosis malignancies’ and that use of PBSCT replaced bone marrow at the Norwegian 
Radium Hospital (NRH) in 1993 for malignant lymphoma.   
 
The recent paper by Tan et al (2007) aimed to identify trends in Europe in BMT patient numbers 
and to anticipate transplant rates for the next 5 years.  The paper referred to the greater use of 
reduced-intensity conditioning regimens followed by transplantation (RIC-HSCT) and increasing 
worldwide donor availability as significant trends likely to lead to increasing use of transplant for a 
range of indications.  The availability of alternative drug treatments was another key factor 
expected to influence trends in transplantation.  The study predicted an increase in autologous 
transplantation in Europe of 6% between 2005-2010, with particular reference to the treatment of 
acute leukaemia and auto-immune diseases.  An even greater increase of about 20% in allogeneic 
transplantation was predicted, with rises in use for all indications except chronic myeloid 
leukaemia, due mainly to the expected increased use of RIC_HSCT in older patients and in 
patients with co-morbidities.   
 
For specific indications, the following trends were noted: 
• For acute lymphoblastic leukaemia (ALL), use of more intense early phase therapy, greater 
use of RIC with allogeneic transplantation in elderly AML patients (already popular for AML 
patients aged over 40), use of HSCT as a consolidation treatment or as a treatment option 
for patients aged between 60 and 75, and an overall expansion in allogeneic transplants for 
ALL. 
• For myeloproliferative disorders, greater use of allogeneic HSCT for myelodysplastic 
syndrome (MDS), with a possible slight decrease in use of allogeneic HSCT for chronic 
myeloid leukaemia (CML), depending on new drug treatments for Imatinib resistant CML. 
• For lymphoproliferative disorders, a modest increase in allogeneic HSCT based on the 
increased likelihood of finding a compatible donor and greater use of RIC-HSCT.   
• For multiple myeloma, possible use of RIC-HSCT after a preceding autologous transplant, 
with almost all MM patients aged up to 65 receiving an autologous transplant; allogeneic 
transplants likely to increase with greater use of RIC, though overall MM patient numbers 
may drop due to the availability of alternative drug treatments.   
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• For solid tumours, RIC-HSCT could provide a new approach for renal cell carcinoma, 
following a marked increase in allogeneic transplantation in the five years from 1997 to 
2002 for solid tumours (mainly due to its application in renal cell carcinoma); a ‘constant but 
steady increase [in use of autologous transplantation] for neuroblastoma and Ewing 
sarcoma, but, due to the introduction of alternative drug treatments and disappointing 
results from autologous transplantation, especially in the treatment of breast cancer, the 
role of autologous transplantation in the treatment of other solid tumours could be 
challenged. 
• For non-malignant disease, autologous transplantation currently mainly used for 
auto-immune diseases but, because ‘different opinions prevail’, future use is difficult to 
predict; growth likely in allogeneic transplantation, due to increased use of RIC_HSCT in 
older patients and those with co-morbidities.   
 
Changes in the characteristics of BMT service delivery and consequent changes in costs and shifts 
in cost distribution are the subject of discussion in a number of papers.  For example, Freeman et 
al (1999) noted that overall treatment-related costs for BMT for patients diagnosed with non-
Hodgkin’s lymphoma (NHL) decreased by 35% between 1998 and 1995, and that the distribution 
of costs changed with reductions in inpatient hospitalisations (71% of total cost in 1992 to 45% in 
1995) and concomitant increases in outpatient visits (26% of total costs in 1992 to 49% in 1995).   
 
Citing previous evidence that organisational improvements and technological advances can have 
large effects on cost improvements, Freeman et al postulated that decreases in average length of 
stay (ALOS) and inpatient admission costs between 1989 and 1995 for NHL patients arose from 
three main sources: (i) organisational changes in relation to hospitals (including increased use 
outpatient facilities, better referral systems and more efficient use of staffing and resource), (ii) 
improvements in technology (for example, though use of granulocyte colony-stimulating factors or 
G-CSF mobilised SCT, more cost-effective laboratory procedures and advances in pharmacology), 
and (iii) improvements in patient case-mix and provider changes.  Regarding pharmacy costs, 
while costs decreased overall, the relative proportion of outpatient pharmaceuticals increased 10-
fold.   
 
In terms of disaggregated costing data, the most comprehensive analyses were: 
• a 2002 Dutch study of a cost analysis for HLA-identical sibling and voluntary unrelated 
allogeneic bone marrow and peripheral blood stem cell transplantation in adults with AML 
or ALL (van Agthoven et al 2002); and  
• a 2005 report prepared for the Technology Assessment Unit of the McGill University Health 
Centre (Canada) on allogeneic transplantation in adults of stem cells from unrelated 
donors.   
 
A study by Prajogo (2004) reporting the results of a cost comparison of high-dose chemotherapy 
and autologous bone marrow transplantation vs. standard dose chemotherapy for patients with 
non-Hodgkin’s lymphoma at the Calvary Mater Misericordiae Hospital in Newcastle provided the 
most relevant Australian analysis (see Section 0).   
 
A3 Regulation, compliance and quality management systems 
 
The Working Group noted the impact that the regulation of BMT services and requirements for 
compliance with quality management systems will have on laboratories and units providing BMT 
services.  In particular: 
• regulation of BMT services by the Therapeutic Goods Administration (TGA) was expected 
by mid-2009; 
• collection units would be required to comply with new National Pathology Accreditation 
Advisory Council (NAPAAC) standards June 2010, with inspection by the National 
Association of Testing Laboratories (NATA); and 
• if not already achieved, paediatric units were likely to want to obtain international 
accreditation with the Foundation for Accreditation Cellular Therapy (FACT).   
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The Working Group indicated the potential staffing, infrastructure and system requirements to 
implement FACT accreditation requirements, based on two Australian facilities that have already 
received TGA licences.  In doing so it referred to a 2004 estimate of costs (150,000 euros or 
$A240,000) for implementing processes to meet FACT standards and for compliance with Joint 
Accreditation Committee – ISCT (International Society for Cellular Therapy) and EBMT (European 
Bone Marrow Transplant Society) (JACIE) standards (Zahnd 2004).   
 
Estimates were developed by the National Institute for Clinical Excellence (NICE) in 2003 of the 
additional funds required to implement the JACIE standards throughout England and Wales.  
Funds of from £25.2 to £51.5 (or $A70.63 - $A144.34 (2007)) were expected to be required, 
depending on decisions regarding minimum levels of BMT services that might be provided by 
hospitals (NICE 2003).  The additional costs included the costs of providing specialist diagnostic 
services; of establishing and resourcing multi-disciplinary teams; of resourcing additional Clinical 
Nurse Consultants to deliver patient centred care; and of providing infrastructure, facilities and 
resources for high-dose therapy and transplant services. 
 
A4 Stages of transplantation 
 
In undertaking the project, it was necessary to allocate the care of transplant patients into stages 
or component periods of time based on clinical practice and reasons.  While some of the literature 
reflected the need for categorisation of BMT services, this varied across the range of studies.  In 
general, however, there was little reference, especially in economic evaluations, to the need to 
distinguish between costs with a direct link to transplantation versus costs that would have been 
incurred irrespective of whether a transplant was performed or not.  Eckstein et al (2007) found 
that, for heart-lung transplants, there was an argument that the costs incurred by being a candidate 
for transplant ‘should not be allocated to the cost of the transplant, since they would be incurred, at 
any rate, to maintain the patient or keep the patient alive, regardless of whether the patient is 
waiting for a transplant or not’ (from Hauboldt and Ortner 2002 in Eckstein et al 2007). 
 
Examples of studies that articulated stages or categories for which costs were derived include: 
• mobilisation and recovery of PBPC; post-mobilisation phase; conditioning and transplant; 
critical haematological reconstitution; non-critical haematological reconstitution; death 
(Barosi et al 99) 
• pre-transplant, transplant, post-transplant follow-up (Mishra et al 2001) 
• harvesting (including G-CSF assisted stem cell mobilisation, cryopreservation, pharmacy 
costs and nursing care) and high-dose chemotherapy phases for autologous 
transplantation (Mishra et al 2003 and 2005) 
• induction chemotherapy, post-induction/post-remission chemotherapy, transplantation and 
complications arising (Redaelli et al 2004). 
 
A5 Cost drivers 
 
Many of the studies identified factors that have an important impact on costs.  The cost drivers 
discovered depended partly on the type(s) of BMT services being studied, the aim of the study, the 
country in which the study was undertaken, data availability and the study methodology.  While, 
some studies found that there was no association between patient baseline characteristics and 
costs (for example, Lee et al 2000), several studies highlighted the importance of post-transplant 
complications, including disease relapse as well as infections and, in the case of allogeneic 
transplants, graft-vs.-host disease (GVHD) in terms of predicting high-cost (for example, Griffiths 
1993 in Westerman and Bennett 1996, Esperou et al 2004).   
 
A number of studies noted the fundamental structural differences between the United States and 
Europe in terms of health service delivery, resulting in different cost drivers for BMT services 
depending on where studies are conducted.   
 
One cost component that receives funding from the US Department of Health and Human Services 
is the National Bone Marrow Donor Registry ($US23m in 2005-06 budget, including $US10 for the 
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Cord Blood Stem Cell Bank) to assist the approximately 16,000 people under 55 diagnosed with 
leukaemia or another blood or genetic disorder who would need a blood stem cell transplant (FY 
2005 Budget in Brief. USA).  For patients with private health insurance, the costs of transplantation 
for certain types of cancer are covered by that insurance, while government financial assistance 
programs (through Medicaid and Medicare) are limited.  In 2005, the cost of tissue typing (range 
$US65 to $US96 or $A 90.38-$A 133.48 (2007)) was also funded by the donor, either fully or in 
part with the remainder covered by the donor centre.  Patient care costs for participants in clinical 
trials that are funded by the National Cancer Institute are often covered - either by patients’ health 
insurers or by Medicare (National Cancer Institute, U.S. National Institutes of Health).   
 
Gajewski et al (2004) discussed attempts during the past 20 years for the leading payers of US 
health care to control growth in health-care spending through managed care strategies.  Providers 
of expensive services such as BMT are particularly scrutinized, with their clinical programs subject 
to new methods of pricing medical services and financial accountability.  To protect themselves 
from excessive financial risk, providers have developed different payment rates for different types 
of transplant, eg, autologous versus HLA or genotypically matched related versus HLA 
mismatched transplants.  Because at certain times in the HCT process risk is more unpredictable, 
HCT providers require different payment system strategies for the different time periods of care 
such as evaluation, pre-transplant disease management, harvesting, and cell processing, as well 
as short and long-term follow-up.  These case rate agreements attempt to manage the 
unpredictable consequences of BMT such as regimen-related toxicities, infections and GVHD.   
 
Thus, hospital inpatient, medical staff costs and overheads along with pharmacy costs are much 
higher in the United States than in Europe or countries with so-called ‘socialised medicine’.  US-
based studies, therefore, tend to report significantly higher costs per patient than non-US based 
studies reflecting this difference in healthcare systems (Beard 2004).  Redaelli’s review of studies 
of AML (2004) found that, while hospital stays comprised 47-56% of total costs regardless of the 
country of study, the high overall cost found in US studies was due to higher hospital stay and 
pharmacy costs combined (34% and 31% respectively, from Du Foir 1992 and Bennett 1999 in 
Redaelli 2004).  That study also found that pharmacy costs were a considerably smaller proportion 
of overall costs in Europe (11-16%), while laboratory costs (in particular, pathology tests) and 
blood products were reported as major cost drivers in Europe (Westerman and Bennett 1996).   
 
For studies of autologous BMT, examples of cost drivers include: 
• Number of hospital days and blood products (for the period from hospital admission to 
discharge only) – (Hartmann et al 1997) 
• Stem cell mobilisation costs (harvest phase), nursing costs and pharmacy (Mishra et al 
2003 and 2005) 
• Room costs, laboratory, pharmacy, medical consultant fees; radiology and supportive care 
(Freeman et al 1999)  
• Total body irradiation (TBI) and conditioning regimens, number of hospital days, blood 
products, antibiotic and supportive care (Vicent et al 2001)  
• Induction chemotherapy (and within this, the number of cycles to achieve remission); post-
induction: blood products, inpatient costs (medical staff and accommodation), lab/radiology 
and pharmacy (Redaelli et al 2004) 
• Number of hospital days, number of stem cells collected, phase and type of disease, post-
transplant GVHD prophylaxis; whether patient is a child or adult (Barosi et al 99). 
 
For allogeneic transplants, examples of cost drivers include: 
• Tissue typing and donor stem cell collection costs, medical and nursing staff costs, 
pharmacy, blood products and laboratory costs (Mishra et al 2001)  
• Pharmacy, number of hospital days (Dooley et al 2007) 
• Number of hospital days, medical and nursing staff costs (Van Agthoven et al 2002)  
• Number of hospital days, post-transplant complications (Esperou et al 2004). 
 
For studies involving both autologous and allogeneic BMT, cost drivers include: 
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• Whether donor stem cells are matched or mismatched, year of transplantation and 
complications (infections, veno-occlusive disease, GVHD, death) (Lee et al 2000) 
• Pharmacy, blood bank and nursing costs (Yoder 98). 
In terms of overall costs, systematic reviews by Moeremans and Annemans (2006), Simnett et al 
(2000) and Redaelli et al (2004) provided cost summaries, as follows.   
Table 37:  Overall costs from studies of autologous transplantation using peripheral blood 
stem cells for patients with multiple myeloma 






Country Norway Norway Canada Netherlands Norway 






Can $ 32320 
(payer 
perspective) 






$A (2007)  $42,204 $58,896 $35,565 $114,167- 
$136,247 
$52,440 






90 months 36 months  36 months 
Source: Moeremans and Annemans 2006 
 
Simnett et al (2000) reported five studies (one randomised and four non-randomised comparisons) 
that compared use of high-dose chemotherapy and autologous transplantation with conventional 
chemotherapy for patients with either non-Hodgkin’s lymphoma, multiple myeloma, relapsed 
Hodgkin’s lymphoma or breast cancer, as follows: 
Table 38:  Overall costs from studies of high-dose chemotherapy and autologous 
transplantation with NHL, MM, relapsed HL or breast cancer 
 Uyl-de Groot et 
al (1995) 
Zaidi et al 1996 Henon et al 
(1995) 
Desch et al 
(1992) 






































42 11 22 - - 
 
For acute myeloid leukaemia, five studies published between 1989 and 1999 yielded proportions of 
cost drivers and total costs for BMT (for both autologous and allogeneic transplantation) as follows: 
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Table 39:  Overall costs from studies of BMT for acute leukaemia 
 Bennett et al 
(1999) 
Dufoir et al 
(1992) 
Viens-Bitker 
et al (1989) 




Dufoir et al 
(1992) 
Country US France France Canada Netherlands France 
Time horizon Transplant 5 years 12 months 18 months 2 years 5 years 
Medical staff and 
accommodation 
34% 24% 32% 51% 55% 23% 
Drugs 31% 15% 17% 11% 14% 8% 




13% 30% 29% 38% 13% 19% 
Other 11% 6% 5%  -  -  6% 
























BMT type Allogeneic Allogeneic Allogeneic Allogeneic Autologous Autologous 
Source: Redaelli et al 2004 
 
Beard et al (2004) reported total direct medical costs of high-dose chemotherapy with stem cell 
support (either autologous bone marrow transplantation or peripheral blood stem cell 
transplantation) for 15 studies of patients with either non-Hodgkin’s lymphoma or other 
malignancies such as breast cancer and leukaemia.  Some studies were retrospective (study 
periods range from 1989 to 1999) and each covered one or more stages including: induction 
(mobilisation and harvesting), treatment, post-transplant and post-discharge period.  Comparisons 
were therefore difficult, with costs ranging from $US9,100 (or $A19,312 (2007)) for PBSCT with 
G-SCF for NHL (from Lee et al 1998) to $US74,000 (or $A157,049 (2007)) for PBSC for lymphoma 
(Bennett et al 1995). 
 
A6 Detailed cost analyses, by stage of transplant. 
 
A6.1 Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone 
marrow and peripheral blood stem cell transplantation in adults with AML or ALL 
 
In a cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and 
peripheral blood stem cell transplantation in adults with AML or ALL in four Dutch hospitals, van 
Agthoven et al (2002) retrospectively allocated direct medical costs for patients treated between 
1994 and 1999, in two ways:  
• by multiplying the medical consumption units used by patients by the unit cost of each item; 
and 
• by identifying cost not tied to the patient’s medical registration from hospitals’ financial 
departments and by expert opinion 
The analysis included costs for patients prepared for, but who did not undergo, transplantation, 
and covered all stages from pre-transplant tissue typing up to 24 months after transplantation.  
Costs were separately identified for three transplant types (bone marrow transplant, matched 
unrelated donor and peripheral blood stem cell transplant) according to the following categories:  
• pre-transplant screening of patient using serological and molecular methods (average total 
cost 2.342 euros (2002) (or $A4,620 (2007)) 
• stem cell harvesting in one session (for BMT patients), or two sessions (for PBSCT 
patients);  
• CD34 selection or T-cell depletion; 
• donor lymphocyte infusion (if patients needed one or more additional infusions);  
• total body irradiation and transplantation personnel.   
Costs were further allocated either to the pre-transplant phase, transplantation phase, or to one of 
the three follow-up phases (that is, 1-6 months, 6-12 months and 12-24 months after 
transplantation).   
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For unrelated donors, the costs included ‘donor costs’ involving family HLA-typing and typing of the 
selected donor; the cost of requesting blood samples or donor grafts; sample typing (HLA-retyping 
of blood samples collected in each of the Dutch hospitals); and Europdonor intermediation).  The 
calculation of average costs was based on unit costs of hospital days, day care treatments and 
outpatient visits (van Agthoven 2002 Table 1, p.  245), as well as personnel costs based on FTE 
requirements and employer costs per FTE (van Agthoven 2002 Table 3, p.  247). Table 40 shows 
average costs per patient for the transplant phase.  
Table 40:  Average costs per patient for transplantation stage components  
Cost component BMT MUD PBSCT 
 Euro 2002 Euro 2002 Euro 2002 
Pretransplantation 
screening 
2342 2342 2342 
Donor costs 10 843 47 063 11 137 
Haematology ‘isolation’ 
hospital days 
16 248 17 622 17 716 
Consultations 98 113 120 
Cytostatics 94 102 124 
Antibiotics 2700 3394 2058 
Hematopoietic growth 
factors 
337 34 103 
Immunosuppressants 510 638 720 
ATG anti-thymocyte 
globulin 
0 2723 0 
Other medication 451 473 497 
Blood components 1303 2405 2552 
Parenteral nutrition 602 645 341 
TBI (P&M-9) 1441 1441 1441 
Laboratory diagnostics 2038 2763 2610 
Microbiology diagnostics 1047 1452 1271 
Pathology diagnostics 993 752 1306 
Radiology diagnostics 396 509 817 
Other imaging diagnostics 290 182 300 
Other procedures 396 295 279 
Total costs, excluding 
personnel costs 
42 129 84 948 45 734 
Total costs, excluding 
personnel costs $A (2007) 
83,820 16,9013 90,992 
Source: van Agthoven 2002, Table 4 p 248 
 
Table 41 shows average costs per living patient for the three follow-up phases, and Table 42 
shows average costs per transplanted patient.  The analysis directly links allogeneic infrastructure 
requirements in the Netherlands to costs.   
 
 
Centre for Health Service Development 
 
Page 72    Final Report: A Costing Study of Blood & Marrow Transplantation Services in NSW 
 
Table 41:  Average costs per (living) patient in follow-up phases 
Cost component Follow-up phase 1 Follow-up phase 2 Follow-up phase 3 






















6066 8801 4121 3993 5866 3103 3912 5620 2129 
Intensive Care 
hospital days 
0 543 0 0 1143 0 0 0 0 
Haematology 
outpatient visits 
1436 1216 1253 805 678 593 654 1696 365 
Other 
consultations 
402 707 657 286 523 482 326 572 402 
Antibiotics 11 1006 109 132 166 12 0 0 0 
Hematopoietic 
growth factors 
0 368 0 0 0 0 0 0 0 
Other medication 7 116 88 9 35 4 0 6 0 
Day care 
department 
106 260 112 46 14 15 104 46 0 
Radiotherapy 0 0 0 0 216 0 83 0 0 
Blood components 1317 2740 1127 1006 1735 1027 599 1270 210 
Laboratory 
diagnostics 
2717 4796 2486 1800 3161 2769 1358 2256 1403 
Microbiology 
diagnostics 
732 1180 706 359 757 766 255 202 493 
Pathology 
diagnostics 
1692 2413 2201 811 1765 1159 411 509 706 
Radiology 
diagnostics 
525 1119 441 394 879 1133 163 714 293 
Other imaging 
diagnostics 
469 1060 567 340 904 1065 129 398 261 








16587 30292 15051 10157 18473 12265 8093 13331  6313 



















Total costs, excl 
personnel costs 
($A) (2007)** 
33,001 60,269 29,945 20,208 36,754 24,402 16,101 26,523 12,560 
Follow-up phase 1 = from first discharge after transplantation up to 6 months after transplantation date.  Follow-up phase 
2 = 6–12 months after transplantation date.  Follow-up phase 3 = 12–24 months after transplantation date. 
Source: van Agthoven 2002, Table 6 p 249 
* Not escalated  ** Escalated using Reserve Bank of Australia Inflation Calculator (RBA) www.rba.gov.au  
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Table 42:  Average costs per transplanted patient 

































Personnel 26543  26543 26543  26543 26543  26543 
Transplantation 42129 100 42129 84948 100 84948 45734 100 45734 
FU1-phase 16587 98 16255 30292 90 27263 15051 92 13847 
FU2-phase 10157 81 8227 18473 48 8867 12265 77 9444 
FU3-phase 8093 64 5180 13331 31 4133 6313 54 3409 
Total costs 103509  98334 173587  151754 105906  98977 
Total costs 
($A 2007) 
205,942  195,646 345,369  301,930 210,711  196,925 
Source: van Agthoven 2002, Table 7 p 249 
 
A6.2 Study 2 – Evaluation of the use of cord blood as alternative stem cell source 
 
The Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC) reported 
on an evaluation of the use of umbilical cord blood as an alternative source of donor stem cells for 
treatment of adults at that centre, for allogeneic transplantation from unrelated donors.  Costs were 
calculated separately for: (i) the transplantation procedure up to the time of hospital discharge, and 
(ii) subsequent costs up to 10 years after transplantation.  Costs were obtained from the Finance 
Department at MUHC and based on resource use by 15 patients who underwent allogeneic stem 
cell transplantation from related donors, and 2 patients who underwent cord blood transplantations 
from unrelated donors in 2004. 
Table 43:  Hospitalisation cost of an allogeneic stem cell transplantation at MUHC 
 Cost estimate at the MUHC 
(CDN 2005) 
Allogeneic peripheral blood stem 
cell transplantation (N=15) 
Cost estimate at the MUHC 
(CDN 2005) 
Allogeneic cord blood stem cell 
transplantation (N=2) 
Mean length of stay (days)  38 45 
Staff (Transplant coordinator, 
nursing*)  
$15,646 $18,528 
Supplies  $1,191 $1,410 
Pharmacy  $18,324 $18,324 
Imaging and diagnostic tests  $989 $989 
Laboratory  $1,582 $1,582 
HLA matching  $753 $753 
Stem cells laboratory (virology and 
microbiology tests, staff and 
supplies)  
$1,823 $1,823 
Haematologist fees  $1,835 (38 x $48.30§) $2,070 (40 x $48.30 + 5 x $27.5) 
Infectologist consultation fees  $77 ($95.40 x 81%)¶ $77 ($95.40 x 81%)¶ 
Total cost of an allogeneic stem cell 
transplantation at the MUHC  
$42,220 $45,556 
Total cost of an allogeneic stem 
cell transplantation at the MUHC 
($A 2007) 
$48,516 $52,349 
Note: Excludes overhead, bone marrow harvesting and donor costs. 
 
The MUHC results were compared with the estimated direct hospitalisation costs obtained from 
five European economic analyses of stem cell transplantation (four of stem cell transplantation and 
one of allogeneic stem cell transplantation) of from $34,475 to $66,500 (CDN 2005) (or $A39,616 
to $A52,349 (2007)).   
 
MUHC also estimated the costs of complications that might occur during a 10 year follow-up period 
(see Table 44), while noting that only ‘extremely meagre’ data on which to base estimates existed.  
Based on possible relapses, infections and chronic GVHD, MUHC estimated that the total cost of 
an allogeneic stem cell transplantation including a 10-year follow-up (excluding the cost of 
procurement of stem cells) in an adult patient at the MUHC would be approximately CDN$57,000 
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and CDN$60,500 (or $A65,500 and $A69,522 (2007)) for bone marrow and cord blood 
respectively.   
Table 44:  Costs during the follow-up period 
Treatment Unit cost (CDN 2005) Unit cost 
$A (2007) 
Relapses $4,169 Chemotherapy 
$2,165 – palliative care  




Infection $4,097 $4,988 
Chronic GVHD $3,228 (outpatient visit, nursing costs and physician fee – 3x per week, 
pathology, medication costs (cyclosporine, prednisolone) 
$3,709 
 
Follow-up visits $60 (physician fee $20; nursing cost $11 for 15 mins; lab tests $29 $68 
Note: Costs discounted 3% 
 
A7 Casemix and transplantation 
 
Two studies found that Diagnosis Related Group (DRG) based reimbursement underestimated the 
average total costs of BMT services.  A study in Norway (based on a small sample of only 17 
patients) collected costs prospectively for blood and bone marrow transplantation for patients 
diagnosed with leukaemia (both chronic myeloid and acute lymphatic leukaemia ) and 
myelodysplastic syndrome.  Costs for pre-transplant services, the transplant itself and 1 year 
post-transplant follow-up services were collected and compared with hospital reimbursement.  The 
results indicated that DRG reimbursement costs for blood and bone marrow transplantation greatly 
underestimated the actual costs, with treatment being heavily subsidised by basic hospital grants 
(Mishra et al 2001).   
 
A French 2004 study found a similar discrepancy between the DRG prospective payment system 
in that country and actual costs (Esperou et al 2004). 
 
An Australian analysis found that some Australian DRG cost weights were too low, with 
consequent adverse impacts on the funding of State-wide referral services (Antioch and 
Walsh 2004).  The study was targeted towards high-complexity DRGs relating to State-wide 
referral services, specifically, for respiratory, cardiology and stroke conditions.  Given that the 
analysis was completed almost 5 years ago, and that the three Australian BMT DRGs encompass 
a wide range of increasingly complex and costly BMT service types, it is reasonable to apply the 
conclusion from that study to the current situation regarding BMT services. 
 
A8 Previous cost estimates 
 
State government officials from the relevant departments in Victoria, Queensland, South Australia 
and Western Australia were contacted regarding the existence of any documented costing studies 
in those states.  Only two studies were discovered – a very small scale study undertaken in 
Queensland in 2004, and a study undertaken by the Royal Melbourne Hospital.  Permission to 
include details of the latter study has not yet been granted and remains the subject of negotiation 
with Royal Melbourne Hospital.  
 
A8.1 Queensland – 2004 
 
A study of approximate costs of bone marrow transplants, by transplant type, undertaken at the 
Royal Brisbane and Women’s Hospital dated 2004 yielded overall costs per patient type only.  It 
should be noted that the study used a very small sample of only two patients in each costing type. 
 
Costs included: 
• direct inpatient ward costs 
• indirect patient costs 
• pharma/drug costs 
• pathology costs 
• medical imaging costs 
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• bone marrow transplant lab costs 
• bone marrow transplant donor costs 
• bone marrow transplant courier costs 
• total body irradiation 
• allied health professional costs 
• day therapy unit/clinic costs. 
 
Costs were estimated using either direct patient costs or estimated costs calculated on the basis of 
the number of separations/bed days per patient. 
Table 45:  Total costs by transplant type (2004) 
Transplant Type Unit Range ($A) Unit Range ($A2007) 
Allogeneic BMT – MUD (voluntary unrelated donor) 115,411-276,575 125,545- 300,861 
Allogeneic BMT – sibling 85,106-180,392 92,579- 196,232 
Non myelo-ablative (mini) Allogeneic BMT – MUD 
(voluntary unrelated donor)/sibling 
14,552***-135,748 15,830- 147,668 
Autologous BMT – Lymphoma 45,848**-47,207 49,874- 51,352 
Autologous BMT – Myeloma 48,751-53,503 53,032- 58,201 
Note: All patients survived after transplant with one exception - **deceased at 12 days post-transplant 
***Excludes transition inpatient costs. 
 
Based on these costs, senior bone marrow staff were consulted to determine mean approximate 
minimum costs for autologous and allogeneic transplants.  Figures of $50,000 and $120,000 (or 
approx $54,500 and $130,5007) respectively were agreed. 
 
A8.2 Newcastle Mater Misericordiae Hospital (NMMH)- 2004 
 
In analysis undertaken for a (2004) Master of Medical Science thesis, Prajogo investigated the 
costs of high-dose chemotherapy and autologous bone marrow transplantation vs. standard 
chemotherapy in patients with relapsed non-Hodgkin’s lymphoma.   
 
Data was obtained for a small sample of eligible local patients with intermediate-high grade NHL 
treated at NMMH from January 1995 to June 2002.  Out of a total of 69 patients with NHL, 23 
patients were included in the study which examined direct medical costs drawn from medical 
records for the period from induction chemotherapy to conditioning and transplant only.  The costs 
of each chemotherapy cycle were assumed to be constant.  High-dose chemotherapy 
encompassed three doses of ESHAC (etoposide, solumedreol, Ara-C and carbolatin) followed by 
LACE (lomustine, Ara-C, cyclophosphamide and etoposide) and transplantation.  Costs comprised 
pharmaceuticals (chemotherapy drugs, G-CSF, antibiotics, antivirals, antiemetics, other), 
laboratory, radiology, blood component therapy, special medical consultations, allied health 
services (dietician, physio, social worker, pastoral care), inpatient admissions and outpatient 
attendances.   
 
Unit prices were used to calculate costs for hospital bed-days (NSW Health 2000 charges), 
medical procedures, pathology, radiology, blood bank services (Medicare Benefits Schedule 
2001), transplant procedure charge (Medicare item 13700) and drugs (Pharmaceutical Benefits 
Schedule August 2001 or MIMS 2001). 
 
A8.3 Induction Phase Costs  
 
Each patient received three cycles of ESHAC delivered in the outpatient setting, as reflected in the 
higher outpatient attendance costs relative to inpatient admissions.   
                                                
7 Escalated using Reserve Bank of Australia Inflation Calculator (RBA) www.rba.gov.au  
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Table 46:  Pharmaceuticals - induction phase 
Item Mean cost per cycle 
($A 2001) 
Mean cost per cycle ($A 2007)* 
Chemotherapy 1233 1453 
G-CSF 1227 1446 
Antibiotics, Antivirals 53 62 
Antiemetics 81 95 
other drugs 18 21 
Total 2,612 3,078 
(from Prajogo 2004, Table 4.24 p.  63) 
*  Escalated using Reserve Bank of Australia Inflation Calculator (RBA) www.rba.gov.au  
Table 47:  Non-pharmaceuticals - induction phase 
Item Mean cost per cycle ($A 2001) Mean cost per cycle ($A 2007)* 
Laboratory 287 338 
Radiology 188 221 
Blood component therapy 39 45 
Medical consultation 103 121 
Inpatient admissions 686 808 
Outpatient attendances 1645 1938 
Total 2,948 3,516 
(from Prajogo 2004, Table 4.25 p.  64) 
*  Escalated using Reserve Bank of Australia Inflation Calculator (RBA) www.rba.gov.au  
 
Table 46 shows that G-CSF alone comprised almost 50% of total pharmaceutical cost per cycle.  
When pharmaceutical and non-pharmaceutical costs were combined, the total mean cost per 
patient per cycle for the induction phase was $5560. 
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A8.4 Conditioning and BMT phase 
Table 48:  Pharmaceuticals - conditioning and BMT phase 
 Mean cost per patient % of total Mean cost per patient* 
 $ ($A 2001)  ($A 2007) 
Chemo (conditioning) 2402 33 2830 
G-CSF 1867 25 2200 
Antibiotics, Antivirals, antifungals 2049 28 2414 
Antiemetics 658 9 775 
other drugs 312 5 367 
Total 7,288 100 8,518 
(from Prajogo 2004, Table 4.27 p.  66) 
*  Escalated using Reserve Bank of Australia Inflation Calculator (RBA) www.rba.gov.au  
 
Table 49:  Non-pharmaceuticals per cycle - conditioning and BMT phase 
 Mean cost per patient % of total  Mean cost per patient* 
 $ ($A 2001)  ($A 2007) 
Laboratory 2391 17 2817 
Radiology 1377 10 1622 
Blood component therapy 1045 6 1231 
Medical consultation 1078 8 1270 
Inpatient admissions 7000 49 8249 
Outpatient attendances 1409 10 1660 
Total 14,300 100 16,852 
(from Prajogo 2004, Table 4.28 p.  67) 
Note: Assumes cost of allied health services is included in inpatient admissions costs 
*  Escalated using Reserve Bank of Australia Inflation Calculator (RBA) www.rba.gov.au  
 
Examination of Table 48 and Table 49 together show that the cost of inpatient admissions 
comprised almost 50% of the total non-pharmaceuticals cost for the conditioning and BMT phase, 
that is, about the same proportion of total cost as pharmaceuticals for this phase.  Addition of costs 
for pharmaceuticals and non-pharmaceuticals shows that the mean total cost per patient for the 
conditioning and BMT phase was $21589 (or $25,370 (2007)). 
 
Table 50 shows mean costs per patient for induction, conditioning and BMT combined.  The total 
pharmaceuticals and non-pharmaceuticals cost per patient are shown, as well as the component 
costs within each of the two main groups.  
Table 50:  Total mean costs per patient - induction, conditioning and BMT 
 Mean cost ($A 2001) % Mean cost ($A 2007)* 
Pharmaceuticals 14757 39 17391 
Non-pharmaceuticals 22733 61 26791 
Total 37,490 100 44,182 
Pharmaceuticals (total)    
Chemotherapy (conditioning) 5928 40 6986 
G-CSF 5376 36 6335 
Antibiotics, Antivirals, antifungals 2200 15 2592 
Antiemetics 890 6 1048 
Other drugs 363 3 427 
Total 14,757 100 17,391 
    
Non-pharmaceuticals    
Laboratory 3212 14 3785 
Radiology 1915 8 2256 
Blood component therapy 1157 5 1363 
Medical consultation 1373 6 1618 
Inpatient admissions 8962 40 10561 
Outpatient attendances 6114 27 7205 
Total 22,733 100 26,791 
(from Prajogo 2004, Tables 4.30, 4.31 and 4.32 pp.  69-71) 
*  Escalated using Reserve Bank of Australia Inflation Calculator (RBA) www.rba.gov.au  
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A8.5 Cost drivers 
This study found that non-pharmaceuticals comprised the largest overall cost (61%) of the 
induction, conditioning and BMT stages of treatment for NMMH patients with relapsed NHL using 
high-dose chemotherapy and autologous bone marrow transplantation between 1995 and 2002.  
This was due mainly to the cost of inpatient stay (40% of total non-pharmaceuticals cost).  In terms 
of component costs of pharmaceuticals, the largest cost drivers were chemotherapy and G-CSF. 
 
The estimated total mean cost per patient of $37,490 (2001) can be compared with costs reported 
in two Dutch studies of autologous transplantation (i) in patients with lymphoma and acute 
leukaemia, and (ii) in patients with NHL.  Total costs were equivalent to $A70,7698 and $A59,5009  
respectively (from Uyl-De Groot 1995a and 1995b, in Prajogo).  The differences between these 
costs and those reported by Prajogo can be attributed, in part, to use of total body irradiation 
before transplantation in the Dutch studies, as well as lower utilisation rates (for example, medical 
consultations) in Australia, and differences in the costs of hospitalisation and blood products 
between the two countries.  Also germane were: (i) the much lower proportion of total costs of 
pharmaceuticals in the second Dutch study (13% compared with 39% in Prajogo), consistent with 
the introduction of G-CSF and the greater role of the outpatient setting in the latter study; and (ii) 
the use of PBSCT rather than ABMT, leading to shorter hospital stays and reduced blood product 
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Appendix 3 Cost by cost bucket allogeneic transplants  
 
 St Vincent's Royal North Shore Westmead Sydney Children's Hospital Children’s Hospital 
Westmead 
Cost Bucket Mean % of Total Mean % of Total Mean % of Total Mean % of Total Mean % of Total  
Allied Health costs $653 0.76% $4,625 7.07% $3,018 3.26% $2,768 1.92% $4,220 2% 
Emergency Dept cost $23 0.03% $65 0.10% $0 0.00% $22 0.02% $33 0% 
ICU costs $1,040 1.21% $0 0.00% $9,860 10.67% $12,328 8.55% $30,253 17% 
Imaging costs $759 0.88% $969 1.48% $484 0.52% $1,649 1.14% $2,041 1% 
Medical cost $8,940 10.41%  0.00% $5,427 5.87% $18,790 13.03% $7,836 4% 
Oncosts $4,700 5.47% $1,977 3.02% $4,011 4.34% $5,256 3.65% $6,644 4% 
Other costs $1,902 2.21% $1,703 2.60% $3,238 3.50% $7,180 4.98% $7,898 4% 
Pathology costs $4,704 5.48% $3,829 5.86% $6,806 7.36% $7,539 5.23% $11,386 6% 
Pharmacy cost $30,561 35.60% $27,013 41.32% $27,183 29.41% $33,388 23.16% $46,850 26% 
Ward costs $32,571 37.94% $25,189 38.53% $32,412 35.06% $55,264 38.33% $59,795 34% 
Total cost $85,853 100.00% $65,368 100.00% $92,440 100.00% $144,184 100.00% $176,955 100.00% 
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Appendix 4 Cost by cost bucket autologous transplants  
 
 St Vincent's Royal North Shore Westmead Prince of Wales St George Nepean 
Cost Bucket Mean % of 
Total 
Mean % of 
Total 
Mean % of 
Total 
Mean % of 
Total 
Mean % of 
Total 
Mean % of 
Total  
Allied Health costs $411 0.86% $2,797 5.72% $715 1.95% $264 0.50% $825 2.49% $904 2.63% 
Emergency Dept cost  0.00% $162 0.33%  0.00%  0.00%  0.00%  0.00% 
ICU costs $4,044 8.46% $1,158 2.37% $1,012 2.76% $1,497 2.82% $616 1.86% $1,166 3.39% 
Imaging costs $504 1.05% $1,097 2.24% $237 0.65% $441 0.83% $561 1.69% $1,354 3.93% 
Medical cost $3,800 7.95%  0.00% $3,600 9.81% $1,397 2.64% $2,106 6.36% $2,899 8.42% 
Oncosts $2,721 5.69% $1,930 3.95% $1,963 5.35%  0.00% $1,300 3.92% $1,538 4.47% 
Other costs $1,292 2.70% $1,565 3.20% $1,891 5.15% $3,264 6.16% $878 2.65% $735 2.14% 
Pathology costs $2,776 5.80% $2,904 5.94% $3,392 9.24% $2,029 3.83% $2,239 6.76% $729 2.12% 
Pharmacy cost $13,930 29.13% $16,944 34.66% $6,330 17.25% $29,937 56.47% $7,267 21.93% $7,199 20.92% 
Ward costs $18,340 38.35% $20,335 41.59% $17,548 47.83% $14,182 26.75% $17,341 52.34% $17,892 51.99% 
Total cost $47,818 100.00% $48,892 100.00% $36,688 100.00% $53,011 100.00% $33,133 100.00% $34,415 100.00% 
 




Cost Bucket Mean % of 
Total 
Mean % of 
Total 
Allied Health costs $714 2% $1,192 3% 
Emergency Dept cost $0 0% $576 2% 
ICU costs $4,197 11% $1,937 5% 
Imaging costs $503 1% $738 2% 
Medical cost $5,331 14% $1,859 5% 
Oncosts $1,630 4% $1,047 3% 
Other costs $2,802 8% $1,745 5% 
Pathology costs $1,822 5% $2,367 6% 
Pharmacy cost $7,925 22% $8,204 22% 
Ward costs $11,918 32% $18,451 48% 
Total cost $36,841 100% $38,117 100% 
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Appendix 5 The NSW cost data collection  
 
Table 51 below shows the results of the 2006/07 NSW Department of Health annual hospital cost 
data collection for the three BMT AR-DRGs. 
Table 51:   Average total BMT cost (NSW Health Cost Data Collection) 
 
AR-DRG AO7Z = Allogeneic Bone Marrow Transplant 
AR-DRG AO8A = Autologous Bone Marrow Transplant with catastrophic complications or comorbidities   
AR-DRG AO8B = Autologous Bone Marrow Transplant without catastrophic complications or comorbidities   
 
Hospital A07Z A08A A08B 
St Vincent's Hospital $81,365 $63,883 $30,234 
Westmead Hospital $127,402 $38,508 $23,453 
Royal North Shore Hospital $67,180 $55,525 $28,518 
Royal Prince Alfred Hospital $100,196 $64,720 $36,798 
Concord Hospital $0 $43,891 $19,050 
Gosford Hospital $0 $54,786 $23,544 
Liverpool Hospital $0 $39,006 $19,810 
John Hunter Hospital $0 $104,129 $24,014 
Nepean Hospital $0 $130,240 $35,373 
Newcastle Mater Hospital $0 $37,697 $8,485 
Prince of Wales Hospital $0 $66,355 $33,546 
St George Hospital $0 $38,743 $23,063 
Wollongong Hospital $0 $44,102 $18,380 
Sydney Children's Hospital $163,867 $64,372 $8,789 
Children's Hospital Westmead $191,334 $56,522 $17,915 
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Appendix 6 The National Hospital Cost Data Collection  
 
Table 52 below presents summary results for Round 11 (2006/07) of the National Hospital Cost 
Data Collection for the three BMT AR-DRGs. 
 




AR-DRG Description Average Cost 





 National    
A07Z Allogeneic Bone Marrow Transplant $95,303 343 19 
A08A Autologous Bone Marrow Transplnt+Ccc $44,301 478 36 
A08B Autologous Bone Marrow Transplnt-Ccc $15,127 394 35 
  New South Wales - Estimated        
A07Z Allogeneic Bone Marrow Transplant $115,121 118 9 
A08A Autologous Bone Marrow Transplnt+Ccc $56,555 137 15 
A08B Autologous Bone Marrow Transplnt-Ccc $22,157 121 15 
  Victoria - Estimated        
A07Z Allogeneic Bone Marrow Transplant $86,313 91 5 
A08A Autologous Bone Marrow Transplnt+Ccc $38,086 164 8 
A08B Autologous Bone Marrow Transplnt-Ccc $11,477 96 8 
  Queensland - Estimated        
A07Z Allogeneic Bone Marrow Transplant $62,676 78 2 
A08A Autologous Bone Marrow Transplnt+Ccc $42,757 90 5 
A08B Autologous Bone Marrow Transplnt-Ccc $19,014 50 5 
  South Australia - Estimated        
A07Z Allogeneic Bone Marrow Transplant $83,092 18 2 
A08A Autologous Bone Marrow Transplnt+Ccc $30,793 35 3 
A08B Autologous Bone Marrow Transplnt-Ccc $13,391 43 2 
  Western Australia - Estimated        
A07Z Allogeneic Bone Marrow Transplant $128,873 37 3 
A08A Autologous Bone Marrow Transplnt+Ccc $41,916 31 4 
A08B Autologous Bone Marrow Transplnt-Ccc $4,453 55 4 
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 Appendix 7 Related Inpatient Episodes – Cost by AR-DRG 
DRG DRG title Number of 
Episodes 





Q60A Reticuloendothelial and Immunity Disorders W 
Catastrophic or Severe CC 
45.3 $912,264 $1,415 14.22 
R60A Acute Leukaemia W Catastrophic CC 14.8 $741,796 $2,111 23.7 
R60C Acute Leukaemia W/O Catastrophic or Severe 
CC 
181.8 $665,420 $1,644 2.2 
R61B Lymphoma and Non-Acute Leukaemia W/O 
Catastrophic CC 
86.3 $594,017 $1,513 4.5 
A06Z Tracheostomy or Ventilation >95 hours 4.2 $362,841 $2,452 35.5 
T60A Septicaemia W Catastrophic or Severe CC 23.5 $326,041 $1,672 8.3 
R61A Lymphoma and Non-Acute Leukaemia W 
Catastrophic CC 
11.3 $310,478 $1,568 17.5 
R60B Acute Leukaemia W Severe CC 19.8 $266,755 $1,524 8.8 
T62A Fever of Unknown Origin W CC 29.0 $244,690 $1,537 5.5 
R03A Lymphoma and Leukaemia with other OR 
procedures W catastrophic or severe CC 
4.2 $181,917 $1,487 29.4 
B66B Nervous System Neoplasm W/O Catastrophic 
or Severe CC 
31.0 $140,497 $1,489 3.0 
B60B Established Paraplegia/Quadriplegia W or W/O 
O.R. Procs W/O Catastrophic CC 
1.0 $136,776 $1,169 117.0 
B02A Craniotomy W Catastrophic CC 1.0 $124,249 $2,845 43.7 
B66A Nervous System Neoplasm W Catastrophic or 
Severe CC 
11.0 $119,202 $1,568 6.9 
F75B Other Circulatory System Diagnoses W Severe 
CC 
9.3 $97,569 $1,517 6.9 
E62B Respiratory Infections/Inflammations W Severe 
or Moderate CC 
6.5 $79,850 $1,369 9.0 
Q60B Reticuloendothelial and Immunity Disorders 
W/O Cat or Severe CC W Malignancy 
9.0 $76,778 $1,525 5.6 
R61C Lymphoma and Non-Acute Leukaemia, Same 
Day 
128.7 $71,729 $557 1.0 
G02A Major Small and Large Bowel Procedures W 
Catastrophic CC 
1.0 $70,473 $1,499 47.0 
L02A Operative insertion of peritoneal catheter for 
dialysis W cat or Severe CC 
1.0 $69,575 $1,449 48.0 
Q61C Red Blood Cell Disorders W/O Catastrophic or 
Severe CC 
17.3 $69,574 $1,273 3.2 
G60A Digestive Malignancy W Catastrophic or Severe 
CC 
8.7 $69,083 $1,524 5.2 
X63A Sequelae of Treatment W Catastrophic or 
Severe CC 
2.5 $62,301 $1,016 24.5 
T62B Fever of Unknown Origin  W/O CC 8.3 $58,855 $1,682 4.2 
I65B Connective Tissue Malignancy, including 
Pathological Fx W/O Cat or Sev CC 
13.3 $58,710 $2,072 2.1 
L09A Other Procedures for Kidney and Urinary Tract 
Disorders W Cat CC 
0.3 $54,474 $1,993 82.0 
R64Z Radiotherapy 19.3 $53,515 $2,768 1.0 
T01A O.R. Procedures for Infectious and Parasitic 
Diseases W Catastrophic CC 
1.7 $53,493 $1,888 17.0 
Q60C Reticuloendothelial and Immunity Disorders 
W/O Cat or Sev CC W/O Malignancy 
10.8 $51,956 $1,332 3.6 
F67A Hypertension W CC 1.7 $51,276 $1,690 18.2 
R01A Lymphoma and Leukaemia W Major O.R. 
Procedures W Catastrophic or Severe CC 
1.7 $51,000 $477 64.2 
T60B Septicaemia W/O Catastrophic or Severe CC 4.8 $48,977 $1,477 6.9 
F75A Other Circulatory System Diagnoses W 
Catastrophic CC 
2.0 $48,124 $1,641 14.7 
G46A Complex Gastroscopy W Catastrophic or 2.7 $46,786 $1,477 11.9 
 




Page 84    Final Report: A Costing Study of Blood & Marrow Transplantation Services in NSW 
DRG DRG title Number of 
Episodes 






G12A Other Digestive System O.R. Procedures W 
Catastrophic or Severe CC 
2.0 $46,601 $1,571 14.8 
Q61B Red Blood Cell Disorders W Severe CC 6.0 $45,538 $1,469 5.2 
T63A Viral Illness Age >59 or W CC 4.2 $45,360 $1,495 7.3 
Q61A Red Blood Cell Disorders W Catastrophic CC 2.0 $44,851 $1,583 14.2 
A41A Intubation Age<16 W CC 1.3 $35,983 $2,570 10.5 
F04A Cardiac Valve Proc W CPB Pump W/O Invasive 
Cardiac Inves W Cat CC 
1.0 $35,500 $2,958 12.0 
F75C Other Circulatory System Diagnoses W/O 
Catastrophic or Severe CC 
7.0 $35,421 $1,586 3.2 
I04Z Knee Replacement and Reattachment 0.3 $35,141 $1,506 70.0 
D67A Oral and Dental Disorders Except Extractions 
and Restorations 
3.0 $33,743 $1,066 10.6 
S65B HIV-Related Diseases W Severe CC 2.0 $32,920 $1,606 10.3 
L63A Kidney and Urinary Tract Infections W 
Catastrophic CC 
1.7 $32,358 $1,184 16.4 
K64B Endocrine Disorders W/O Catastrophic or 
Severe CC 
8.3 $31,926 $1,520 2.5 
E01A Major Chest Procedures W Catastrophic CC 1.0 $31,843 $2,123 15.0 
E01B Major Chest Procedures W/O Catastrophic CC 2.3 $31,552 $2,868 4.7 
R63Z Chemotherapy 31.0 $29,750 $960 1.0 
S65A HIV-Related Diseases W Catastrophic CC 1.5 $29,531 $3,109 6.3 
E62A Respiratory Infectn/Inflamm+Cc 0.8 $29,253 $1,463 24.0 
L60B Renal Failure W Severe CC 1.3 $29,000 $1,338 16.3 
I65A Connective Tissue Malignancy, including 
Pathological Fx W Cat or Sev CC 
3.0 $27,439 $1,914 4.8 
G60B Digestive Malignancy W/O Catastrophic or 
Severe CC 
9.0 $26,842 $1,610 1.85 
Z64B Other Factors Influencing Health Status, Same 
Day Geriatric 
26.3 $25,926 $985 1.0 
T64A Other Infectious and Parasitic Diseases W 
Catastrophic or Severe CC 
2.3 $24,141 $1,766 5.9 
G67A Oesophagitis, Gastroent & Misc Digestive 
System Disorders Age >9 W Cat/Sev CC 
4.2 $21,080 $1,318 3.8 
R01B Lymphoma and Leukaemia W Major O.R. 
Procedures W/O Catastrophic or Severe CC 
2.0 $20,585 $1,287 8.0 
K64A Endocrine Disorders W Catastrophic or Severe 
CC 
3.3 $20,428 $2,043 3.0 
B07A Peripheral and Cranial Nerve & Other Nervous 
System Procedures W CC 
1.0 $19,647 $756 26.0 
D63A Otitis Media and URI W CC 3.7 $18,555 $1,295 3.9 
S60Z HIV, Same Day 26.5 $18,546 $700 1.0 
K62B Miscellaneous Metabolic Disorders Age >74 or 
W Severe CC 
3.7 $16,394 $1,329 3.4 
E71B Respiratory Neoplasms W Severe or Moderate 
CC 
4.3 $16,391 $1,891 2.0 
G67B Oesophagitis, Gastroent & Misc Digestive 
System Disorders Age >9 W/O Cat/Sev CC 
3.8 $15,572 $857 4.7 
G12B Other Digestive System O.R. Procedures W/O 
Catastrophic or Severe CC 
1.0 $15,335 $2,556 6.0 
E75B Other Respiratory System Diagnosis Age >64 or 
W CC 
3.5 $15,198 $1,216 3.6 
R03B Lymphoma and Leukaemia W Other O.R. 
Procedures W/O Catastrophic or Severe CC 
2.0 $15,116 $2,387 3.2 
L63C Kidney and Urinary Tract Infections Age <70 
W/O Catastrophic or Severe CC 
1.3 $14,615 $4,872 2.3 
B02C Craniotomy W/O CC 0.3 $14,331 $1,869 23.0 
Q02A Other O.R. Procedure of Blood & Blood Forming 0.8 $14,253 $586 29.2 
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Organs W Cat or Sev CC 
A41B Intubation Age<16 W/O CC 0.3 $13,224 $2,204 18.0 
F63A Venous Thrombosis W Catastrophic or Severe 
CC 
1.3 $12,673 $939 10.1 
J68A Major Skin Disorders 2.0 $12,516 $1,211 5.2 
X63B Sequelae of Treatment W/O Catastrophic or 
Severe CC 
1.3 $12,383 $728 12.8 
I66A Inflammatory Musculoskeletal Disorders W Cat 
or Severe CC 
1.0 $12,231 $1,595 7.7 
I28A Other connective tissue Procedures W CC 0.5 $11,771 $1,070 22.0 
Z62Z Follow Up W/O Endoscopy 18.0 $11,249 $625 1.0 
F21A Other Circulatory System O.R. procedure w 
Catastrophic CC 
0.3 $11,117 $1,588 21.0 
D40Z Dental Extractions and Restorations 3.0 $11,113 $3,704 1.0 
K62C Miscellaneous Metabolic Disorders Age <75 
W/O Catastrophic or Severe CC 
2.0 $10,679 $2,464 2.2 
G68A Gastroenteritis Age <10 W CC 3.0 $9,909 $1,651 2.0 
K61Z Severe Nutritional Disturbance 0.5 $9,854 $1,159 17.0 
L60C Renal Failure W/O Catastrophic or Severe CC 2.3 $9,839 $1,181 3.6 
E02A Other Respiratory System O.R. Procedures W 
Catastrophic CC 
0.3 $9,644 $1,447 20.0 
L03B Kidney, Ureter and Major Bladder Procedures 
for Neoplasm W/O Cat or Sev CC 
0.7 $9,093 $2,728 5.0 
B81A Other Disorders of the Nervous System W 
Catastrophic or Severe CC 
1.3 $8,894 $1,721 3.9 
G69Z Oesophagitis and Misc Digestive System 
Disorders Age<10 
1.0 $8,891 $1,667 5.3 
D64Z Laryngotracheitis and Epiglottitis 0.3 $8,840 $1,894 14.0 
K63Z Inborn Errors of Metabolism 1.7 $8,511 $1,824 2.8 
I12A Infect/Inflam of Bone & Joint W Misc Musc Sys 
& Conn Tiss Procs W Cat CC 
0.5 $8,497 $2,832 6.0 
F71B Non-Major Arrhythmia and Conduction 
Disorders W/O Catastrophic or Severe CC 
1.8 $8,031 $1,662 2.6 
G66A Abdominal Pain or Mesenteric Adenitis W CC 1.3 $7,957 $1,591 3.8 
K03Z Adrenal Procedures 0.7 $7,934 $2,645 4.5 
I68A Non-surgical Spinal Disorders W CC 0.8 $7,902 $1,693 5.6 
M62A Inflammation of Male Reproductive System W 
CC 
0.5 $7,579 $842 18.0 
Q62Z Coagulation Disorders 6.2 $7,498 $1,046 1.2 
Q01Z Splenectomy 0.3 $7,457 $1,721 13.0 
T61A Postoperative and Post-Traumatic Infections 
Age > 54 or W (Cat or Sev CC) 
0.5 $7,102 $1,015 14.0 
D06Z Sinus, Mastoid and Complex Middle Ear 
Procedures 
1.0 $7,017 $7,017 1.0 
I71B Other Musculotendinous Disorders Age >69 or 
W CC 
1.3 $6,775 $1,452 3.5 
T01B O.R. Procedures for Infectious and Parasitic 
Diseases W Severe or Moderate CC 
0.3 $6,742 $1,190 17.0 
F71A Non-Major Arrhythmia and Conduction 
Disorders W Catastrophic or Severe CC 
0.8 $6,697 $913 8.8 
L63B Kidney and Urinary Tract Infections Age >69 or 
W Severe CC 
1.0 $6,531 $1,399 4.7 
L67B Other Kidney and Urinary Tract Diagnoses W 
Severe CC 
1.7 $6,280 $1,570 2.4 
L62B Kidney and Urinary Tract Neoplasms W/O 
Catastrophic or Severe CC 
2.3 $6,053 $1,513 1.7 
L65A Kidney and Urinary Tract Signs and Symptoms 
W Catastrophic or Severe CC 
0.8 $5,992 $1,160 6.2 
G44A Other ColonoscopyWCatastrophic or Severe cc  0.5 $5,969 $853 14.0 
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G45A Other Gastroscopy for Non-Major Digestive 
Disease 
0.5 $5,137 $856 12.0 
H64A Disorders Of Biliary Tract +Cc 0.3 $5,124 $1,025 15.0 
K60A Diabetes W Catastrophic or Severe CC 0.3 $4,983 $2,492 6.0 
G66B Abdominal Pain or Mesenteric Adenitis W/O CC 0.7 $4,943 $2,471 3.0 
L03A Kidney, Ureter and Major Bladder Procedures 
for Neoplasm W Catastrophic CC 
0.3 $4,729 $2,837 5.0 
C63A Other Disorders of the eye W CC 0.7 $4,609 $1,728 4.0 
T61B Postoperative & Post-traumatic Infections Age 
<55 W/O Cat or Sev CC 
0.7 $4,278 $1,426 4.5 
I66B Inflammatory Musculoskeletal Disorders W/O 
Cat or Sev CC  
2.5 $4,130 $1,652 1.0 
I08B Other Hip & Femur Pr -Cscc 0.3 $3,892 $1,061 11.0 
Z64A Other Factors Influencing Health Status 1.3 $3,777 $2,266 1.3 
E71C Respiratory Neoplasms W/O CC 1.0 $3,654 $2,741 1.3 
G68B Gastroenteritis Age <10 W/O CC 0.7 $3,466 $1,486 3.5 
L62A Kidney and Urinary Tract Neoplasms W 
Catastrophic or Severe CC 
1.0 $3,455 $1,727 2.0 
X62A Poisoning/Toxic Effects of Drugs & Other 
Substances Age >59 or W CC 
0.3 $3,121 $1,873 5.0 
G46B Complex Gastroscopy W/O Catastrophic or 
Severe CC 
0.5 $3,063 $875 7.0 
I12B Infect/Inflam of Bone & Joint W Misc Musc Sys 
& Conn Tiss Procs W Sev CC 
0.3 $3,015 $393 23.0 
F73A Syncope and Collapse W Catastrophic or 
Severe CC 
1.5 $2,935 $839 2.3 
B76A Seizure W Catastrophic or Severe CC 0.7 $2,918 $2,189 2.0 
J68B Major Skin Disorders, Same Day 0.3 $2,886 $8,657 1.0 
J67A Minor Skin Disorders 0.3 $2,814 $1,055 8.0 
S65C HIV-Related Diseases W/O Catastrophic or 
Severe CC 
0.5 $2,761 $5,522 1.0 
M04A Testes Procedures W CC 0.7 $2,757 $4,136 1.0 
I76B Other Musculoskeletal Disorders Age >69 or W 
CC 
1.5 $2,716 $1,811 1.0 
B70D Stroke, Died or Transferred < 5 days 0.3 $2,620 $1,965 4.0 
E02C Other Respiratory System OR Procedures W/O 
CC 
0.3 $2,496 $2,496 1.0 
I25Z Bone and Joint Diagnostic Procedures including 
Biopsy 
0.3 $2,449 $1,837 4.0 
D61Z Dysequilibrium 0.3 $2,374 $1,780 4.0 
E71A Respiratory Neoplasms W Catastrophic CC 0.7 $2,028 $1,521 2.0 
B67A Degenerative Nervous System Disorders W Cat 
or Sev CC 
0.3 $1,940 $1,940 3.0 
Z60A Rehabilitation + Cscc 0.3 $1,757 $479 11.0 
B62Z Admit for Apheresis 1.8 $1,666 $909 1.0 
D13Z Myringotomy W Tube Insertion 0.3 $1,616 $2,425 2.0 
E67B Respiratory Signs and Symptoms W/O 
Catastrophic or Severe CC 
1.0 $1,533 $1,533 1.0 
N09Z Conisation, Vagina, Cervix and Vulva 
Procedures 
1.0 $1,409 $1,409 1.0 
M60A Malignancy, Male Reproductive System W 
Catastrophic or Severe CC 
0.3 $1,250 $1,874 2.0 
U65Z Anxiety Disorders 0.7 $1,241 $1,861 1.0 
F42A Circulatory Disorders W/O AMI W Invasive 
Cardiac Inves Proc W Complex DX/Pr 
0.5 $1,199 $2,398 1.0 
I61Z Distal Femoral Fractures 0.3 $1,173 $1,760 2.0 
960Z Ungroupable 0.3 $1,101 $3,304 1.0 
E67A Respiratory Signs and Symptoms W 0.3 $930 $1,396 2.0 
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Catastrophic or Severe CC 
G03B Stomach, Oesophageal and Duodenal 
Procedures W/O Malignancy W Cat or Sev CC 
0.3 $908 $2,725 1.0 
L65B Kidney and Urinary Tract Signs and Symptoms 
W/O Catastrophic or Severe CC 
1.3 $904 $452 1.5 
E69B Bronchitis and Asthma Age >49 or W CC 0.3 $863 $1,295 2.0 
G44C Other Colonoscopy, Same Day 1.0 $807 $807 1.0 
G70A Other Digestive System Diagnoses W CC 0.3 $804 $2,412 1.0 
L41Z Cystourethroscopy, Same Day 0.3 $769 $2,308 1.0 
T64B Other Infectious and Parasitic Diseases W/O 
Catastrophic or Severe CC 
0.3 $731 $2,194 1.0 
P67D Neonate, AdmWt > 2499 g W/O Significant O.R. 
Procedure W/O Problem 
0.3 $696 $1,044 2.0 
Z01A O.R. Procedures W Diagnoses of Other 
Contacts W Health Services W Cat/Sev CC 
0.3 $620 $1,860 1.0 
E74C Interstitial Lung Disease W/O Catastrophic or 
Severe CC 
0.3 $557 $1,670 1.0 
E65B Chronic Obstrct Airway Dis-Cscc 0.7 $549 $823 1.0 
I68C Non-surgical Spinal Disorders, Same Day 0.8 $509 $611 1.0 
I64A Osteomyelitis W CC 0.3 $493 $1,480 1.0 
R62B Other Neoplastic Disorders W/O CC 0.7 $411 $617 1.0 
G45B Other Gastroscopy for Non-Major Digestive 
Disease, Same Day 
1.0 $409 $409 1.0 
F74Z Chest Pain 0.5 $356 $712 1.0 
D66A Other Ear, Nose, Mouth and Throat Diagnoses 
W CC 
0.3 $343 $1,028 1.0 
C60B Ac & Mjr Eye Infectn A<55-Cscc 0.3 $332 $996 1.0 
D63B Otitis Media & Uri - Cc 1.3 $295 $221 1.0 
L61Z Admit for Renal Dialysis 0.3 $264 $791 1.0 
D62Z Epistaxis 0.3 $202 $607 1.0 
J67B Minor Skin Disorders, Same Day 0.3 $108 $325 1.0 
M60B Malignancy, Male Reproductive System W/O 
Catastrophic or Severe CC 
0.3 $52 $157 1.0 
All  996.5 $7,828,507 $1,538 4.9 
 ** Includes only costs that occurred in year of separation for ending episodes 
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